Download Annual Meeting Express Print By Day.rdl

ASCO Annual Meeting Express Print
Saturday, May 31, 2014
Program data current as of Friday, May 9, 2014
Session Title: How to Navigate the Annual Meeting (Fellows and Junior Faculty Only)
Session Type: Education Session
Track: Professional Development
Time: 7:30 AM - 8:00 AM
Location: S501
•
How to Make the Most of Your Meeting
Ezra E.W. Cohen, MD - Chair
•
Technology and Tools to Optimize Your Meeting Experience
Don S. Dizon, MD
Session Title: Beyond Stage I Germ Cell Tumors
Session Type: Education Session
Track: Genitourinary Cancer
Time: 8:00 AM - 9:15 AM
Location: E Hall D2
•
First-line and Second-line Chemotherapy for Intermediate-Risk and Poor-Risk Germ Cell
Tumor
Darren Richard Feldman, MD - Chair
•
Optimizing the Selection Criteria for Postchemotherapy Surgery
Andrew J. Stephenson, MD
•
Post-treatment Long-term Toxicities and Implications for Follow-up
Hege Sagstuen Haugnes, MD, PhD
•
Panel Question and Answer
Session Title: Integrative Oncology: The Evidence Base
Session Type: Education Session
Track: Professional Development
Time: 8:00 AM - 9:15 AM
Location: S404
•
Integrative Oncology: Overview
Barrie R. Cassileth, PhD - Chair
•
Mind-Body Therapies
Lorenzo Cohen, PhD
•
Nutrition: Special Diets and Supplements
Michelle Harvie, PhD
•
Panel Question and Answer
Session Title: Management of Acute Myeloid Leukemia in the Genomic Era
Session Type: Education Session
Track: Leukemia, Myelodysplasia, and Transplantation
Time: 8:00 AM - 9:15 AM
Location: E354a
•
New Molecular Abnormalities and Clonal Architecture in Acute Myeloid Leukemia: From
Reciprocal Translocations to Whole-Genome Sequencing
Timothy A. Graubert, MD
•
Allogeneic Hematopoietic Stem Cell Transplantation in the Genomic Era: Evolution of
Transplant Criteria over the Past 50 Years
Frederick R. Appelbaum, MD - Chair
•
Novel Therapeutic Agents in the Treatment of Acute Myeloid Leukemia: Reason for Hope or
Just Hype?
William G. Blum, MD
•
Panel Question and Answer
Session Title: Progress in Prevention and Opportunities for the Future
Session Type: Education Session
Track: Cancer Prevention/Epidemiology
Time: 8:00 AM - 9:15 AM
Location: S100bc
•
Dietary Prevention Strategies: Progress and Opportunities for the Future
Jeffrey A. Meyerhardt, MD, MPH
•
Role of Hormones in Cancer Prevention
Victor G. Vogel, MD - Chair
•
Cancer Interception to Prevent Cancer through Reverse Migration
Waun Ki Hong, MD
•
Panel Question and Answer
Session Title: The BRAF Pathway: An Emerging Therapeutic Target in Childhood Cancer
Session Type: Education Session
Track: Pediatric Oncology
Time: 8:00 AM - 9:15 AM
Location: S504
•
The BRAF Pathway: Biology and Application to Central Nervous System Tumors
Mark W. Kieran, MD, PhD - Chair
•
Histiocytosis in the Era of BRAF Mutations
Robert John Arceci, MD, PhD
•
Childhood Melanoma: BRAF Mutations and Therapy Implications
Alberto S. Pappo, MD
•
Panel Question and Answer
Session Title: The Changing Landscape of Federally Sponsored Trials
Session Type: Education Session
Track: Clinical Trials
Time: 8:00 AM - 9:15 AM
Location: S100a
•
ASCO’s Community Research Forum for Overcoming Local Challenges
Nicholas J. Robert, MD
•
The Future of National Cancer Institute–Sponsored Trials
Jeffrey S. Abrams, MD
•
Community Involvement in Clinical Trials: From the Community Clinical Oncology Program to
the National Cancer Institute Community Oncology Research Program
Robin Zon, MD, FACP, FASCO - Chair
•
Panel Question and Answer
Session Title: The Best Therapy for a Newly Diagnosed Patient with Advanced-Stage Ovarian
Cancer - Ticketed Session
Session Type: Meet the Professor Session
Track: Gynecologic Cancer
Time: 8:00 AM - 9:15 AM
Location: E451a
•
Intraperitoneal Chemotherapy Remains the Standard Therapy for Patients with Optimally
Cytoreduced Ovarian Cancer
Joan L. Walker, MD
•
Dose-Dense Chemotherapy Is Now the Standard Therapy for Patients with Ovarian Cancer
Keiichi Fujiwara, MD, PhD
Session Title: Breast Cancer Central Nervous System Metastases: A Strategic Approach to
Integrating Local and Systemic Therapies - Ticketed Session
Session Type: Clinical Problems in Oncology Session
Track: Breast Cancer
Time: 8:00 AM - 9:15 AM
Location: E451b
•
Optimizing Local Therapy for Central Nervous System Metastatic Breast Cancer
Matthew G. Ewend, MD - Chair
•
Selection of Systemic Therapy for Central Nervous System Metastatic Breast Cancer
Nancy U. Lin, MD
•
Clinical Trial Development for Central Nervous System Metastatic Breast Cancer:
Achievements and Challenges
Minesh P. Mehta, MD
Session Title: Advances in Tumor Biology
Session Type: Clinical Science Symposium
Track: Tumor Biology
Time: 8:00 AM - 9:30 AM
Location: S406
•
Chair
Mark M. Moasser, MD
•
Effect of multiparametric MRI of the breast on diagnostic accuracy. (Abstract 11009)
Katja Pinker-Domenig
•
Pushing the Envelope: Breast Cancer Screening
Savannah C. Partridge, PhD
•
Exploratory biomarker analysis of a phase I study of AZD4547, an inhibitor of fibroblast
growth factor receptor (FGFR), in patients with advanced solid tumors. (Abstract 11010)
Elaine Kilgour
•
Potential Biomarkers for FGFR-Inhibitor Therapy
Michael J. Birrer, MD, PhD
•
Clinical outcome with correlation to disseminated tumor cell (DTC) status after DTC-driven
secondary adjuvant treatment with docetaxel in early breast cancer (BrCa). (Abstract 11011)
Bjorn Naume
•
Is There a Prognostic Value for Disseminated Tumor Cells in Adjuvant Therapy?
Jean-Yves Pierga, MD, PhD
•
Panel Question and Answer
Session Title: Emerging Combination Strategies
Session Type: Clinical Science Symposium
Track: Developmental Therapeutics
Time: 8:00 AM - 9:30 AM
Location: E Arie Crown Theater
•
Chair
Andres Forero-Torres, MD
•
Chair
Stephen Maxted Ansell, MD
•
Safety/efficacy of MK-8669 (ridaforolimus) plus MK-2206 (AKT inhibitor) in patients with
advanced breast cancer with low RAS signature and PTEN deficient prostate cancer.
(Abstract 2509)
Shilpa Gupta
•
Phase I study of oral BKM120 and oral olaparib for high-grade serous ovarian cancer (HGSC)
or triple-negative breast cancer (TNBC). (Abstract 2510)
Ursula Matulonis
•
Rational Combinations of Targeted Therapies
Timothy Anthony Yap, MD, PhD
•
Phase 1 study of the BRAF inhibitor dabrafenib (D) with or without the MEK inhibitor
trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation–positive
unresectable or metastatic melanoma (MM). (Abstract 2511)
Igor Puzanov
•
Combinatorial effect of dabrafenib, trametinib, and adoptive cell transfer (ACT) in an
immune-competent murine model of BRAFV600E mutant melanoma. (Abstract 2512)
Siwen Hu-Lieskovan
•
Combining Kinase Inhibitors with Immunotherapeutics
Jonathan S. Cebon, MBBS, FRACP, PhD
•
Panel Question and Answer
Session Title: Incorporating Advanced MR and PET Imaging in the Clinic: Are We Ready?
Session Type: Clinical Science Symposium
Track: Central Nervous System Tumors
Time: 8:00 AM - 9:30 AM
Location: E450
•
Chair
Jaishri O'Neill Blakeley, MD
•
Chair
Christina Tsien, MD
•
Contrast-enhanced T1-weighted digital subtraction maps combined with diffusion MRI to
identify recurrent glioblastoma patients that benefit from bevacizumab therapy. (Abstract
2008^)
Benjamin M. Ellingson
•
Advanced MRI as a Biomarker
Christina Tsien, MD
•
Prospective analysis of serial FLT-PET scanning to discriminate between true and
pseudoprogression in glioblastoma. (Abstract 2009)
Martha W. den Hollander
•
Advanced PET as a Biomarker
Elizabeth Robins Gerstner, MD
•
Diagnosis of pseudoprogression using ferumoxytol perfusion MRI in patients with
glioblastoma to predict better outcome. (Abstract 2010)
Edward A. Neuwelt
•
Applying State-of-the-Art Brain Imaging Modalities in Clinical Trials and Practice
Rajan Jain, MD
•
Panel Question and Answer
Session Title: Optimizing Access to Clinical Trials in Community Practice
Session Type: Clinical Science Symposium
Track: Health Services Research
Time: 8:00 AM - 9:30 AM
Location: E253
•
Chair
Aditya Bardia, MD, MPH
•
Clinical Trials in the Community: A Retrospective
Worta J. McCaskill-Stevens, MD
•
Discussions about clinical trials among patients with lung and colorectal cancer. (Abstract
6509)
Kenneth L. Kehl
•
Clinical trial subjects compared to “real world” patients: Generalizability of renal cell
carcinoma trials. (Abstract 6510)
Aaron Philip Mitchell
•
Impact of the NCI Community Cancer Centers Program (NCCCP) on clinical trial (CT)
activities in a community cancer center in rural Nebraska. (Abstract 6511)
Mehmet Sitki Copur
•
The clinical trial assessment of infrastructure matrix tool (CT AIM) to improve the quality of
research conduct in the community. (Abstract 6512)
Eileen P. Dimond
•
Clinical Trials in the Community: Moving Forward
Richard L. Schilsky, MD
•
Panel Question and Answer
Session Title: Targeting EGFR: The Next 10 Years
Session Type: Clinical Science Symposium
Track: Lung Cancer
Time: 8:00 AM - 9:30 AM
Location: E Hall D1
•
Chair
Melissa Lynne Johnson, MD
•
Chair
Tetsuya Mitsudomi, MD, PhD
•
Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR
inhibitor–resistant non-small cell lung cancer (NSCLC). (Abstract 8009^)
Pasi A. Janne
•
First-in-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase
inhibitor of mutations of EGFR (activating and T790M). (Abstract 8010^)
Lecia V. Sequist
•
Clinical activity and safety of HM61713, an EGFR-mutant selective inhibitor, in advanced nonsmall cell lung cancer (NSCLC) patients (pts) with EGFR mutations who had received EGFR
tyrosine kinase inhibitors (TKIs). (Abstract 8011)
Dong-Wan Kim
•
Breaking the Barrier of Acquired Resistance
Thomas James Lynch, MD
•
Overall response rate (ORR) as a potential surrogate for progression-free survival (PFS): A
meta-analysis of metastatic non-small cell lung cancer (mNSCLC) trials submitted to the U.S.
Food and Drug Administration (FDA). (Abstract 8012)
Gideon Michael Blumenthal
•
Getting the Right Drug to the Right Patient Faster
Lawrence H. Schwartz, MD
•
Panel Question and Answer
Session Title: Developing a Geriatric Oncology Presence at Your Academic Institution or
Community-Based Practice
Session Type: Special Session
Track: Geriatric Oncology
Time: 8:00 AM - 11:00 AM
Location: S103
•
Moderator
Ira Russell Parker, DDS, MPH - Chair
•
Welcome
Hyman Bernard Muss, MD
•
Setting the Stage: Geriatric Oncology—Why, Who, and How?
Heidi D. Klepin, MD, MS
•
Existing Geriatric Oncology Models: Opportunities and Barriers—Oncologist-Centered Models
Lodovico Balducci, MD
•
Existing Geriatric Oncology Models: Opportunities and Barriers—Oncologist-Centered Models
Andrew E. Chapman, DO
•
Existing Geriatric Oncology Models: Opportunities and Barriers—Geriatrician-Centered Models
Holly Michelle Holmes, MD
•
Existing Geriatric Oncology Models: Opportunities and Barriers—Geriatrician-Centered Models
William Dale, MD, PhD
•
A Successful Geriatric Oncology Team Approach: Perspectives of a Geriatrician and an
Oncologist
Beatriz Korc-Grodzicki, MD, PhD
•
A Successful Geriatric Oncology Team Approach: Perspectives of a Geriatrician and an
Oncologist
William P. Tew, MD
•
Open Discussion
Miriam B. Rodin, MD, PhD
•
Open Discussion
Supriya Gupta Mohile, MD, MS
•
Economic Models of Geriatric Oncology Care: Making the Argument to Your Administrator
Arash Naeim, MD, PhD
•
An International Geriatric Oncology Perspective: Australian Models of Care
Christopher B. Steer, MBBS, FRACP
•
Thoughts and Perspectives: Recent Geriatric Oncology Trainee Graduates and Their First
Employment Experiences and Challenges
Ronald John Maggiore, MD
•
Open Discussion and Brainstorming
Harvey Jay Cohen, MD
•
Closing Remarks and Adjournment
Arti Hurria, MD
Session Title: Gastrointestinal (Colorectal) Cancer
Session Type: General Poster Session
Track: Gastrointestinal (Colorectal) Cancer
Time: 8:00 AM - 11:45 AM
Location: S Hall A2
Board 1
•
Early predictors of prolonged overall survival (OS) in patients (pts) on first-line chemotherapy
(CT) for metastatic colorectal cancer (mCRC): An ARCAD study with individual patient data
(IPD) on 10,962 pts. (Abstract 3538)
Dirkje Willemien Sommeijer
Board 2
•
Correlation of PI3KCA and extended RAS gene mutation status with outcomes from the
phase III AGITG MAX involving capecitabine (C) alone or in combination with bevacizumab
(B) with or without mitomycin C (M) in advanced colorectal cancer (CRC). (Abstract 3539^)
Timothy Jay Price
Board 3
•
Survival outcomes for patients with metastatic colorectal cancer (mCRC) based on primary
site, right (R) colon versus left (L) colon versus rectal (Rec) primary: Results from the South
Australian Registry of mCRC. (Abstract 3540)
Yoko Tomita
Board 4
•
Survival of high-grade neuroendocrine carcinomas (HGNEC) of the colon and rectum:
Analysis of the Surveillance, Epidemiology, and End Results (SEER) database. (Abstract
3541)
Hammad Shafqat
Board 5
•
The effect of chemotherapy delivered until progression versus complete stop on the overall
survival of patients with metastatic colorectal cancer: A meta-analysis of randomized trials.
(Abstract 3542)
Allan Andresson Lima Pereira
Board 6
•
An internally and externally validated nomogram to predict severe neutropenia in Japanese
patients (pts) with advanced colorectal cancer (aCRC) treated with irinotecan (IRI)-based
regimens. (Abstract 3543)
Wataru Ichikawa
Board 7
•
A phase II trial of combined chemotherapy with oral S-1 and 24-hour infusions of irinotecan
plus bevacizumab in patients with metastatic colorectal cancer. (Abstract 3544)
Sotaro Sadahiro
Board 8
•
Asia-Pacific colorectal screening score and colorectal cancer screening in asymptomatic Asian
population. (Abstract 3545)
Joseph JY Sung
Board 9
•
MLN0264, an investigational antiguanylyl cyclase C (GCC) antibody-drug conjugate (ADC), in
patients (pts) with advanced gastrointestinal (GI) malignancies: Phase I study. (Abstract
3546)
Cristina Cruz Zambrano
Board 10
•
The 12-gene colon cancer assay validation and utility: Summary of clinical evidence.
(Abstract 3547)
Emily Burke
Board 11
•
A phase 1b study of VEGFR inhibitor fruquintinib in patients with pretreated advanced
colorectal cancer. (Abstract 3548)
Jin Li
Board 12
•
Prognostic value of KRAS exon 2 gene mutations in stage III colon cancer: Post hoc analyses
of the PETACC8 trial. (Abstract 3549)
Julien Taïeb
Board 13
•
Survival outcomes in patients (pts) with KRAS/NRAS (RAS) wild-type (WT) metastatic
colorectal cancer (mCRC) and non-liver-limited disease (non-LLD): Data from the PRIME
study. (Abstract 3550^)
Jean-Yves Douillard
Board 14
•
Phase 1 study of biweekly (Q2W) anti-EGFR monoclonal antibody (mAb) mixture Sym004 in
patients (pts) with metastatic colorectal cancer (mCRC) resistant to previous anti-EGFR
treatment. (Abstract 3551)
Guillem Argilés
Board 15
•
Impact of chemotherapy partner on efficacy of targeted therapy in metastatic colorectal
cancer (mCRC): A meta-analysis. (Abstract 3552)
David Chan
Board 16
•
Pulmonary metastasectomy in colorectal cancer patients with previously resected liver
metastasis: Pooled analysis. (Abstract 3553)
Samer Salah
Board 17
•
Neoadjuvant mFOLFOX6 for stage II/III rectal cancer patients with a T3/T4 tumor. (Abstract
3554)
Junichi Koike
Board 18
•
CA 11-19 as a tumor marker for the diagnosis of colorectal cancer. (Abstract 3555)
Bergein F Overholt
Board 19
•
Patterns of progression, treatment of progressive disease, and postprogression survival in
the new EPOC study. (Abstract 3556)
Sian Alexandra Pugh
Board 20
•
Survival outcomes in the PRIME study for patients (pts) with RAS/BRAF wild-type (WT)
metastatic colorectal cancer (mCRC), by baseline Eastern Cooperative Oncology Group
(ECOG) performance status (PS). (Abstract 3557^)
Marc Peeters
Board 21
•
Second-line therapies in patients with KRAS wild-type metastatic colorectal cancer (mCRC)
after first-line therapy with FOLFIRI in combination with cetuximab or bevacizumab in the
AIO KRK0306 (FIRE 3) trial. (Abstract 3558^)
Dominik Paul Modest
Board 22
•
Cell-free DNA levels in colorectal cancer patients treated with irinotecan, healthy controls and
non-cancer patients with comorbidity. (Abstract 3559)
Karen-Lise Garm Spindler
Board 23
•
Phase II trial of panitumumab plus FOLFOX4 or FOLFIRI in subjects with KRAS wild-type
colorectal cancer and liver-limited disease: The PLANET study. (Abstract 3560)
Albert Abad
Board 24
•
Impact of delay in adjuvant oxaliplatin-based chemotherapy for stage III colon cancer.
(Abstract 3561)
Renata D'Alpino Peixoto
Board 25
•
Comparison of ColoPrint risk classification with clinical risk in the prospective PARSC trial.
(Abstract 3562)
Ramon Salazar
Board 26
•
Association outcome with genes involved in immune response and checkpoints in patients
with resected colorectal liver metastases. (Abstract 3563)
Stefan Stremitzer
Board 27
•
Influence of genetic variations of the angiopoietin and pericyte pathways in resected
colorectal liver metastases. (Abstract 3564)
Stefan Stremitzer
Board 28
•
Influence of genetic variants of genes potentially associated with brain metastases on overall
survival in 70 colorectal cancer patients. (Abstract 3565)
Matthias Preusser
Board 29
•
Analysis of progression-free survival in the new EPOC study in an “all wild-type” population.
(Abstract 3566)
John A. Bridgewater
Board 30
•
Randomized controlled trials (RCTs) examining continuous (CS) versus intermittent strategies
(IS) of delivering systemic treatment (Tx) for untreated metastatic colorectal cancer (mCRC):
An updated meta-analysis from the Cancer Care Ontario program in evidence-based care.
(Abstract 3567)
Scott R. Berry
Board 31
•
Updated analysis of KRAS/NRAS and BRAF mutations in study 20050181 of panitumumab
(pmab) plus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC).
(Abstract 3568)
Marc Peeters
Board 32
•
Multivariate prospective pharmacogenetic analysis in patients with resectable metastatic
colorectal cancer (mCRC) receiving FOLFOX chemotherapy. (Abstract 3569)
Marie-Christine Etienne-Grimaldi
Board 33
•
Bichemotherapy versus single-agent therapy with 5FU in elderly patients with metastatic
colorectal cancer: A meta-analysis. (Abstract 3570)
Gaetan Des Guetz
Board 34
•
Biomarker validation study: Genes involved in ubiquitin proteasome system (UPS) dependent
EGFR-degradation for prediction of efficacy in metastatic colorectal cancer patients treated
with cetuximab. (Abstract 3571)
Sebastian Stintzing
Board 35
•
Molecular profiling of patients (pts) with advanced colorectal cancer (CRC): Princess
Margaret Cancer Center experience. (Abstract 3572)
Joanne Wing-Yan Chiu
Board 36
•
FC?RIIa and FC?RIIIa polymorphisms (SNPs) and cetuximab (C) benefit in the EXPERT-C
trial. (Abstract 3573)
Francesco Sclafani
Board 37
•
Pharmacokinetic (PK)-guided optimization of 5-fluorouracil (5FU) exposure in colorectal
cancer (CRC) patients: U.S.-based clinical practices experience. (Abstract 3574)
Fadi S. Braiteh
Board 38
•
Panex: A pooled analysis of EXPERT and EXPERT-C, two trials of neoadjuvant chemotherapy
(NACT) and chemoradiotherapy (CRT) in high-risk locally advanced rectal cancer (LARC).
(Abstract 3575)
Francesco Sclafani
Board 39
•
Chemotherapy use in stage III colon cancer: A National Cancer Data Base (NCDB) analysis.
(Abstract 3576)
Sumit Dahal
Board 40
•
Do patients achieving pathologic complete response (pCR) following neoadjuvant treatment
for locally advanced rectal cancer (LARC) need adjuvant chemotherapy? (Abstract 3577)
Anis Hamid
Board 41
•
Early predictors of improved long-term outcomes in first-line antiangiogenics plus
chemotherapy (anti-ANG/CT) in metastatic colorectal cancer (mCRC): Analysis of individual
patient (pt) data from the ARCAD database. (Abstract 3578)
Everardo D. Saad
Board 42
•
Comparative effectiveness of contemporary adjuvant chemotherapy among older rectal
cancer patients. (Abstract 3579)
Jennifer Leigh Lund
Board 43
•
LGR5 rs17109924 to predict chemoresistance to 5FU-based chemotherapy in adjuvant colon
cancer. (Abstract 3580)
Armin Gerger
Board 44
•
The prognostic and therapeutic value of EpHA2 in early colorectal cancer (CRC). (Abstract
3581)
Sonali Dasgupta
Board 45
•
Identifying an early indicator of drug efficacy in patients (pts) with metastatic colorectal
cancer (mCRC): A prospective evaluation of circulating tumor cells (CTC), 18Ffluorodeoxyglucose positron-emission tomography (PET), and the RECIST criteria. (Abstract
3582)
Brigette Ma
Board 46
•
Hepatic oligometastases treated with stereotactic body radiation therapy: Updated 10-year
analysis of the Indiana University experience. (Abstract 3583)
Ben Goodman
Board 47
•
A randomized controlled trial evaluating efficacy of adjuvant oral uracil-tegafur (UFT) with
leucovorin (LV) after resection of colorectal cancer liver metastases: The UFT/LV study.
(Abstract 3584)
Akira Kobayashi
Board 48
•
Colon cancer: Characteristics and survival rates in young versus old patients. (Abstract 3585)
Shams Aziz Mistry
Board 49
•
Updated results of the SOFT study: A randomized phase III trial of S-1/oxaliplatin (SOX) plus
bevacizumab versus 5-FU/l-LV/oxaliplatin (mFOLFOX6) plus bevacizumab in patients with
metastatic colorectal cancer (mCRC). (Abstract 3586)
Masato Nakamura
Board 50
•
Randomized controlled trial on the skin toxicity of panitumumab in third-line treatment of
KRAS wild-type metastatic colorectal cancer: HGSG1001 (Japanese Skin Toxicity Evaluation
Protocol with Panitumumab: J-STEPP)—Additional analysis of antitumor efficacy. (Abstract
3587)
Yoshimitsu Kobayashi
Board 51
•
Effect of 12-week home-based exercise program on fasting insulin in stage II-III colorectal
cancer survivors: A randomized controlled trial. (Abstract 3588)
MI KYUNG LEE
Board 52
•
Four-year survival in patients (pts) undergoing liver surgery after neoadjuvant triplet hepatic
artery infusion (HAI) and intravenous cetuximab (IV-CET) for previously treated and
unresectable liver metastases from kras wt colorectal cancer (LM-CRC) (European trial
OPTILIV, NCT00852228). (Abstract 3589)
Francis Levi
Board 53
•
Benefit of EGFR-inhibition therapy for metastatic colorectal cancer patients with KRASmutated tumors and high plasma TIMP-1 level: Results from the NORDIC VII study.
(Abstract 3590)
Nils Brunner
Board 54
•
Coexisting KRAS and PIK3CA exon 20 mutations as a potential poor-prognosis factor in
metastatic colorectal cancer (mCRC). (Abstract 3591)
Maria Elena Elez Fernandez
Board 55
•
AIO KRK0306, FIRE3 trial: CEA and CA19-9 influence outcome of patients with KRAS exon
wild-type metastatic colorectal cancer (mCRC) receiving first-line therapy with FOLFIRI plus
cetuximab or bevacizumab. (Abstract 3592^)
Marlies Michl
Board 56
•
Constitutive single nucleotide polymorphisms (SNP) assessment for predicting tolerability and
efficacy of triplet hepatic artery infusion (HAI) and intravenous cetuximab (IV-CET) in
patients (pts) with liver metastases from colorectal cancer (LM-CRC) (European trial
OPTILIV, NCT00852228). (Abstract 3593)
Francis Levi
Board 57
•
The role of JAK1/2-STAT3 as acute resistance mechanism to MEK inhibition in BRAF-mutant
colorectal cancer cell lines. (Abstract 3594)
Basak Celtikci
Board 58
•
Clinical course of patients with oxaliplatin-associated neuropathy: N08CB (Alliance). (Abstract
3595)
Deirdre R. Pachman
Board 59
•
Modified FOLFOXIRI plus cetuximab (cet) as induction treatment in unresectable metastatic
colorectal cancer (mCRC) patients (pts): Preliminary results of the phase II randomized
Macbeth trial by GONO group. (Abstract 3596)
Chiara Cremolini
Board 60
•
Molecular profiling of EGFR pathway according to location of colorectal cancer (CRC):
Analysis of 1,001 patients in single institute. (Abstract 3597)
Eiji Shinozaki
Board 61
•
Compliance and safety of neoadjuvant intensity modulated radiotherapy (IMRT) with
concurrent capecitabine for locally advanced rectal cancer: Updated results from a phase II
trial (ChiCTR-TNC-10001094). (Abstract 3598)
Yongheng Li
Board 62
•
Validation of the NSABP neoadjuvant rectal score (NAR) in a prospective phase II study
evaluating an experimental regimen and a standard chemoradiation cohort with molecular
genotyping. (Abstract 3599)
Theodore S. Hong
Board 63
•
Gender and tumor location as predictors for efficacy: Influence on endpoints in first-line
treatment with FOLFIRI in combination with cetuximab or bevacizumab in the AIO KRK 0306
(FIRE3) trial. (Abstract 3600)
Volker Heinemann
Board 64
•
Survival following stage II/III colon cancer (CC): Accent-based comparison versus matched
general population (MGP). (Abstract 3601)
Lindsay A. Renfro
Board 65
•
Genetic variants of TCF7L2 and AXIN2 predict gender and tumor location-dependent clinical
outcome in FIRE-3 trial: A validation study. (Abstract 3602)
Yan Ning
Board 66
•
Final results from NSABP protocol R-04: Neoadjuvant chemoradiation (RT) comparing
continuous infusion (CIV) 5-FU with capecitabine (Cape) with or without oxaliplatin (Ox) in
patients with stage II and III rectal cancer. (Abstract 3603)
Carmen Joseph Allegra
Board 67
•
Circulating DNA as a strong multimarker prognostic tool in metastatic colorectal cancer
patients. (Abstract 3604)
Safia El Messaoudi
Board 68
•
CpG island methylator phenotype (CIMP) and outcome differences for African Americans
(AA) and Caucasians (C) treated with FOLFOX4 or the combination with bevacizumab (B) in
patients (pts) with metastatic colorectal cancer (MCRC): Results from the Eastern
Cooperative Oncology Group study E3200. (Abstract 3605)
Edith P. Mitchell
Board 69
•
Impact of PI3K aberrations on efficacy of perifosine (P), x-PECT: A phase III randomized
study of P plus capecitabine (PC) versus placebo plus capecitabine (C) in refractory
metastatic colorectal cancer (mCRC) patients. (Abstract 3606)
Cathy Eng
Board 70
•
Rechallenge with anti-EGFR–based therapy in metastatic colorectal cancer: Impact of
intervening time interval and prior anti-EGFR response. (Abstract 3607)
Xiaochun Liu
Board 71
•
S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients
with metastatic colorectal cancer: Updated results from a phase 3 trial. (Abstract 3608)
Young Suk Park
Board 72
•
Single nucleotide polymorphisms (SNPs) in vascular endothelial growth factor ( VEGF) family
genes as predictive or prognostic biomarkers in patients (pts) with metastatic colorectal
cancer (mCRC): Analysis of the phase III MAX study. (Abstract 3609)
Fiona J.M. Chionh
Board 73
•
Perturbations in PI3K pathway and cyclin dependent kinase (CDK) pathway to predict
complete responders in CRC patients treated with ADAPT therapy. (Abstract 3610)
Edward H. Lin
Board 74
•
Functional genomic screens and identification of signaling pathways in oxaliplatin-resistance
in colorectal cancer. (Abstract 3611)
Niharika B. Mettu
Board 75
•
Surveillance for asymptomatic recurrence in resected stage III colon cancer (CC): Does it
result in a more favorable outcome? (Abstract 3612)
Martin Smoragiewicz
Board 76
•
Association between body mass index and all-cause mortality in colorectal cancer patients: A
meta-analysis of prospective cohort studies. (Abstract 3613)
Junga Lee
Board 77
•
Timing of adjuvant therapy in stage II-III colorectal cancer. (Abstract 3614)
Lucas Vieira dos Santos
Board 78
•
IMPACT trial: Predictive factors for maintenance therapy with MGN1703 in patients with
metastatic colorectal carcinoma. (Abstract 3615)
Jorge Riera-Knorrenschild
Board 79
•
Improved disease-free survival with intraportal chemotherapy plus adjuvant chemotherapy
(mFOLFOX6) as adjuvant treatment in colon cancer. (Abstract 3616)
Wenju Chang
Board 80
•
Randomized phase III trial of FOLFOX versus XELOX as adjuvant chemotherapy in patients
with early-stage colorectal adenocarcinoma. (Abstract 3617)
Dimitrios G. Pectasides
Board 81
•
Molecular subtyping of colorectal cancer for identification of patients with a mesenchymal
tumor type who might benefit from TGF-beta inhibition. (Abstract 3618)
Ramon Salazar
Board 82
•
Efficiency of biomarker screening for enriched metastatic colorectal cancer trials: The
ATTACC program experience. (Abstract 3619)
Van Karlyle Morris
Board 83
•
Immune checkpoints expression in MSI versus MSS colorectal cancers and their potential
therapeutic implications. (Abstract 3620)
Nicolas Jose Llosa
Board 84
•
A marker-driven phase II trial of neoadjuvant chemotherapy in locally advanced colon
cancer. (Abstract 3621)
Anders Kristian Moeller Jakobsen
Board 85
•
A new method to analyze adverse events longitudinally in oncology clinical trials. (Abstract
3622)
Gita Thanarajasingam
Board 86
•
Response rates to hepatic arterial infusion (HAI) pump therapy in patients with metastatic
colorectal cancer liver metastases (mCRC LM) after progression on all standard
chemotherapies. (Abstract 3623)
Andrea Cercek
Board 87
•
Molecular evaluation of primary tumor (PT) and synchronous liver metastasis in colorectal
cancer (srLmCRC) patients after cetuximab-based chemotherapy. (Abstract 3624)
Daniela Adua
Board 88
•
Programmed death 1 (PD-1) lymphocytes and ligand (PD-L1) in colorectal cancer and
their relationship to microsatellite instability status. (Abstract 3625)
Zoran Gatalica
Board 89
•
Prognostic impact of reduced lymph node yield in lymph-node negative rectal cancer
specimens following neoadjuvant treatment. (Abstract 3626)
Benjamin Garlipp
Board 90
•
Comparative effectiveness of laparoscopy versus open colectomy among nonmetastatic colon
cancer patients: An analysis using the National Cancer Data Base. (Abstract 3627)
Zhiyuan Zheng
Board 91
•
Association of adjuvant chemotherapy with clinical outcomes in patients treated with
neoadjuvant chemoradiation for locally advanced rectal cancer. (Abstract 3628)
Michael M. Vickers
Board 92
•
Extended RAS analysis and subsequent anti-EGFR and anti-VEGF treatment (tx) in PEAK: A
first-line phase 2 study of FOLFOX6 + panitumumab (pmab) or bevacizumab (bev) in
metastatic colorectal cancer (mCRC). (Abstract 3629)
Fernando Rivera
Board 93
•
Comparison of quantitative methods of assessing the hepatic burden of disease as predictors
of overall survival at the initial diagnosis of stage IV colorectal cancer. (Abstract 3630)
Michael Hayden Rosenthal
Board 94
•
Impact of preoperative treatments on the immune microenvironnement of colorectal liver
metastases. (Abstract 3631)
Frederic Bibeau
Board 95
•
High-throughput exome array for identification of novel polymorphisms associated with
clinical outcome in mCRC patients treated with first-line FOLFOXIRI/BEV versus FOLFIRI/BEV
(TRIBE trial; NCT00719797). (Abstract 3632)
Wu Zhang
Board 96
•
Association of CpG island methylator phenotype (CIMP) with inferior progression-free
survival with anti-EGFR monoclonal antibody therapy in metastatic colorectal cancer.
(Abstract 3633)
Michael Sangmin Lee
Board 97
•
The safety and tolerability of veliparib (V) plus capecitabine (C) and radiation (RT) in
subjects with locally advanced rectal cancer (LARC): Results of a phase 1b study. (Abstract
3634)
Brian G. Czito
Board 98
•
Extended follow-up following aggressive resection of locally recurrent rectal cancer. (Abstract
3635)
Francis Si Wai Zih
Board 99
•
Phase I study of preoperative continuous 5-FU and sorafenib with external radiation therapy
in locally advanced rectal adenocarcinoma. (Abstract 3636^)
Gopi Kesaria Prithviraj
Board 100
•
Molecular profiling of 6,892 colorectal cancer patients to identify potential treatment options.
(Abstract 3637)
Wafik S. El-Deiry
Board 101
•
Axitinib in refractory colorectal metastatic cancer: A phase II study of increasing doses with
dynamic contrast-enhanced ultrasonography monitory of the response. (Abstract 3638)
Michel Ducreux
Board 102
•
The consistency of effect of ziv-aflibercept (Z) in the bevacizumab (B) pre-treated subgroup
of patients (pts) in the velour trial stratified by first-line progression = 9 months (mos)
versus < 9 mos. (Abstract 3639)
Paulo Marcelo Hoff
Board 103
•
mRNA expression levels of candidate genes and clinical outcome in mCRC patients treated
with FOLFOXIRI plus bevacizumab (bev) or FOLFIRI plus bev in the TRIBE study. (Abstract
3640)
Dongyun Yang
Board 104
•
Comparison of survival and nodal staging in rectal cancer patients undergoing sentinel lymph
node mapping versus conventional surgery. (Abstract 3641)
Sukamal Saha
Board 105
•
Effect of chemotherapy on the progress in colorectal cancer survival in the past two decades.
(Abstract 3642)
Irfan Jawed
Board 106
•
Surgical resection and intraoperative radiation therapy for locally recurrent rectal carcinoma.
(Abstract 3643)
David Furfaro
Board 107
•
Incidence of diabetes among patients with colorectal cancer. (Abstract 3644)
Simron Singh
Board 108
•
Monitoring changes in circulating tumor DNA in gastrointestinal malignancies using a novel
next-generation sequencing method. (Abstract 3645)
Edward Samuel James
Board 109
•
A phase II study of 5-FU/l-LV/oxaliplatin (mFOLFOX6) in patients with metastatic or
unresectable small bowel adenocarcinoma. (Abstract 3646)
Norisuke Nakayama
Board 110
•
Molecular profiling of small-bowel adenocarcinomas. (Abstract 3647)
Rebecca Feldman
Board 111A
•
Strategic 1-multi-line therapy trial in unresectable wild-type RAS metastatic colorectal
cancer: A gercor randomized open-label phase III study. (Abstract TPS3648^)
Benoist Chibaudel
Board 111B
•
A randomized phase II study (B2151005) of the intravenous phosphatidylinositol 3-kinase
(PI3K)/mammalian target of rapamycin (mTOR) inhibitor PF-05212384 plus irinotecan versus
cetuximab plus irinotecan in patients with wild-type KRAS metastatic colorectal cancer
(mCRC). (Abstract TPS3649)
Josep Tabernero
Board 112A
•
A phase II trial of maintenance ADAPT therapy targeting colon cancer stem cells in patients
with metastatic colorectal cancer. (Abstract TPS3650)
Edward H. Lin
Board 112B
•
Regorafenib as a single agent for first-line treatment of frail and/or unfit for
polychemotherapy patients with metastatic colorectal cancer (mCRC): A study of the Spanish
Cooperative Group for digestive tumor therapy (TTD). (Abstract TPS3651)
Enrique Grande
Board 113A
•
STEAM: A randomized, open-label, phase 2 trial of sequential and concurrent FOLFOXIRIbevacizumab (BEV) versus FOLFOX-BEV for the first-line (1L) treatment (tx) of patients (pts)
with metastatic colorectal cancer (mCRC). (Abstract TPS3652)
Johanna C. Bendell
Board 113B
•
Bevacizumab and combination chemotherapy in rectal cancer until surgery (BACCHUS): A
phase II, multicenter, open-label, randomized study of neoadjuvant chemotherapy alone
without radiation in patients with MRI-defined high-risk cancer of the rectum not threatening
the circumferential margin. (Abstract TPS3653)
Mark Harrison
Board 114A
•
Randomized phase II study of panitumumab (Pmab) plus irinotecan (CPT-11) versus
cetuximab (Cmab) plus CPT-11 in patients with KRAS wild-type (WT) metastatic colorectal
cancer (mCRC) following treatment with fluoropyrimidine, CPT-11, and oxaliplatin (L-OHP)
chemotherapy: WJOG6510G. (Abstract TPS3654)
Daisuke Sakai
Board 114B
•
Two phase III studies comparing 6 months of either mFOLFOX6 or XELOX with 3 months of
the same regimen as adjuvant chemotherapy in patients with completely resected stage III
colon cancer (ACHIEVE) or high-risk stage II colon cancer (ACHIEVE-2). (Abstract TPS3655)
Takayuki Yoshino
Board 115A
•
Biopsy-driven study to identify biomarkers predictive of clinical response to second-line
regorafenib in patients with metastatic colorectal cancer. (Abstract TPS3656)
Petr Kavan
Board 115B
•
Randomized phase Ib/II study of PF-05212384 plus 5-fluorouracil-leucovorin-irinotecan
(FOLFIRI) versus bevacizumab plus FOLFIRI in metastatic colorectal cancer (B2151007;
NCT01937715). (Abstract TPS3657)
Zev A. Wainberg
Board 116A
•
A randomized, double-blind, placebo-controlled, multicenter, binational, phase II trial of
immunotherapy with L-BLP25 (tecemotide) in patients with colorectal carcinoma following
R0/R1 hepatic metastasectomy. (Abstract TPS3658)
Stefan Kasper
Board 116B
•
Regorafenib assessment guided by metabolic imaging in refractory advanced colorectal
cancer (aCRC): REGARD-C study. (Abstract TPS3659)
Alain Hendlisz
Board 117A
•
The NCIC CTG and AGITG CO.23 trial: A phase III randomized study of BBI608 plus best
supportive care (BSC) versus placebo (PBO) plus BSC in patients (Pts) with pretreated
advanced colorectal carcinoma (CRC). (Abstract TPS3660)
Derek J. Jonker
Board 117B
•
ONC-2012-001: A single-arm phase II study of tivantinib (ARQ 197) plus cetuximab in EGFR
inhibitor-resistant MET high patients (pts) with locally advanced or metastatic colorectal
cancer (CRC) with wild-type KRAS. (Abstract TPS3661)
Lorenza Rimassa
Board 118A
•
Randomized phase II study of regorafenib followed by cetuximab versus reverse sequence
for wild-type KRAS metastatic colorectal cancer previously treated with fluoropyrimidine,
oxaliplatin, and irinotecan (REVERCE). (Abstract TPS3662)
Kohei Shitara
Board 118B
•
A phase III study of the impact of a physical activity program on disease-free survival in
patients with high-risk stage II or stage III colon cancer: A randomized controlled trial (NCIC
CTG CO.21). (Abstract TPS3663)
Christopher M. Booth
Board 119A
•
Phase II randomized study of induction FOLFOXIRI plus bevacizumab (bev) followed by
maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in metastatic
colorectal cancer (mCRC): The MOMA trial. (Abstract TPS3664)
Lisa Salvatore
Board 119B
•
E7208: A randomized phase II trial of irinotecan and cetuximab (IC) versus IC plus
ramucirumab (ICR) in second-line therapy of KRAS wild-type colorectal cancer (CRC).
(Abstract TPS3665)
Howard S. Hochster
Board 120A
•
UCGI 25: A multicentric randomized phase II trial evaluating dual targeting of the epidermal
growth factor (EGFR) using the combination of cetuximab and afatinib versus cetuximab
alone in patients (pts) wih chemotherapy refractory wtRAS metastatic colorectal cancer
(mCRC). (Abstract TPS3666)
Hélène Senellart
Board 120B
•
A phase IB/II study of neoadjuvant chemoradiotherapy with CRLX101 and capecitabine for
locally advanced rectal cancer. (Abstract TPS3667)
Michael Joseph Eblan
Session Title: Gastrointestinal (Noncolorectal) Cancer
Session Type: General Poster Session
Track: Gastrointestinal (Noncolorectal) Cancer
Time: 8:00 AM - 11:45 AM
Location: S Hall A2
Board 121
•
Phase II trial of panitumumab (P) plus mytomicin C (M), 5-fluorouracil (5-FU), and radiation
(RT) in patients with squamous cell carcinoma of the anal canal (SCAC): Safety and efficacy
profile—VITAL study, GEMCAD 09-02 clinical trial. (Abstract 4034)
Jaime Feliu
Board 122
•
Tumor HPV status and invasive squamous cell carcinoma of the anus: Outcomes from a
single institution. (Abstract 4035)
Bhargavi Yalamarti
Board 123
•
Prognostic significance and therapeutic implications of c-MET in esophageal squamous cell
cancer. (Abstract 4036)
Ching Tzao
Board 124
•
Perioperative versus preoperative chemotherapy with surgery in patients with resectable
squamous-cell carcinoma of esophagus: A phase III randomized trial. (Abstract 4037)
YANG ZHAO
Board 125
•
The revised AJCC staging (7th edition) and prognostic stratification in esophagogastric
adenocarcinoma. (Abstract 4038)
Haris Zahoor
Board 126
•
Candidate drug therapies for molecularly defined subgroups of esophageal cancer identified
from high-throughput drug screening. (Abstract 4039)
Irene Yu-Shing Chong
Board 127
•
The effect of FGFR4 Gly388Arg polymorphism on treatment outcomes after
chemoradiotherapy in esophageal cancer patients. (Abstract 4040)
Sanghee Cho
Board 128
•
A phase II study of MK-2206, an allosteric inhibitor of AKT as second-line therapy for
advanced gastric and gastroesophageal junction (GEJ) cancer: A SWOG Cooperative Group
trial (S1005). (Abstract 4041)
Ramesh K. Ramanathan
Board 129
•
Effect of metastasis associated in colon cancer-1 on lymphangiogenesis in human gastric
cancer. (Abstract 4042)
Li Sun
Board 130
•
The R0 resection rate after neoadjuvant bevacizumab (Bev) plus DOF versus DOF in local
advanced gastric carcinoma (LAGC) and its association with circulating tumor cell (CTC).
(Abstract 4043)
Nan Du
Board 131
•
Reduction of heart volume during neoadjuvant chemoradiation in patients with resectable
esophageal cancer. (Abstract 4044)
Nadia Haj Mohammad
Board 132
•
Prognostic factors for patients with advanced thoracic esophageal squamous cell carcinoma
receiving preoperative cisplatin plus 5-fluorouracil (JCOG9907). (Abstract 4045)
Tomoya Yokota
Board 133
•
Molecular profiling of resected esophageal cancer and its correlation with clinical outcome.
(Abstract 4046)
Tomoya Yokota
Board 134
•
Phase I study of epigenetic priming using azacitidine prior to neoadjuvant chemotherapy in
patients with resectable esophageal and gastric adenocarcinoma. (Abstract 4047)
Bryan J. Schneider
Board 135
•
Prevalence of MET and HER2 biomarkers in stage IV gastric cancer. (Abstract 4048)
Robert D. Loberg
Board 136
•
Survival benefit of metastasectomy plus chemotherapy versus chemotherapy alone for
Krukenberg tumors from advanced stomach cancer. (Abstract 4049)
Jang Ho Cho
Board 137
•
Clinical impact of induction chemotherapy followed by surgery for gastric cancer with positive
peritoneal cytology. (Abstract 4050)
Masaki Aizawa
Board 138
•
Safety, tolerability, and pharmacokinetics (PK) of rilotumumab (R) combined with cisplatin
(C) and capecitabine (X) in Japanese patients (pts) with MET-positive metastatic gastric or
gastroesophageal junction (G/GEJ) adenocarcinoma. (Abstract 4051)
Toshihiko Doi
Board 139
•
Association of polymorphisms in the CCL2/CCR2 axis with clinical outcome in localized
advanced gastric cancer (AGC) patients (pts) from United States and Japan. (Abstract 4052)
Yu Sunakawa
Board 140
•
A phase II study of preoperative chemotherapy and chemoradiation for localized gastric and
gastroesophageal junction adenocarcinoma (LGCA). (Abstract 4053)
Elena Elimova
Board 141
•
Visceral fat content, clinical features, and prognosis in a database of 507 upper
gastrointestinal cancers. (Abstract 4054)
Kazuto Harada
Board 142
•
The survival difference between gastric cancer patients from the United Kingdom and Japan
after using weighted propensity score for adjustment of differing background factors.
(Abstract 4055)
Takaki Yoshikawa
Board 143
•
Pretreatment neutrophil to lymphocyte ratio as an independent predictor of disease-specific
survival in resectable GE junction and gastric adenocarcinoma. (Abstract 4056)
Sam C Wang
Board 144
•
REGARD: A phase 3, randomized, double-blind trial of ramucirumab (RAM) and best
supportive care (BSC) versus placebo (PL) and BSC in the treatment of metastatic gastric or
gastroesophageal junction (GEJ) adenocarcinoma following disease progression (PD) on firstline platinum- and/or fluoropyrimidine-containing combination therapy: Age subgroup
analysis. (Abstract 4057)
Charles S. Fuchs
Board 145
•
RAINBOW: A global, phase III, randomized, double-blind study of ramucirumab plus
paclitaxel versus placebo plus paclitaxel patients with previously treated gastric or
gastroesophageal junction (GEJ) adenocarcinoma: Quality-of-life (QoL) results. (Abstract
4058)
Salah-Eddin Al-Batran
Board 146
•
Patient-derived xenografts as models for the identification of predictive biomarkers in
esophagogastric cancer. (Abstract 4059)
Yelena Yuriy Janjigian
Board 147
•
Neoadjuvant versus adjuvant treatment: Which one is better for resectable locally advanced
esophageal squamous cell carcinoma? (Abstract 4060)
Qixun Chen
Board 148
•
Metabolic landscape and prognostic value of HER2 in advanced gastric cancer. (Abstract
4061)
Chan-Young Ock
Board 149
•
Biomarkers to predict sensitivity to HER2-targeting treatment in HER2-positive advanced
gastric cancer. (Abstract 4062)
Tae Yong Kim
Board 150
•
Impact of age on the feasibility and efficacy of neoadjuvant chemotherapy in patients with
locally advanced gastroesophageal cancer: A retrospective pooled analysis of individual
patient data. (Abstract 4063)
Silvia Spörl
Board 151
•
Randomized phase II study of CPT-11 versus PTX versus each combination chemotherapy
with S-1 in patients with advanced gastric cancer refractory to S-1 or S-1 plus CDDP.
(Abstract 4064)
Tomono Kawase
Board 152
•
The relationship between HER2 expression and Lauren classification in Chinese gastric
cancer patients. (Abstract 4065)
Rui-hua Xu
Board 153
•
Simvastatin plus capecitabine-cisplatin (XP) versus placebo plus capecitabine-cisplatin (XP) in
patients with previously untreated advanced gastric cancer: A double-blind randomized
phase 3 study. (Abstract 4066)
Seung Kim
Board 154
•
Quality of life (QoL) analysis from the randomized phase III REAL3 trial of epirubicin,
oxaliplatin, and capecitabine (EOC) with or without panitumumab (P) in advanced
esophagogastric adenocarcinoma. (Abstract 4067)
Tom Samuel Waddell
Board 155
•
MAGIC germline polymorphism analysis. (Abstract 4068)
Elizabeth Catherine Smyth
Board 156
•
Randomized, multicenter, phase III trial to compare S-1 plus docetaxel (DS) with S-1 plus
cisplatin (SP) in gastric cancer patients with stage III (POST trial). (Abstract 4069)
Choong-kun Lee
Board 157
•
Nimotuzumab plus paclitaxel and cisplatin as first-line treatment for esophageal squamous
cell cancer: Final results of a single-center prospective clinical trial. (Abstract 4070)
Ming Lu
Board 158
•
Preoperative chemoradiation versus preoperative chemotherapy alone for esophageal
cancer: Higher response rates but equivalent survival. (Abstract 4071)
Brendon Matthew Stiles
Board 159
•
Concordance study of HER2 fluorescence in situ hybridization (FISH) assays in upper
gastrointestinal (UGI) adenocarcinomas. (Abstract 4072^)
Michael F. Press
Board 160
•
HER-FLOT: Trastuzumab in combination with FLOT as perioperative treatment for patients
with HER2-positive locally advanced esophagogastric adenocarcinoma: A phase II trial of the
AIO Gastric Cancer Study Group. (Abstract 4073^)
Ralf Hofheinz
Board 161
•
A Bayesian multiple-treatments meta-analysis of neoadjuvant treatments for locally
advanced, resectable esophageal cancer. (Abstract 4074)
Kelvin K. Chan
Board 162
•
Outcomes of asymptomatic metastatic gastric cancer (MGC) patients when the initiation of
systemic therapy is delayed. (Abstract 4075)
Roopma Wadhwa
Board 163
•
RAINBOW: A global, phase 3, randomized, double-blind study of ramucirumab plus paclitaxel
versus placebo plus paclitaxel in the treatment of metastatic gastric adenocarcinoma
following disease progression on first-line platinum- and fluoropyrimidine-containing
combination therapy: Results of a multiple Cox regression analysis adjusting for prognostic
factors. (Abstract 4076)
Hansjochen Wilke
Board 164
•
Association of adjuvant chemotherapy with improved survival after esophagectomy without
induction therapy for node-positive adenocarinoma. (Abstract 4077)
Paul J Speicher
Board 165
•
Chemoradiation with or without nimotuzumab in locally advanced esophageal cancer (LAEC):
A randomized phase II study (NICE trial). (Abstract 4078)
Gilberto Castro
Board 166
•
Survivin expression in peripheral blood as a prognostic marker in patients with gastric
cancer. (Abstract 4079)
Masanori Terashima
Board 167
•
Increased circulating levels of VEGF-C to predict outcome in resectable gastric cancer
patients. (Abstract 4080)
Fernando De Vita
Board 168
•
LEOPARD-II: A randomized phase II study of radiochemotherapy (RCT) with 5FU and
cisplatin plus/minus cetuximab (Cet) in unresectable locally advanced esophageal cancer
(LAEC). (Abstract 4081)
Dirk Rades
Board 169
•
Difference in outcomes among patients undergoing open versus laparoscopy-assisted
approach for gastric cancer: A multi-institutional analysis. (Abstract 4082)
Gaya Spolverato
Board 170
•
A phase II and biomarker study of an irreversible pan-human EGF receptor (HER) tyrosine
kinase inhibitor dacomitinib in patients with recurrent and/or metastatic squamous cell
carcinoma of esophagus. (Abstract 4083)
Hyo Song Kim
Board 171
•
Effect of the distribution of lymph node metastases on outcomes for trimodality-eligible
patients with esophageal and esophagogastric junction adenocarcinoma (EAC). (Abstract
4084)
Hironori Shiozaki
Board 172
•
A proprietary multi-analyte test to predict neoadjuvant treatment response for esophageal
and rectal adenocarcinoma patients. (Abstract 4085)
Sunil S. Badve
Board 173
•
Gastric cancer (GC) among California Asians: Analysis of California Cancer Registry (CCR).
(Abstract 4086)
Afsaneh Barzi
Board 174
•
A comparative study of ultrasonography and non-contrast computerized tomography of
upper abdomen as a screening tool for biliary tract cancer detection in endemic community.
(Abstract 4087)
Teerapat Ungtrakul
Board 175
•
Final analysis of European patients from the Global Investigation of Therapeutic Decisions in
Hepatocellular Carcinoma and of its Treatment with Sorafenib (GIDEON) study: Baseline
characteristics and staging systems. (Abstract 4088)
Bruno Daniele
Board 176
•
Radiogenomics of hepatocellular carcinoma: Computed tomography biomarker to predict
microvascular invasion and clinical outcome. (Abstract 4089)
Sudeep Banerjee
Board 177
•
ABC-04: A phase 1b trial of cisplatin, gemcitabine, and selumetinib in patients with advanced
biliary tract cancer. (Abstract 4090)
John A. Bridgewater
Board 178
•
Screening and 6-month surveillance interval ultrasonography in early detection of
cholangiocarcinoma in an endemic area. (Abstract 4091)
Prakongboon Sungkasubun
Board 179
•
A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced
hepatocellular carcinoma (HCC). (Abstract 4092)
Mairead Geraldine McNamara
Board 180
•
Second-line chemotherapy for advanced biliary tract cancer after failure of gemcitabine plus
platinum: Results of an AGEO multicenter retrospective study. (Abstract 4093)
Bertrand Brieau
Board 181
•
Assessment of liver dysfunction in hepatocellular carcinoma (HCC): An international
collaborative study. (Abstract 4094)
Philip James Johnson
Board 182
•
Phase 1 study of PF-03446962 (anti-ALK-1 mAb) in hepatocellular carcinoma (HCC):
Correlation of tumor and serum biomarker data with disease control. (Abstract 4095)
Matteo Simonelli
Board 183
•
Next-generation sequencing of serum microRNA (miRNA) in hepatocellular carcinoma (HCC)
patients on targeted therapy. (Abstract 4096)
Robin Kate Kelley
Board 184
•
Molecular profiling of bile duct and gallbladder cancer to identify different therapeutic
options. (Abstract 4097)
Randall F. Holcombe
Board 185
•
A phase II study of temsirolimus in previously treated advanced hepatocellular carcinoma
(HCC). (Abstract 4098)
Jasgit C. Sachdev
Board 186
•
Sorafenib with or without everolimus in patients with unresectable hepatocellular carcinoma
(HCC): A randomized multicenter phase II trial (SAKK 77/08 and SASL 29). (Abstract 4099)
Dieter Koeberle
Board 187
•
Phase Ib study of RO5137382/GC33 in combination with sorafenib in patients with advanced
hepatocellular carcinoma (HCC) (NCT00976170). (Abstract 4100)
Ghassan K. Abou-Alfa
Board 188
•
Phase II study of everolimus monotherapy as first-line treatment in advanced biliary tract
cancer: RADichol. (Abstract 4101)
Yvonne Yeung
Board 189
•
Randomized phase II trial of intravenous RO5137382/GC33 at 1600 mg every other week
and placebo in previously treated patients with unresectable advanced hepatocellular
carcinoma (HCC; NCT01507168). (Abstract 4102)
Chia-Jui Yen
Board 190
•
Final results of a phase II trial of stereotactic body radiotherapy (SBRT) in patients with
hepatocellular carcinoma (HCC) with Child-Pugh class A (CPC-A). (Abstract 4103)
Foster D Lasley
Board 191
•
Role of FDG-PET-CT (PET) in predicting outcome of advanced hepatocellular carcinoma
(aHCC) patients (pts) treated with sorafenib (SB): A prospective controlled study. (Abstract
4104)
Roberto A. Pazo Cid
Board 192
•
A phase I trial of of cixutumumab (C) (IMC-A12) and sorafenib (S) for treatment of advanced
hepatocellular carcinoma (HCC). (Abstract 4105)
Anthony B. El-Khoueiry
Board 193
•
Prognostic factors of overall survival of stage III or IV adrenocortical carcinomas (ACC): A
multicenter ENS@T study. (Abstract 4106)
Rossella Libe
Board 194
•
Progression-free survival (PFS) with lanreotide autogel/depot (LAN) in enteropancreatic NETs
patients: The CLARINET extension study. (Abstract 4107^)
Martyn E. Caplin
Board 195
•
The association between octreotide dose and tumor control in gastroenteropancreatic
neuroendocrine tumors (NETs). (Abstract 4108)
Sally C Lau
Board 196
•
Study of the gastroenteropancreatic neuroendocrine tumor (gep-net) microenvironment
beyond angiogenesis: The role of lysyl oxidase-like 2 (LOXL2). (Abstract 4109)
Jorge Barriuso
Board 197
•
Antiproliferative activity of octreotide LAR in advanced neuroendocrine tumors. (Abstract
4110)
Christos Toumpanakis
Board 198
•
Lanreotide autogel/depot (LAN) treatment for carcinoid syndrome (CS) symptoms: Patientreported outcomes (PROs) from the SYMNET study. (Abstract 4111^)
Philippe B. Ruszniewski
Board 199
•
Octreotide LAR (OCT-L) among elderly patients with stage IV neuroendocrine tumors (NETs):
A survival analysis of SEER-Medicare data. (Abstract 4112)
Chan Shen
Board 200
•
Profiling of 1,350 neuroendocrine tumors for identification of multiple potential drug targets.
(Abstract 4113)
Igor A. Astsaturov
Board 201
•
Defining the neuroendocrine tumors landscape: A 15-year population-based analysis of
incidence, outcomes, and therapies. (Abstract 4114)
Julie I. Hallet
Board 202
•
Retrospective analysis of CA19-9 decrease in patients with metastatic pancreatic carcinoma
(MPC) treated with FOLFIRINOX or gemcitabine (gem) in a randomized phase III study
(ACCORD11/PRODIGE4). (Abstract 4115)
Marie Robert
Board 203
•
A phase I trial of the ?-secretase inhibitor (GSI) MK-0752 in combination with gemcitabine in
patients with pancreatic ductal adenocarcinoma (PDAC). (Abstract 4116)
Natalie Cook
Board 204
•
Statin use and risk of pancreatic cancer: Results from a large clinic-based case-control study.
(Abstract 4117)
Evan J. Walker
Board 205
•
Serum procarboxypeptidase combined with CA19-9 and accuracy of detection of pancreatic
cancer. (Abstract 4118)
Michelle A. Orlowski
Board 206
•
Treatment, outcomes, and clinical trial participation in very elderly patients (pts) with
metastatic pancreas cancer (mPC). (Abstract 4119)
Daneng Li
Board 207
•
A phase II study of perioperative therapy for patients with resectable and borderlineresectable pancreatic adenocarcinoma. (Abstract 4120)
Andrew L. Coveler
Board 208
•
Predictive cytokine biomarkers for survival in patients with advanced pancreatic cancer
randomized to sequential chemoimmunotherapy comprising gemcitabine and capecitabine
(GemCap) followed by the telomerase vaccine GV1001 compared to concurrent
chemoimmunotherapy in the TeloVac phase III trial. (Abstract 4121)
John P. Neoptolemos
Board 209
•
Gemcitabine(G)/erlotinib(E) versus gemcitabine/erlotinib/capecitabine(C) in the first-line
treatment of patients with metastatic pancreatic cancer (mPC): Efficacy and safety results of
a phase IIb randomized study from the Spanish TTD Collaborative Group. (Abstract 4122)
Manuel Benavides
Board 210
•
Nab-paclitaxel (nab-P) combined with FOLFOX for advanced pancreatic cancer: A phase I
study. (Abstract 4123)
Howard Safran
Board 211
•
Hent1 expression in patients with pancreatic cancer treated with gemcitabine after curative
intended resection: Results from the CONKO-001 trial. (Abstract 4124)
Marianne Sinn
Board 212
•
A UGT1A1 genotype-guided dosing study of modified FOLFIRINOX (mFOLFIRINOX) in
previously untreated patients (pts) with advanced gastrointestinal malignancies. (Abstract
4125)
Manish Sharma
Board 213
•
Impact of gemcitabine (Gem)- or capecitabine (Cape)-based chemoradiation (CRT) on
health-related quality of life (HRQL) in patients with locally advanced pancreatic cancer
(LAPC): Outcomes from the randomized phase II SCALOP trial. (Abstract 4126)
Somnath Mukherjee
Board 214
•
Association of recurrence patterns following resection of pancreatic adenocarcinoma with
overall survival. (Abstract 4127)
Jin He
Board 215
•
Effect of molecular genotyping to predict outcomes in patients with metastatic pancreatic
cancer. (Abstract 4128)
Jason Edward Faris
Board 216
•
Phase II study of the MEK inhibitor refametinib (BAY 86-9766) in combination with
gemcitabine in patients with unresectable, locally advanced, or metastatic pancreatic cancer:
Biomarker results. (Abstract 4129)
Hanno Riess
Board 217
•
Pharmacogenomic modeling of pancreatic cancer (PDAC) for prediction of chemotherapy
response and resistance in second-line treatment setting. (Abstract 4130)
Kenneth H. Yu
Board 218
•
Patterns of chemotherapy (CT) use in a population-based US-wide cohort of patients (pts)
with metastatic pancreatic cancer (MPC). (Abstract 4131)
Thomas Adam Abrams
Board 219
•
Use of first-line chemotherapy for advanced pancreatic cancer: FOLFIRINOX versus
gemcitabine-based therapy. (Abstract 4132)
Thomas H. Cartwright
Board 220
•
A novel biomarker panel examining response to gemcitabine (G) with or without erlotinib (E)
for pancreatic cancer (PA) therapy in NCIC clinical trials group PA.3. (Abstract 4133)
David Shultz
Board 222
•
A phase 2 trial of low-dose multiagent chemotherapy with gemcitabine, docetaxel,
capecitabine, and cisplatin (GTX-C) in subjects with metastatic pancreatic cancer. (Abstract
4135)
Dung T. Le
Board 223
•
Multiplatform molecular profiling of 2,400 pancreatic adenocarcinomas to identify targets for
therapeutic intent. (Abstract 4136)
Sherri Z. Millis
Board 224
•
Infiltrating neutrophils and malignant progression in intraductal papillary mucinous
neoplasms (IPMN): An opportunity for identification of high-risk disease. (Abstract 4137)
Eran Sadot
Board 225
•
FG-3019, a human monoclonal antibody to connective tissue growth factor (CTGF), with
gemcitabine/erlotinib (G/E) in patients with locally advanced or metastatic pancreatic ductal
adenocarcinoma (PDAC). (Abstract 4138)
Vincent J. Picozzi
Board 226
•
A phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole
abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and
peritoneal carcinomatosis. (Abstract 4139)
Kim Anna Reiss
Board 227
•
Cancer of unknown primary in adolescents and young adults: Clinicopathologic features,
prognostic factors, and survival outcomes. (Abstract 4140)
Kanwal Pratap Singh Raghav
Board 228
•
Molecular classification of ampullary adenocarcinoma: Comparative prognostic performance
of the 92-gene assay versus histomolecular analysis. (Abstract 4141)
Aaron Schueneman
Board 229
•
Comprehensive genomic profiling of gallbladder adenocarcinoma and frequent genomicderived targets of therapy. (Abstract 4142)
Phil Stephens
Board 230
•
Potential actionable targets in appendiceal cancer detected by immunohistochemistry (IHC),
fluorescent in situ hybridization (FISH), and mutational analysis. (Abstract 4143)
Erkut Borazanci
Board 231A
•
NeoSCOPE: A phase II randomized comparison of neoadjuvant oxaliplatin/capecitabine
versus carboplatin/paclitaxel-based chemoradiation in operable esophageal cancer. (Abstract
TPS4144)
Thomas Crosby
Board 231B
•
ICORG 10-14: Neo-AEGIS: A randomized clinical trial of neoadjuvant and adjuvant
chemotherapy (modified MAGIC regimen) versus neoadjuvant chemoradiation (CROSS
protocol) in adenocarcinoma of the esophagus and esophagogastric junction. (Abstract
TPS4145)
Niamh Keegan
Board 232A
•
A phase III clinical trial of neoadjuvant chemoradiotherapy followed by surgery versus
surgery alone for locally advanced squamous cell carcinoma of the esophagus. (Abstract
TPS4146)
Hong Yang
Board 232B
•
JAGUAR: A randomized phase II study of the AKT inhibitor ipatasertib (GDC-0068) versus
placebo in combination with mFOLFOX6 chemotherapy in patients (pts) with locally advanced
or metastatic HER2-negative gastric (G) or gastroesophageal junction (GEJ)
adenocarcinoma. (Abstract TPS4147)
Yung-Jue Bang
Board 233A
•
Randomized open-label phase 2 study of MM-111 and paclitaxel (PTX) with trastuzumab
(TRAS) in patients with HER2-expressing carcinomas of the distal esophagus,
gastroesophageal (GE) junction, and stomach who have failed front-line metastatic or locally
advanced therapy. (Abstract TPS4148)
Crystal Shereen Denlinger
Board 233B
•
Randomized phase III study of gemcitabine plus S-1 combination therapy versus
gemcitabine plus cisplatin combination therapy in advanced biliary tract cancer: A
Japan Clinical Oncology Group study (JCOG1113). (Abstract TPS4149)
Chigusa Morizane
Board 234A
•
Phase 3 randomized, double-blind, controlled study of cabozantinib (XL184) versus placebo
in subjects with hepatocellular carcinoma who have received prior sorafenib (CELESTIAL;
NCT01908426). (Abstract TPS4150)
Ghassan K. Abou-Alfa
Board 234B
•
A multicenter, randomized, phase Ib/II trial of the oral c-Met inhibitor MSC2156119J as
monotherapy versus sorafenib in Asian patients with MET-positive (MET+) advanced
hepatocellular carcinoma (HCC) and Child-Pugh Class A liver function. (Abstract TPS4151)
Shukui Qin
Board 235A
•
A randomized controlled trial comparing modified gemcitabine plus oxaliplatin (mGEMOX) to
gemcitabine plus cisplatin in management of unresectable gall bladder cancer. (Abstract
TPS4152)
Atul Sharma
Board 235B
•
A multicenter, open-label, phase 3 trial to compare the efficacy and safety of lenvatinib
(E7080) versus sorafenib in first-line treatment of subjects with unresectable hepatocellular
carcinoma. (Abstract TPS4153)
Richard S. Finn
Board 236A
•
Sorafenib in combination with local microtherapy guided by gadolinium-EOB-DTPA enhanced
MRI in patients with inoperable hepatocellular carcinoma (SORAMIC). (Abstract TPS4154)
Jens Ricke
Board 236B
•
OPTIMIS: An international observational study to assess the use of sorafenib after
transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC).
(Abstract TPS4155)
Markus Peck-Radosavljevic
Board 237A
•
RESORCE: An ongoing randomized, double-blind, phase III trial of regorafenib (REG) in
patients with hepatocellular carcinoma (HCC) progressing on sorafenib (SOR). (Abstract
TPS4156^)
Jordi Bruix
Board 237B
•
A phase II trial of cabozantinib in patients with carcinoid and pancreatic neuroendocrine
tumors. (Abstract TPS4157)
Jason Edward Faris
Board 238A
•
NEONAX: Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for
resectable pancreatic cancer—A phase II study of the AIO Pancreatic Cancer Group.
(Abstract TPS4158)
Thomas Jens Ettrich
Board 238B
•
A phase 2b, randomized, controlled, multicenter, open-label study of the efficacy and
immune response of GVAX pancreas vaccine and CRS-207 compared to chemotherapy or to
CRS-207 alone in adults with previously treated metastatic pancreatic adenocarcinoma
(ECLIPSE Study). (Abstract TPS4159)
Dung T. Le
Board 239A
•
A phase 2, multicenter study of FOLFIRINOX followed by ipilimumab in combination with
allogeneic GM-CSF transfected pancreatic tumor vaccine in the treatment of metastatic
pancreatic cancer. (Abstract TPS4160)
Rina Khatri Patel
Board 239B
•
A phase 2, open-label study of rucaparib in patients with pancreatic cancer and a known
deleterious BRCA mutation. (Abstract TPS4161)
Susan M. Domchek
Board 240A
•
APACT: A phase 3 randomized, open-label, multicenter trial evaluating the use of adjuvant
nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients (pts) with surgically
resected ductal pancreatic adenocarcinoma (PDA). (Abstract TPS4162^)
Margaret A. Tempero
Board 240B
•
A randomized, double-blinded, placebo-controlled phase II trial of gemcitabine (gem) plus
nab-paclitaxel (n-pac) combined with OGX-427 (apatorsen) or placebo in patients (pts) with
metastatic pancreatic cancer (mPaCa): The Rainier Trial. (Abstract TPS4163)
Johanna C. Bendell
Session Title: Gynecologic Cancer
Session Type: General Poster Session
Track: Gynecologic Cancer
Time: 8:00 AM - 11:45 AM
Location: S Hall A2
Board 319
•
Frequent use of complex surgeries and survival outcomes in ovarian cancer patients: A
propensity score analysis from the Korean Gynecologic Oncology Group. (Abstract 5537)
Sokbom Kang
Board 320
•
Carboplatin hypersensitivity reaction (HSR): Analysis of safety and success of a short
outpatient platinum rechallenge protocol (PRP) in epithelial ovarian carcinoma (EOC).
(Abstract 5538)
Los Vincent Newton
Board 321
•
Female germ cell tumors (GCT): The Memorial Sloan Kettering Cancer Center (MSKCC)
experience. (Abstract 5539)
Jane Lowe Meisel
Board 322
•
Independent radiologic review of AURELIA, a phase 3 trial of bevacizumab (BV) plus
chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC). (Abstract
5540^)
Amreen Husain
Board 323
•
Phase I trial of pegylated liposomal doxorubicin in combination with BIBF 1120 (nintedanib)
in platinum-resistant ovarian cancer: Hoosier Oncology Group GYN10-149. (Abstract 5541^)
Maria Creselda deLeon
Board 324
•
Expression of angiopoietin (Ang) pathway markers and their relationship to progression-free
survival (PFS) in TRINOVA-1. (Abstract 5542)
Andres Poveda
Board 325
•
Adjuvant radiation for patients (pts) with high-grade serous ovarian cancer (HGSC) and Tcell infiltration. (Abstract 5543)
Aalok Kumar
Board 326
•
Relative influence of factors determining a woman’s preference for treatment options in
ovarian cancer. (Abstract 5544)
Laura Jean Havrilesky
Board 327
•
Pretreatment serum mitochondrial DNA (mtDNA) correlates with shorter progression-free
and overall survival in patients with advanced ovarian cancer (OC). (Abstract 5545)
Kassondra S. Grzankowski
Board 328
•
A randomized phase II trial of bevacizumab (BV) plus oral everolimus (EV) versus
bevacizumab alone for recurrent or persistent epithelial ovarian (EOC), fallopian tube (FTC),
or primary peritoneal cancer (PPC). (Abstract 5546)
William P. Tew
Board 329
•
High-dose chemotherapy (HDCT) for recurrent ovarian germ cell tumors (OGCT): Indiana
University (IU) experience. (Abstract 5547)
Natraj Reddy Ammakkanavar
Board 330
•
Analysis of outcomes in patients (pts) with recurrent ovarian clear cell carcinoma (ROCCC):
Time to rethink our approach to treatment. (Abstract 5548)
David Shao Peng Tan
Board 331
•
Duration of systemic therapy for ovarian cancer: A systematic review and meta-analysis.
(Abstract 5549)
Adnan Nagrial
Board 332
•
Protein network mapping of glucose metabolism in ovarian cancer. (Abstract 5550)
Maria Isabella Sereni
Board 333
•
Trabectedin plus pegylated liposomal doxorubicin (PLD) prior to subsequent platinum
chemotherapy in patients with platinum-resistant (PR) recurrent ovarian cancer (ROC):
Results from OVA-301 follow-up. (Abstract 5551)
Nicoletta Colombo
Board 334
•
Pertuzumab (P) plus chemotherapy (CT) for platinum-resistant ovarian cancer: Safety run-in
results of the PENELOPE trial. (Abstract 5552)
Antonio Gonzalez-Martin
Board 335
•
A phase II study of intermittent sorafenib with bevacizumab (B) in B-naive and prior Bexposed epithelial ovarian cancer (EOC) patients. (Abstract 5553)
Jung-min Lee
Board 336
•
Surgical site infection after primary debulking surgery for epithelial ovarian cancer: Predictors
and impact on survival. (Abstract 5554)
Christine Wei-Yin Tran
Board 337
•
Phase I/Ib clinical and immunologic assessment of immunotherapeutic vaccine, DPX-Survivac
in women with ovarian, Fallopian tube, or peritoneal cancer (OC). (Abstract 5555)
Michelle Wilson
Board 338
•
Independent review of AGO-OVAR 12, a GCIG/ENGOT-Intergroup phase III trial of
nintedanib (N) in first-line therapy for ovarian cancer (OC). (Abstract 5556^)
Gunnar Kristensen
Board 339
•
Inhibition of MEK1 increases carboplatin sensitivity in ovarian cancer. (Abstract 5557)
Balazs Gyorffy
Board 340
•
Ketoconazole as inhibitor of the enzyme CYP17 in locally advanced or disseminated
granulosa cell tumors of the ovary (the GreKo I study) (gethi 11-03). (Abstract 5558)
Laia Garrigos
Board 341
•
Comparison of recurrent and nonrecurrent ovarian and uterine cancer patients undergoing
adjuvant folate receptor vaccine therapy. (Abstract 5559)
Erika J Schneble
Board 342
•
What factors influence advanced ovarian cancer patient (AOC pt) outcomes to phase I trial
treatments? (Abstract 5560)
Timothy Anthony Yap
Board 343
•
Prognostic significance of urinary neopterin in ovarian cancer a study of the Austrian
Gynecologic Oncology Group. (Abstract 5561)
Christian Marth
Board 344
•
Surgical staging and its prognostic impact on patients with borderline ovarian tumors (BOT):
A subanalysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT study.
(Abstract 5562)
Fabian Trillsch
Board 345
•
Genome-wide association study for identification of candidate SNPs associated with
carboplatin and paclitaxel clearance in ovarian cancer patients. (Abstract 5563)
Bo Gao
Board 346
•
A phase II trial on the combination of bevacizumab and irinotecan in recurrent ovarian
cancer. (Abstract 5564)
Huichung Tina Ling
Board 347
•
Temsirolimus in women with platinum-resistant ovarian cancer or advanced/recurrent
endometrial cancer: A multicenter phase II trial of the AGO Study Group (AGO-GYN 8).
(Abstract 5565)
Guenter Emons
Board 348
•
Weekly administration of bevacizumab, eribulin, and oxalilplatin in patients with platinumresistant and refractory ovarian carcinomas: A phase II study. (Abstract 5566)
Yuji Ikeda
Board 349
•
Microscopic residual carcinoma at interval debulking surgery after neoadjuvant
chemotherapy in patients with IIIc/IV Müllerian carcinoma. (Abstract 5567)
Kyoko Nishikimi
Board 350
•
Phase II study of gemcitabine and vinorebline in patients with persistent or recurrent
platinum-resistant ovarian or primary peritoneal cancer: A study of the Korean Cancer Study
Group. (Abstract 5568)
Sook Hee Hong
Board 351
•
Evaluation of the hematologic safety of same day versus standard administration of
pegfilgrastim in gynecology oncology patients undergoing platinum-based chemotherapy.
(Abstract 5569)
Caroline C Billingsley
Board 352
•
Molecular analysis of non-epithelial ovarian cancer by histologic subtype. (Abstract 5570)
Maise Al Bakir
Board 353
•
Relationship of pharmacokinetics (PK), toxicity, and initial evidence of clinical activity with
IMGN853, a folate receptor alpha (FRa) targeting antibody drug conjugate in patients (Pts)
with epithelial ovarian cancer (EOC) and other FRa-positive solid tumors. (Abstract 5571)
Kathleen N. Moore
Board 354
•
Impact of neoadjuvant chemotherapy cycles prior to interval surgery in patients with
advanced epithelial ovarian cancer. (Abstract 5572)
Pierre-Emmanuel Colombo
Board 355
•
Blocking and randomization to improve molecular biomarker discovery. (Abstract 5573)
Li-Xuan Qin
Board 356
•
Genome-wide association study (GWAS) of pazopanib efficacy and safety in patients with
ovarian cancer who have not progressed following first-line standard therapy. (Abstract
5574)
Giovanni Scambia
Board 357
•
Frequency and timing of thoracic tumor spread in 198 consecutive patients with advancedstage high-grade serous ovarian cancer (HGSC). (Abstract 5575)
Atul B. Shinagare
Board 358
•
Effect of intraperitoneal chemotherapy on survival for ovarian cancer in clinical practice and
frequency of use. (Abstract 5576)
Alexi A. Wright
Board 359
•
Identification of predictive factors of response to the BH3-mimetic molecule ABT-737: An ex
vivo experiment in human serous ovarian carcinoma. (Abstract 5577)
Stephanie Lheureux
Board 360
•
Molecular profiling in gynecologic cancer and matched targeted therapy: A step toward
improving personalized medicine. (Abstract 5578)
Ana C. Garrido-Castro
Board 361
•
Expression III: Final results of an international survey in eight European countries with 1,830
patients—What are the differences in expectations from their doctors and therapy
management of patients with primary and recurrent ovarian cancer? (NOGGO/ENGOT-ov4
study). (Abstract 5579)
Gülten Oskay-Özcelik
Board 362
•
Phase II trial of oxaliplatin and 5-FU in patients (pts) with platinum-resistant recurrent (PRR)
ovarian carcinoma (OVCA). (Abstract 5580)
Joseph N. Kerger
Board 363
•
Phase II clinical trial evaluating CRLX101 in recurrent ovarian, tubal, and peritoneal cancer.
(Abstract 5581)
Carolyn N. Krasner
Board 364
•
Early-stage ovarian cancer: Clinical outcome and analysis of prognostic factors—Results from
a prospective registry of GEICO (Spanish Group for Ovarian Cancer Research). (Abstract
5582)
Belen Ojeda
Board 365
•
Central pathology review of early-stage ovarian carcinoma: Description and correlation with
follow-up—A study by the Spanish Group for Ovarian Cancer Research (GEICO). (Abstract
5583)
Jose Antonio Lopez-Guerrero
Board 366
•
Autoantibodies (AA) against the EGF/EGFR and VEGFA/VEGFR1 as prognosticator in
epithelial ovarian cancer (EOC) patients. (Abstract 5584)
Elena Ioana Braicu
Board 367
•
Pharmacodynamic biomarkers from phase II study of the SMAC (Second MitochondrialDerived Activator of Caspases)-mimetic birinapant (TL32711; NSC 756502) in relapsed
platinum-resistant epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or
fallopian tube cancer (FTC) (NCT01681368). (Abstract 5585)
Kristen Paige Bunch
Board 368
•
Current practice and use of neoadjuvant therapy in ovarian cancer in the National Cancer
Database. (Abstract 5586)
Angela Jain
Board 369
•
Patterns of care and overall survival in the Medicare ovarian cancer population. (Abstract
5587)
Larissa Meyer
Board 370
•
Primary versus interval debulking surgery and the risk to induce platinum resitance. (Abstract
5588)
Alexandre Andre Balieiro Anastacio da Costa
Board 371
•
Laparoscopic versus laparotomic cytoreduction in patients with advanced ovarian cancer
submitted to NACT: Evaluation of oncologic safety. (Abstract 5589)
Giovanni Favero
Board 372
•
Randomized phase II trial comparing IG-001 versus paclitaxel against first-line advanced
ovarian cancer. (Abstract 5590)
Vuong N. Trieu
Board 373
•
The impact of tumor molecular profile-directed treatment on survival in recurrent ovarian
cancer. (Abstract 5591)
Kate Eleanor Oliver
Board 374
•
A phase II study of medroxyprogesterone acetate plus metformin as fertility-sparing
treatment for atypical endometrial hyperplasia and endometrial cancer. (Abstract 5592)
Akira Mitsuhashi
Board 375
•
Phase 2 clinical trial of ixabepilone in metastatic cervical carcinoma. (Abstract 5593)
Mauricio Emmanuel Burotto Pichun
Board 376
•
Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1
(ALK1) receptor-fusion protein, for treatment of recurrent/persistent endometrial cancer:
GOG-0229N. (Abstract 5594)
Vicky Makker
Board 377
•
A cohort study of gastric-type adenocarcinoma (GAS) of the uterine cervix: Multi-institutional
study by Gynecologic Cancer Study Group of the Japan Clinical Oncology Group (JCOG).
(Abstract 5595)
Shin Nishio
Board 378
•
Obesity and robotic surgery: Associated ventilator indices and perioperative pulmonary
complications. (Abstract 5596)
Weiya Zhang Wysham
Board 379
•
Pelvic sentinel lymph node status and risk of aortic nodal metastasis in patients with
endometrial cancer. (Abstract 5597)
Robert W. Holloway
Board 380
•
Systemic chemotherapy compared with radiation therapy as adjuvant therapy after radical
surgery in high-risk stage IB-IIB cervical adenocarcinoma. (Abstract 5598)
Toshiyuki Seki
Board 381
•
Endometrial cancer survivors: What is their knowledge about obesity? (Abstract 5599)
Leslie Horn Clark
Board 382
•
Feasibility of circulating tumour cell (CTC) enumeration and molecular profiling (MP) as a
biomarker in advanced endometrial cancer (aEC). (Abstract 5600)
Charlotte Rose Lemech
Board 383
•
Prediagnostic diabetes, body mass index, and survival of endometrial cancer: A prospective
study. (Abstract 5601)
Kristina Lindemann
Board 384
•
The effect of raloxifene hydrochloride for the prevention of health care problems of patients
who underwent surgeries for endometrial cancer: A multicenter clinical trial. (Abstract 5602)
Koji Nakamura
Board 385
•
Effects of temozolomide and bevacizumab in patients with pretreated relapsed uterine
leiomyosarcoma. (Abstract 5603)
Naoki Sasaki
Board 386
•
Carboplatin-based chemoradiotherapy in advanced cervical cancer: An alternative to
cisplatin-based regimen? (Abstract 5604)
Ana Morais Sebastião
Board 387
•
Population-based analysis of mortality over time in endometrial cancer. (Abstract 5605)
Michael Joseph Eblan
Board 388
•
Absence of occult micrometastases in histologically negative lymph nodes among patients
with distant recurrent endometrial cancer. (Abstract 5606)
Amanda Lynn Jackson
Board 389
•
A retrospective analysis of the relationship between diabetes, metformin use, and survival in
advanced endometrial cancer patients treated with chemotherapy. (Abstract 5607)
Obiageli Chinaka Ezewuiro
Board 390
•
Resection margin and locoregional control in vulvar cancer: A subset analysis of the AGO
CARE-1 multicenter study. (Abstract 5608)
Linn Lena Woelber
Board 391
•
Evaluation of the diagnostic accuracy of cervical biopsy and determination of associated risk
factors for positive margin status in recurrent cervical dysplasia after leep or conization.
(Abstract 5609)
Diana Peta-gay English
Board 392
•
ADXS11-001 immunotherapy targeting HPV-E7: Final results from a phase 2 study in Indian
women with recurrent cervical cancer. (Abstract 5610)
Partha Basu
Board 393A
•
ICON8: An international randomized trial comparing two dose-dense regimens, 3-weekly
carboplatin plus weekly paclitaxel (CwT), and weekly carboplatin-paclitaxel (wCwT), to
standard 3-weekly treatment in women with newly diagnosed ovarian, fallopian tube, and
primary peritoneal cancer. (Abstract TPS5611)
Jane Hook
Board 393B
•
A phase 3 study of trabectedin (T) plus pegylated liposomal doxorubicin (PLD) versus PLD
for treatment of advanced-relapsed epithelial ovarian, primary peritoneal, or fallopian tube
cancer. (Abstract TPS5612)
Robert L. Coleman
Board 394A
•
PENELOPE/AGO-OVAR 2.20: A double-blind placebo (PLA)-controlled randomized phase III
ENGOT trial evaluating chemotherapy (CT) with or without pertuzumab (P) for platinumresistant ovarian cancer. (Abstract TPS5613)
Christian Kurzeder
Board 394B
•
A randomized, open-label, phase II study assessing the efficacy and the safety of
bevacizumab in neoadjuvant therapy in patients with FIGO stage IIIc/IV ovarian, tubal, or
peritoneal adenocarcinoma, initially unresectable. (Abstract TPS5614)
Roman Rouzier
Board 395A
•
Measuring subjective improvement of palliative chemotherapy in women with platinumresistant or -refractory ovarian cancer: The symptom benefit study (ANZGOG-0701/
GCIG/PoCoG). (Abstract TPS5615)
Michael Friedlander
Board 395B
•
SOLO1 and SOLO2: Randomized phase III trials of olaparib in patients (pts) with ovarian
cancer and a BRCA1/2 mutation (BRCAm). (Abstract TPS5616)
Kathleen N. Moore
Board 396A
•
A phase 2 study of live-attenuated listeria monocytogenes cancer immunotherapy (ADXS11001) in the treatment of persistent or recurrent cancer of the cervix (GOG-0265). (Abstract
TPS5617)
Warner King Huh
Board 396B
•
The MEK Inhibitor in Low-Grade Serous Ovarian Cancer (??L?)/ENGOT-ov11 study: A
multinational, randomized, open-label phase 3 study of binimetinib (MEK162) versus
physician’s choice chemotherapy in patients with recurrent or persistent low-grade serous
carcinomas of the ovary, fallopian tube, or primary peritoneum. (Abstract TPS5618)
Bradley J. Monk
Board 397A
•
ARIEL 2/3: An integrated clinical trial program to assess activity of rucaparib in ovarian
cancer and to identify tumor molecular characteristics predictive of response. (Abstract
TPS5619)
Elizabeth M. Swisher
Board 397B
•
Phase II study of oral ENMD-2076 administered to patients with ovarian clear cell carcinoma:
A trial of the Princess Margaret Phase II Consortium. (Abstract TPS5620)
Cristina Martin-Lorente
Board 398A
•
The PARAGON phase 2 trial of anastrozole in women with potentially hormone responsive
recurrent/metastatic gynecologic neoplasms. (Abstract TPS5621)
Katrin Marie Sjoquist
Board 398B
•
Double-blind, placebo-controlled, randomized, phase 2 study to evaluate the efficacy and
safety of maintenance therapy with anti-TA-MUC1 monoclonal antibody PankoMab after
chemotherapy in patients with recurrent epithelial ovarian carcinoma. (Abstract TPS5622)
Jonathan A. Ledermann
Board 399A
•
A first-in-human dose escalation and dose-finding phase I/II trial of IMAB027 in patients with
recurrent advanced ovarian cancer (GM-IMAB-002-01). (Abstract TPS5623)
Dirk Jaeger
Board 399B
•
Randomized phase II study of 3 versus 6 courses of neoadjuvant carboplatin-paclitaxel
chemotherapy in stage IIIC or IV epithelial ovarian cancer. (Abstract TPS5624)
Claudio Zamagni
Board 400A
•
A phase 3 randomized double-blind trial of maintenance with niraparib versus placebo in
patients with platinum-sensitive ovarian cancer (ENGOT-OV16/NOVA trial). (Abstract
TPS5625)
Ursula Matulonis
Board 400B
•
Open-label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced
nonresectable granulosa cell ovarian tumors: The GREKO II study. (Abstract TPS5626)
Alicia Hurtado
Board 401A
•
The REZOLVE phase II trial to evaluate the safety and potential palliative benefit of
intraperitoneal bevacizumab in patients with symptomatic ascites due to advanced,
chemotherapy-resistant ovarian cancer. (Abstract TPS5627)
Katrin Marie Sjoquist
Board 401B
•
A phase III trial of postoperative chemotherapy or no further treatment for patients with
node-negative stage I-II intermediate- or high-risk endometrial cancer. ENGOT-EN2DGCG/EORTC 55102. (Abstract TPS5628)
Mansoor Raza Mirza
Board 402A
•
Phase II study of XL184 (cabozantinib) in recurrent or metastatic endometrial cancer: A trial
of the PMH, Chicago, and California Phase II Consortia. (Abstract TPS5629)
Michelle Wilson
Board 402B
•
ZoptEC: Phase III study of zoptarelin doxorubicin (AEZS-108) in platinum-taxane pretreated
endometrial cancer (Study AEZS-108-050). (Abstract TPS5630^)
David S. Miller
Board 403A
•
A phase 1/2 study of ipilimumab in women with metastatic or recurrent HPV-related cervical
carcinoma: A study of the Princess Margaret and Chicago N01 Consortia. (Abstract TPS5631)
Stephanie Lheureux
Board 403B
•
A phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment
for locally advanced cervical cancer compared to chemoradiation alone: Outback
(ANZGOG0902/GOG0274/RTOG1174). (Abstract TPS5632)
Linda R. Mileshkin
Session Title: Melanoma/Skin Cancers
Session Type: General Poster Session
Track: Melanoma/Skin Cancers
Time: 8:00 AM - 11:45 AM
Location: S Hall A2
Board 241
•
Incidence and survival of dermatofibrosarcoma protuberans in the United States. (Abstract
9037)
Kathryn L Kreicher
Board 242
•
Prognostic significance of PD-L1 expression, angiogenesis, and hypoxia in melanoma brain
metastases (MBM): A histopathologic analysis. (Abstract 9038)
Stergios J. Moschos
Board 243
•
The FAM-GEM-1 study: Frequency and characteristics of familial melanoma in Spain.
(Abstract 9039)
Ivan Marquez Rodas
Board 244
•
Effect of restoration of microRNA-18a on improvement of imatinib therapy on secondary
imatinib-resistance metastatic melanoma. (Abstract 9040)
Jun Guo
Board 245
•
Intralesional treatment of stage III metastatic melanoma patients with L19-IL2: Clinical and
systemic immunological responses. (Abstract 9041^)
Dario Neri
Board 246
•
Incidence and characteristics of melanoma brain metastases appearing during vemurafenib
treatment. (Abstract 9042)
Lucie Peuvrel
Board 247
•
Landscape of genetic alterations in patients with metastatic uveal melanoma. (Abstract
9043)
Sophie Piperno-Neumann
Board 248
•
A pilot trial of hu14.18-IL2 in patients with completely resectable recurrent stage III or stage
IV melanoma. (Abstract 9044)
Mark R. Albertini
Board 249
•
Final overall survival from a phase 3 trial of nab-paclitaxel versus dacarbazine (DTIC) in
chemotherapy-naive patients with metastatic melanoma. (Abstract 9045)
Evan Hersh
Board 250
•
Clinical utility of serum miRNAs for the prediction and early detection of recurrence in
melanoma patients. (Abstract 9046)
Nathaniel H. Fleming
Board 251
•
Biochemotherapy with interleukin-2 for metastatic melanoma: Long-term results in 100
patients. (Abstract 9047)
David R. Minor
Board 252
•
microRNA (miRNA) expression profiling predicts clinical outcome of carboplatin/paclitaxelbased therapy (CP) in metastatic melanoma (MM) treated on the intergroup trial E2603.
(Abstract 9048)
Liza Cosca Villaruz
Board 253
•
Role of platinum-based chemotherapy for Merkel cell tumor in adjuvant and metastatic
settings. (Abstract 9049)
Shailesh R. Satpute
Board 254
•
Randomized, double-blind phase II trial of NY-ESO-1 ISCOMATRIX vaccine and ISCOMATRIX
adjuvant alone in patients with resected stage IIc, III, or IV malignant melanoma. (Abstract
9050)
Jonathan S. Cebon
Board 255
•
A phase 1b dose-escalation study of BYL719 plus binimetinib (MEK162) in patients with
selected advanced solid tumors. (Abstract 9051)
Dejan Juric
Board 256
•
Analysis of recurrence patterns in acral versus non-acral melanoma: Should histologic
subtype influence treatment guidelines? (Abstract 9052)
Priyanka Gumaste
Board 257
•
Phase I/II study of weekly LOC-paclitaxel (LOC-pac) injection in patients (pts) with
metastatic melanoma (MM). (Abstract 9053)
Rodabe Navroze Amaria
Board 258
•
Improved median overall survival (OS) in patients with metastatic melanoma (mM) treated
with high-dose (HD) IL-2: Analysis of the PROCLAIM 2007-2012 national registry. (Abstract
9054)
Gregory A. Daniels
Board 259
•
Tumor-infiltrating lymphocytes (TILs) and expression of PD-L1 in melanoma brain
metastases (BM). (Abstract 9055)
Anna Sophie Berghoff
Board 260
•
Ipilimumab in acral melanoma: A retrospective review. (Abstract 9056)
Douglas Buckner Johnson
Board 261
•
Vitamin D level at diagnosis and its variation during follow-up as prognostic factor of
cutaneous melanoma. (Abstract 9057)
Philippe Saiag
Board 262
•
Dissecting the effect of age on immune response in melanoma patients. (Abstract 9058)
Nathaniel H. Fleming
Board 263
•
Clinicopathologic characteristics and management trends of cutaneous melanoma among
older patients: A National Cancer Data Base (NCDB) analysis. (Abstract 9059)
Vijaya Raj Bhatt
Board 264
•
Is transhepatic chemoembolization with CPT-11 charged microbeads in combination with
systemic fotemustine (f-TACE) effective in uveal melanoma liver metastases? A retrospective
analysis of 127 consecutive patients. (Abstract 9060)
Sara Valpione
Board 265
•
Vemurafenib treatment in patients with BRAF-mutated melanoma failing MEK inhibition with
trametinib. (Abstract 9061)
Helen Gogas
Board 266
•
Effect of the BRAF inhibitor LGX818 on endoplasmic reticulum stress and sensitivity of NRASmutant melanoma cells to the MEK inhibitor binimetinib. (Abstract 9062)
Friedegund Elke Meier
Board 267
•
Effect of pregnant sera and a pregnancy-associated metalloproteinase (PAPP-A) on
melanoma in vitro and in vivo: Insights into melanoma progression during pregnancy and
potential new therapeutic targets. (Abstract 9063)
Prashanth Prithviraj
Board 268
•
Is extensive lymphadenectomy necessary for regional control of stage III cutaneous
melanoma? (Abstract 9064)
Manabu Fujita
Board 269
•
A comparison of cutaneous melanoma patients who recur following a negative sentinel
lymph node biopsy to those with a positive sentinel lymph node biopsy. (Abstract 9065)
Edward L Jones
Board 270
•
A randomized phase II study of ipilimumab (IPI) with carboplatin and paclitaxel (CP) in
patients with unresectable stage III or IV metastatic melanoma (MM). (Abstract 9066)
Rahima Jamal
Board 271
•
Predictive importance of ulceration on the efficacy of adjuvant interferon-a (IFN): An
individual patient data (IPD) meta-analysis of 15 randomized trials in more than
7,500 melanoma patients (pts). (Abstract 9067)
Stefan Suciu
Board 273
•
Detection of BRAF mutations in the plasma of melanoma patients as an early marker of
treatment efficiency. (Abstract 9069)
Marc G. Denis
Board 274
•
RAGE ligand S100A8/A9 as a novel prognostic biomarker for high-risk melanoma patients.
(Abstract 9070)
Christoffer Gebhardt
Board 275
•
Adjuvant therapy with pegylated interferon alfa-2a (PEG-IFN) versus low-dose interferon
alfa-2a (IFN) in patients with malignant melanoma in stages IIa(T3a): IIIb (AJCC 2002)—
Decog-trial. (Abstract 9071)
Thomas K. Eigentler
Board 276
•
Preclinical testing supports combined BET and BRAF inhibition as a promising therapeutic
strategy for melanoma. (Abstract 9072)
Luca Paoluzzi
Board 277
•
The Memorial Sloan Kettering Cancer Center (MSKCC) experience of systemic therapy in
mucosal melanoma. (Abstract 9073)
Christiana Bitas
Board 278
•
Assessment of overall survival from time of metastastasis in mucosal, uveal, and cutaneous
melanoma. (Abstract 9074)
Michael Andrew Postow
Board 279
•
Phase II study of vemurafenib in patients with locally advanced, unresectable stage IIIc or
metastatic melanoma and activating exon 15 BRAF mutations other than V600E. (Abstract
9075^)
Sigrun Hallmeyer
Board 280
•
Outcome with stereotactic radiosurgery (SRS) and ipilimumab (Ipi) for malignant melanoma
brain metastases (mets). (Abstract 9076)
Sana Shoukat
Board 281
•
Lesion-specific patterns of response and progression with anti-PD-1 treatment in metastatic
melanoma (MM). (Abstract 9077)
Megan Kate Lyle
Board 282
•
Safety and clinical activity of combining systemic ipilimumab with isolated limb infusion in
patients with in-transit melanoma. (Abstract 9078)
Charlotte Eielson Ariyan
Board 283
•
Treatment with tumor-infiltrating lymphocytes (TIL) in metastatic melanoma and clinical
benefit regardless of site of origin, mutation status, or prior checkpoint blockade. (Abstract
9079)
Isabella Claudia Glitza
Board 284
•
The impact of clinical response to anti-CTLA4 treatment on overall survival (OS) in metastatic
melanoma (MM). (Abstract 9080)
Xiaolan Feng
Board 285
•
Vismodegib for advanced basal cell carcinoma: Duration of response after vismodegib
discontinuation and response to vismodegib retreatment upon disease progression. (Abstract
9081)
Aleksandar Sekulic
Board 286
•
Quantitative assessment of melanoma spread in sentinel and non-sentinel lymph nodes and
survival. (Abstract 9082)
Anja Ulmer
Board 287
•
On-demand Gamma Knife combined with BRAF inhibitors for the treatment of melanoma
brain metastases. (Abstract 9083)
Caroline Gaudy-Marqueste
Board 288
•
Polymorphisms in the apoptosis pathway and prognosis in cutaneous melanoma. (Abstract
9084)
Cristiane Oliveira
Board 289
•
Correlation of tumor-derived circulating cell free DNA (cfDNA) measured by digital PCR
(DigPCR) with tumor burden measured radiographically in patients (pts) with BRAFV600E
mutated melanoma (mel) treated with RAF inhibitor (RAFi) and/or ipilimumab (Ipi). (Abstract
9085)
Parisa Momtaz
Board 290
•
Phase I/II study of resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination
in patients with melanoma. (Abstract 9086)
Rachel Lubong Sabado
Board 291
•
A unique gene expression signature in tumor positive or negative sentinel lymph nodes in
patients with melanoma. (Abstract 9087)
Ahmad A. Tarhini
Board 292
•
Sentinel lymph node biopsy among elderly patients with melanoma. (Abstract 9088)
Michael S. Sabel
Board 293
•
New graded prognostic index (GPI) for melanoma patients with brain metastasis (MBM).
(Abstract 9089)
Vyshak Alva Venur
Board 294
•
Efficacy of two ipilimumab (IPI) doses (10 vs. 3 mg/kg) in Alberta, Canada, tertiary cancer
centers. (Abstract 9090)
Richard M. Lee-Ying
Board 295
•
Response rate and durability of chemotherapy for metastatic Merkel cell carcinoma among
62 patients. (Abstract 9091)
Jayasri G Iyer
Board 296
•
Severe skin rash during vemurafenib treatment: A predictive factor of early positive response
in metastatic melanoma? (Abstract 9092)
Nora Kramkimel
Board 297
•
Efficacy and safety of mechlorethamine (MCH) 0.04% gel in mycosis fungoides (MF) after
treatment with topical MCH 0.02%. (Abstract 9093)
Youn H. Kim
Board 298
•
The genetic variants in interleukin locus at 1q32.1 as markers of melanoma survival.
(Abstract 9094)
Justin Rendleman
Board 299
•
Integration of melanoma genotyping in clinical care. (Abstract 9095)
Ines Esteves Domingues Pires Da Silva
Board 300
•
Correlation of absolute and relative eosinophil counts with immune-related adverse events in
melanoma patients treated with ipilimumab. (Abstract 9096)
Katja Schindler
Board 301
•
Interobserver variability in ultrasound (US) guided fine needle aspiration cytology (FNAC) of
sentinel nodes (SN): Experience in 1,000 melanoma patients. (Abstract 9097)
Christiane A. Voit
Board 302
•
A phase IB study of ipilimumab with peginterferon alfa-2b for patients with unresectable
stages IIIB/C/IV melanoma. (Abstract 9098)
Ragini Reiney Kudchadkar
Board 303
•
Association of natural killer (NK) cell exhaustion with melanoma progression. (Abstract 9099)
Ines Esteves Domingues Pires Da Silva
Board 304
•
Clinical characteristics of patients with non-V600 BRAF mutant melanomas. (Abstract 9100)
Dae Won Kim
Board 305
•
A phase I trial of BKM120 combined with vemurafenib in BRAFV600E/k mutant advanced
melanoma. (Abstract 9101)
Alain Patrick Algazi
Board 306A
•
NEMO: A phase 3 trial of binimetinib (MEK162) versus dacarbazine in patients with untreated
or progressed after first-line immunotherapy unresectable or metastatic NRAS-mutant
cutaneous melanoma. (Abstract TPS9102)
Keith Flaherty
Board 306B
•
A phase II study of intratumoral application of L19IL2/L19TNF in melanoma patients in
clinical stage III or stage IV M1a with presence of injectable cutaneous and/or subcutaneous
lesions. (Abstract TPS9103^)
Riccardo Danielli
Board 307A
•
A phase II study to assess vismodegib in the neoadjuvant treatment of locally advanced
basal cell carcinoma (laBCC): The Vismodegib Neoadjuvant (VISMONEO) study. (Abstract
TPS9104)
Laurent Mortier
Board 307B
•
Phase I-II study of the combination vemurafenib plus peg-interferon in advanced melanoma
patients harboring the V600BRAF mutation. (Abstract TPS9105)
Paolo Antonio Ascierto
Board 308A
•
Phase II, open-label study of dabrafenib plus trametinib in patients with BRAF mutationpositive melanoma brain metastases: A GSK-sponsored trial. (Abstract TPS9106)
Michael A. Davies
Board 308B
•
Targeted modified IL-2 (NHS-IL2, MSB0010445) combined with stereotactic body radiation in
advanced melanoma patients after progression on ipilimumab: Assessment of safety, clinical,
and biologic activity in a phase 2a study. (Abstract TPS9107)
Howard Kaufman
Board 309A
•
Phase 1 study of MEDI4736, an anti-PD-L1 antibody, in combination with dabrafenib and
trametinib or trametinib alone in patients with unresectable or metastatic melanoma.
(Abstract TPS9108)
Michael S. Gordon
Board 309B
•
BeyPro1: A phase II single-arm study for the treatment after recurrence of advanced
melanoma patients harboring the V600BRAF mutation and pretreated with vemurafenib, with
the association of vemurafenib plus fotemustine. (Abstract TPS9109)
Paola Queirolo
Board 310A
•
Dose-seeking and efficacy study of combination BRAFi and high-dose IFN (HDI) for therapy
of advanced melanoma. (Abstract TPS9110)
Diwakar Davar
Board 310B
•
The influence of a gene expression signature on the diagnosis and recommended treatment
of melanocytic tumors by dermatopathologists. (Abstract TPS9111)
Loren E Clarke
Board 311A
•
Pharmacokinetic and pharmacodynamic analysis of preoperative therapy with dabrafenib
alone and in combination with trametinib in patients with BRAF mutation–positive melanoma
with metastases to the brain (BRV116521). (Abstract TPS9112)
Michael A. Davies
Board 311B
•
The GERMELATOX DeCOG-trial: German melanoma patients and their attitude toward
toxicity during adjuvant interferon treatment. (Abstract TPS9113^)
Katharina C. Kaehler
Board 312A
•
Biomarker study evaluating the combination of dabrafenib (D) with trametinib (T) versus the
combination after 8 weeks of monotherapy with dabrafenib or trametinib in patients with
metastatic and unresectable stage IIIC or IV melanoma: GSK study 116613. (Abstract
TPS9114^)
Christine Mateus
Board 312B
•
NLG-0304: A phase 2B study of ipilimumab with or without dorgenmeltucel-L (HyperAcuteMelanoma) immunotherapy for patients with stage IV melanoma. (Abstract TPS9115)
Adam I Riker
Board 313A
•
A phase II, single-armed, multicenter trial of neoadjuvant vismodegib in patients with large
and/or recurrent basal cell carcinoma: NICCI. (Abstract TPS9116^)
Ulrike Leiter
Board 313B
•
Phase 1/2 trial of the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod plus
ipilimumab for the treatment of unresectable stage 3 or 4 melanoma. (Abstract TPS9117)
Eugene Kennedy
Board 314A
•
BRIM8: A phase III, randomized, double-blind, placebo-controlled study of vemurafenib
adjuvant therapy in patients with surgically resected, cutaneous BRAF-mutant melanoma at
high risk for recurrence (NCT01667419). (Abstract TPS9118^)
Karl D. Lewis
Board 314B
•
Phase I/II study of the TLR3 agonist poly-ICLC as an adjuvant for NY-ESO-1 protein
vaccination with or without Montanide ISA-51 vg in patients with melanoma. (Abstract
TPS9119)
Rachel Lubong Sabado
Board 315A
•
NCI 8628: A randomized phase II study of ziv-aflibercept (Z) and high-dose interleukin-2
(HD IL-2) or HD IL-2 alone for inoperable stage III or IV melanoma—Efficacy and biomarker
study. (Abstract TPS9120)
Madeeha Ashraf
Board 315B
•
MIKIE: A randomized, double-blind, regimen-controlled, phase II, multicenter study to
assess the efficacy and safety of two different vismodegib regimens in patients with multiple
basal cell carcinomas. (Abstract TPS9121)
Rainer Kunstfeld
Session Title: Opening Session with Fellows of the American Society of Clinical Oncology, Guest
Speaker's Address, Presidential Address, ASCO Humanitarian Award, and David A. Karnofsky
Memorial Award and Lecture
Session Type: Special Session
Track: Special Session
Time: 9:30 AM - 12:00 PM
Location: N Hall B1
•
Conquer Cancer Foundation Top Donor Recognition Awards and Mission Endowment
Recognition Awards
William Charles Penley, MD
•
Presentation of the Fellows of the American Society of Clinical Oncology (FASCO)
Sandra M. Swain, MD, FACP
•
Guest Speaker's Address: Systems Medicine and the Revolution in Health Care and Society
Leroy E. Hood, MD, PhD
•
Introduction
Allen S. Lichter, MD
•
President’s Address: Science and Society–Fifty Years Later
Clifford A. Hudis, MD, FACP
•
Humanitarian Award
Surendra S. Shastri, MBBS, MD, DPh, DHA
•
David A. Karnofsky Memorial Award and Lecture: Understanding
H. M. (Bob) Pinedo, MD, PhD
Session Title: Pediatric Oncology Award and Lecture
Session Type: Special Session
Track: Special Session
Time: 1:15 PM - 2:30 PM
Location: S504
•
Childhood Cancer Survivors: A Lifetime of Risk and Responsibility
Leslie L. Robison, PhD
Session Title: Burnout in Health Care Professionals: Improving the Care You Provide by Caring for
Your Mental and Physical Well-being
Session Type: Education Session
Track: Professional Development
Time: 1:15 PM - 2:30 PM
Location: E450
•
Caring for Oneself to Care for Others: Strategies for Preventing and Reducing Burnout
Anthony Back, MD - Chair
•
Improving Compassion-Fatigue Resiliency in Oncology Nurses
Patricia Potter, RN, PhD
•
Addressing the Potential for Burnout: Lessons Learned from Care of Disaster Workers
Paul Deignan, MSW
•
Panel Question and Answer
Session Title: Electronic Health Records and How to Optimize Their Use
Session Type: Education Session
Track: Practice Management and Information Technology
Time: 1:15 PM - 2:30 PM
Location: S404
•
Why We Need Electronic Health Records: The Evolution and Overview
Jeremy Warner, MD, MS
•
How to Make Meaningful Use in Electronic Health Records More Meaningful
David R. Artz, MD
•
Limitations of Electronic Health Records and the Importance of the Rapid Learning System
CancerLinQ
Peter Paul Yu, MD - Chair
•
Panel Question and Answer
Session Title: Frontline Approach to Metastatic BRAF- Mutant Melanoma: Diagnosis, Molecular
Evaluation, and Treatment Choice
Session Type: Education Session
Track: Melanoma/Skin Cancers
Time: 1:15 PM - 2:30 PM
Location: S406
•
Molecular Workup of Melanoma: Biopsy Techniques and Genetic Assay Options
Paul B. Chapman, MD - Chair
•
The Role of Surgical Resection for Limited-Volume or Oligometastatic Melanoma
Vernon K. Sondak, MD
•
Advantages and Disadvantages of Kinase Inhibitors or Immunotherapy as Frontline
Treatment of Melanoma
Axel Hauschild, MD
•
Panel Question and Answer
Session Title: Practical Considerations in the Design of Clinical Trials of Targeted Therapies and
Immunotherapy
Session Type: Education Session
Track: Clinical Trials
Time: 1:15 PM - 2:30 PM
Location: S100a
•
Early-Phase Trial Designs and Endpoints for Targeted Therapies in Rare Genotype Subsets
Sumithra J. Mandrekar, PhD
•
Rare Tumors, Low Marker Prevalence, and Pediatric Oncology: Examples of Real Clinical
Trials
Meenakshi Devidas, PhD
•
One Size Does Not Fit All: What We Have Learned from Immunotherapy Trials
Mario Sznol, MD - Chair
•
Panel Question and Answer
Session Title: The Nuts and Bolts of Liver-Directed Therapies: How Are Procedures Done, What
Are the Side Effects, and What Are the Data?
Session Type: Education Session
Track: Gastrointestinal (Colorectal) Cancer
Time: 1:15 PM - 2:30 PM
Location: E Hall D1
•
Radiation Oncology-Based Approaches: Radioembolization and Local Radiation Therapy
Techniques (SBRT, CyberKnife, Proton Beam)
Andrew S. Kennedy, MD, FACRO
•
Interventional Radiology Approaches: Chemotherapy and Bland Embolization, and Radio
Frequency Ablation
David M. Liu, MD
•
Surgical Approaches, Alone and in Combination with Other Interventions
Timothy M. Pawlik, MD, MPH, PhD - Chair
•
Panel Question and Answer
Session Title: The Value of Cancer Care and the Professional and Ethical Obligations of the
Practicing Oncologist: A Debate
Session Type: Education Session
Track: Ethics
Time: 1:15 PM - 2:30 PM
Location: E253
•
"Value" and "Values" in Cancer Care: Can We Balance Our Duties to Patients and Society?
Beverly Moy, MD, MPH - Chair
•
Advocating for the Individual Patient's Good Should Be the Oncologist's Priority
Daniel Sulmasy, MD, PhD
•
The Oncologist's Duty to Society
Reshma Jagsi, MD, DPhil
•
Panel Question and Answer
Session Title: Intermediate Risk of Head and Neck Squamous Cell Carcinoma - Ticketed Session
Session Type: Meet the Professor Session
Track: Head and Neck Cancer
Time: 1:15 PM - 2:30 PM
Location: E451a
•
Intermediate-Risk Head and Neck Squamous Cell Carcinoma
Danny Rischin, MD, MBBS
Session Title: Harnessing Biology and Immunology to Develop Novel Biomarkers
Session Type: Clinical Science Symposium
Track: Breast Cancer
Time: 1:15 PM - 2:45 PM
Location: N Hall B1
•
Co-Chair
Daniel F. Hayes, MD
•
Chair
Alexandra Thomas, MD, FACP
•
Association of genomic analysis of immune function genes and clinical outcome in the
NCCTG (Alliance) N9831 adjuvant trastuzumab trial. (Abstract 509)
Edith A. Perez
•
The Role of the Immune System in Therapeutic Response to HER2-Targeted Therapy
Sherene Loi, MD,PhD
•
Expression of immunologic genes in triple-negative and HER2-positive breast cancer in the
neoadjuvant GEPARSIXTO trial: Prediction of response to carboplatin-based chemotherapy.
(Abstract 510)
Carsten Denkert
•
Immune Profiling: Promises and Pitfalls
Sunil S. Badve, MD
•
Tracking tumor-specific mutations in circulating-free DNA to predict early relapse after
treatment of primary breast cancer. (Abstract 511)
Nicholas C. Turner
•
The Future of Innovative Blood-Based Biomarkers
Minetta C. Liu, MD
•
Panel Question and Answer
Session Title: Targeted Therapies in Early, Mid, and Late Development
Session Type: Clinical Science Symposium
Track: Lymphoma and Plasma Cell Disorders
Time: 1:15 PM - 2:45 PM
Location: E Arie Crown Theater
•
Chair
Andrew David Zelenetz, MD, PhD
•
Chair
Michael E. Williams, MD
•
A phase 1 dose-escalation study of the oral selective inhibitor of nuclear export (SINE) KPT330 (selinexor) in patients (pts) with heavily pretreated non-Hodgkin lymphoma (NHL).
(Abstract 8518)
Martin Gutierrez
•
Nuclear Export Inhibition in Lymphoid Malignancies and Beyond
Owen A. O'Connor, MD, PhD
•
Preliminary results of a phase II randomized study (ROMULUS) of polatuzumab vedotin
(PoV) or pinatuzumab vedotin (PiV) plus rituximab (RTX) in patients (Pts) with
relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL). (Abstract 8519)
Franck Morschhauser
•
Antibody Drug Conjugates as Therapies for Lymphomas
Ronald Levy, MD
•
Effect of lenalidomide combined with R-CHOP (R2CHOP) on negative prognostic impact of
nongerminal center (non-GCB) phenotype in newly diagnosed diffuse large B-cell lymphoma:
A phase 2 study. (Abstract 8520)
Grzegorz S. Nowakowski
•
Building on R-CHOP by Tackling the Lymphoma Microenvironment
Andre Goy, MD
•
Panel Question and Answer
Session Title: Cancer Prevention/Epidemiology
Session Type: Oral Abstract Session
Track: Cancer Prevention/Epidemiology
Time: 1:15 PM - 4:15 PM
Location: S100bc
•
Chair
Marie Wood, MD
•
Chair
James M. Foran, MD
•
Predictors of colorectal cancer screening adherence among African Americans. (Abstract
1501)
Praveen Ramakrishnan Geethakumari
•
Breast cancer screening in younger women. (Abstract 1502)
Nina Beri
•
Screening in Underserved Populations
Electra D. Paskett, PhD
•
Panel Question and Answer
Panel Discussion
•
Menopausal hormone therapy and breast cancer by body mass index (BMI) and African
ancestry. (Abstract 1503)
Rowan T. Chlebowski
•
Effects of equivalent weight loss, with or without exercise, on sex hormones related to breast
cancer risk in postmenopausal women: The SHAPE-2 trial. (Abstract 1504)
Anne Maria May
•
Effect of weight loss intervention on inflammatory and metabolic markers in breast cancer
survivors: The lifestyle, exercise, and nutrition (LEAN) study. (Abstract 1505)
Erikka Loftfield
•
Body Mass Index, Weight Loss, and Breast Cancer
Wendy Demark-Wahnefried, PhD, RD
•
Panel Question and Answer
•
Proportion of BRCA mutation frequency in young black women with breast cancer. (Abstract
1506)
Tuya Pal
•
The impact of oophorectomy on survival after breast cancer in BRCA1 and BRCA2 mutation
carriers. (Abstract 1507)
Kelly A. Metcalfe
•
Quality of life in BRCA1 and BRCA2 mutation carriers (B1/2) following risk-reducing salpingooophorectomy (RRSO). (Abstract 1508)
Susan M. Domchek
•
BRCA1/2 Mutations: Prevalence, Prevention, and Quality of Life
Mark E. Robson, MD
•
Panel Question and Answer
Panel Discussion
Session Title: Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics
Session Type: Oral Abstract Session
Track: Developmental Therapeutics
Time: 1:15 PM - 4:15 PM
Location: E Hall D2
•
Chair
Miguel Angel Villalona-Calero, MD
•
Chair
Emiliano Calvo, MD, PhD
•
A phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and
pharmacodynamics of lucitanib in advanced solid tumors. (Abstract 2500)
Jean-Charles Soria
•
Phase 1 study of JNJ-42756493, a pan-fibroblast growth factor receptor (FGFR) inhibitor, in
patients with advanced solid tumors. (Abstract 2501)
Rastislav Bahleda
•
Phase 1 open label, dose escalation study of RXDX101, an oral pan-trk, ROS1, and ALK
inhibitor, in patients with advanced solid tumors with relevant molecular alterations.
(Abstract 2502)
Filippo G. De Braud
•
Patient Selection in Early-Phase Trials
David B. Solit, MD
•
Panel Question and Answer
•
Phase I trial of AZD1775 (MK1775), a wee1 kinase inhibitor, in patients with refractory solid
tumors. (Abstract 2503)
Khanh Tu Do
•
A phase I study of DNIB0600A, an antibody-drug conjugate (ADC) targeting NaPi2b, in
patients (pts) with non-small cell lung cancer (NSCLC) or platinum-resistant ovarian cancer
(OC). (Abstract 2504)
Howard A. Burris
•
A first-in-human phase 1 study of anticancer stem cell agent OMP-54F28 (FZD8-Fc), decoy
receptor for WNT ligands, in patients with advanced solid tumors. (Abstract 2505)
Antonio Jimeno
•
Novel Targets in Oncology
Jeffrey S. Abrams, MD
•
Panel Question and Answer
Panel Discussion
•
A first-in-human (FIH) phase I study of SAR125844, a novel selective MET kinase inhibitor, in
patients (pts) with advanced solid tumors: Dose escalation results. (Abstract 2506)
Eric Angevin
•
Phase 1, open-label, dose-escalation, and expansion study of ABT-700, an anti-C-met
antibody, in patients (pts) with advanced solid tumors. (Abstract 2507)
John H. Strickler
•
First-in-human study of AMG 337, a highly selective oral inhibitor of MET, in adult patients
(pts) with advanced solid tumors. (Abstract 2508)
David S. Hong
•
Targeting the HGF/MET Pathway
Gerald Steven Falchook, MD
•
Panel Question and Answer
Panel Discussion
Session Title: Gynecologic Cancer
Session Type: Oral Abstract Session
Track: Gynecologic Cancer
Time: 1:15 PM - 4:15 PM
Location: E354a
•
Chair
Rebecca Sophie Kristeleit, MD, PhD
•
Chair
Jonathan S. Berek, MD
•
A randomized phase 2 trial comparing efficacy of the combination of the PARP inhibitor
olaparib and the antiangiogenic cediranib against olaparib alone in recurrent platinumsensitive ovarian cancer. (Abstract LBA5500)
Joyce Liu
•
Genomic alterations in paired pretreatment (pre) and progression (prog) tumor samples from
ovarian cancer patients (pts) treated with pazopanib (pazo) or placebo (plb). (Abstract 5501)
Florian Heitz
•
Molecular subgroup of high-grade serous ovarian cancer (HGSOC) as a predictor of outcome
following bevacizumab. (Abstract 5502)
Charlie Gourley
•
MITO-11: A randomized multicenter phase II trial testing the addition of pazopanib to weekly
paclitaxel in platinum-resistant or -refractory advanced ovarian cancer (AOC). (Abstract
5503^)
Sandro Pignata
•
Evolving Therapy against Angiogenesis
Jonathan A. Ledermann, MD, FRCP
•
Panel Question and Answer
•
Progression-free survival in ovarian cancer patients in second remission with mucin-1
autologous dendritic cell therapy. (Abstract 5504)
Heidi J. Gray
•
Lurbinectedin (PM01183), an active compound in platinum-resistant/refractory ovarian
cancer (PRROC) patients: Results of a two-stage, controlled phase II study. (Abstract 5505)
Andres Poveda
•
Genotype matched treatment for patients with advanced type I epithelial ovarian cancer
(EOC). (Abstract 5506)
Anna Spreafico
•
Novel Targeting Approaches in Ovarian Cancer
Paul Haluska, MD, PhD
•
Panel Question and Answer
Panel Discussion
•
Randomized phase III trial of paclitaxel/carboplatin (PC) versus cisplatin/irinotecan (CPT-P)
as first-line chemotherapy in patients with clear cell carcinoma (CCC) of the ovary: A
Japanese Gynecologic Oncology Group (JGOG)/GCIG study. (Abstract 5507)
Aikou Okamoto
•
Comparison of treatment invasiveness between upfront debulking surgery versus interval
debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and
peritoneal cancers in phase III randomized trial: JCOG0602. (Abstract 5508)
TAKASHI ONDA
•
Challenging the Dogma in Ovarian Cancer Treatment
Dennis Chi, MD
•
Panel Question and Answer
Panel Discussion
Session Title: Gastrointestinal (Colorectal) Cancer
Session Type: Poster Highlights Session
Track: Gastrointestinal (Colorectal) Cancer
Time: 1:15 PM - 6:00 PM
Display and Networking Time: 1:15 PM - 4:15 PM
Display and Networking Location: E354b
Discussion Time: 4:45 PM - 6:00 PM
Discussion Location: E Hall D2
•
Co-Chair
Steven J. Cohen, MD
•
Co-Chair
Neil Howard Segal, MD, PhD
Board 1
•
Antitumor effects of dabrafenib, trametinib, and panitumumab as single agents and in
combination in BRAF-mutant colorectal carcinoma (CRC) models. (Abstract 3513)
LI Liu
Board 2
•
Phase I study of the selective BRAFV600 inhibitor encorafenib (LGX818) combined with
cetuximab and with or without the a-specific PI3K inhibitor BYL719 in patients with advanced
BRAF-mutant colorectal cancer. (Abstract 3514)
Robin Van Geel
Board 3
•
Efficacy and tolerability in an open-label phase I/II study of MEK inhibitor trametinib (T),
BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in combination in
patients (pts) with BRAF V600E mutated colorectal cancer (CRC). (Abstract 3515)
Johanna C. Bendell
Board 4
•
Phase 1B study of vemurafenib in combination with irinotecan and cetuximab in patients with
BRAF-mutated advanced cancers and metastatic colorectal cancer. (Abstract 3516)
David S. Hong
Board 5
•
Phase 1-2 trial of the BRAF inhibitor dabrafenib (D) plus MEK inhibitor trametinib (T) in BRAF
V600 mutant colorectal cancer (CRC): Updated efficacy and biomarker analysis. (Abstract
3517)
Ryan Bruce Corcoran
Board 6
•
VE-BASKET, a Simon 2-stage adaptive design, phase II, histology-independent study in
nonmelanoma solid tumors harboring BRAF V600 mutations (V600m): Activity of
vemurafenib (VEM) with or without cetuximab (CTX) in colorectal cancer (CRC). (Abstract
3518^)
Josep Tabernero
Board 7
•
Subgroup analyses in RAS mutant, BRAF mutant and all-wt mCRC pts treated with
FOLFOXIRI plus bevacizumab (bev) or FOLFIRI plus bev in the TRIBE study. (Abstract 3519)
Fotios Loupakis
Board 8
•
Combined epiregulin (EREG) and amphiregulin (AREG) expression levels as a biomarker of
prognosis and panitumumab benefit in RAS-wt advanced colorectal cancer (aCRC). (Abstract
3520)
Jenny F. Seligmann
Board 9
•
Amphiregulin (AREG) SNP rs161511 to predict cetuximab efficacy independent of AREG
mRNA levels: Data from FIRE3 (AIO KRK-0306). (Abstract 3521)
Sebastian Stintzing
Board 10
•
Influence of mRNA expression of epiregulin (EREG) and of amphiregulin (AREG) and RAS
mutations on outcome of patients with metastatic colorectal cancer treated with 5-FU/LV
plus irinotecan or irinotecan plus oxaliplatin as first-line treatment (FIRE 1-trial). (Abstract
3522)
Arndt Stahler
Board 11
•
Mir-31-3p as a predictive biomarker of cetuximab effects in a post hoc analysis of new EPOC
phase III trial. (Abstract 3523)
Pierre Laurent-Puig
Board 12
•
Phase II study of single-agent cetuximab in KRAS G13D mutant metastatic colorectal cancer
(mCRC). (Abstract 3524)
Marta Schirripa
Board 14
•
Overall survival result and outcomes by KRAS, BRAF, and DNA mismatch repair in relation
to primary tumor site in colon cancers from a randomized trial of adjuvant chemotherapy:
NCCTG (Alliance) N0147. (Abstract 3525)
Frank A. Sinicrope
Board 15
•
Evolution of heterogeneous mechanisms of acquired resistance to cetuximab-based therapy
in colorectal cancer. (Abstract 3526)
Clara Montagut
Board 16
•
Surgical resection of primary tumors (SRPT) in asymptomatic patients with stage IV
colorectal cancer (CRC): A Canadian province experience. (Abstract 3527)
Shahid Ahmed
Board 17
•
Surgical outcome for pulmonary metastasis of colorectal cancer in the modern chemotherapy
era: Results of a retrospective Japanese multicenter study. (Abstract 3528)
Tomoyuki Hishida
Board 18
•
A comparison of survival by site of metastatic resection (MR) in metastatic colorectal cancer
(mCRC). (Abstract 3529)
Brandon David Bernard
Board 19
•
Complete neoadjuvant therapy in rectal cancer (CONTRE): A Brown University Oncology
Research Group phase II study. (Abstract 3530)
Kimberly Perez
Board 20
•
Neoadjuvant radiotherapy (RT) combined with capecitabine (Cape) and sorafenib (Sor) in
patients (pts) with locally advanced, k-ras-mutated rectal cancer (LARC): A phase I/II trial
SAKK 41/08. (Abstract 3531)
Roger Von Moos
Board 21
•
External validation of the neoadjuvant rectal (NAR) score and Valentini prediction nomogram
(VPN): A multicenter study. (Abstract 3532)
Soundouss Raissouni
Board 22
•
Neoadjuvant rectal cancer (RC) score to predict survival: Potential surrogate endpoint for
early phase trials. (Abstract 3533)
Greg Yothers
Board 23
•
A randomized phase III trial of mFOLFOX6 plus bevacizumab versus FOLFIRI plus
bevacizumab as first-line treatment for metastatic colorectal cancer: West Japan Oncology
Group study 4407G (WJOG4407G). (Abstract 3534)
Kentaro Yamazaki
Board 24
•
Metformin (M), diabetes (DM), and colorectal cancer (CRC) survival among U.S. veterans.
(Abstract 3535)
Jessica K Paulus
Board 25
•
Racial differences in KRAS/BRAF mutation rates and survival in colon cancer (NCCTG N0147
[Alliance]). (Abstract 3536)
Harry H. Yoon
Board 26
•
Body mass index (BMI) as prognostic in metastatic colorectal cancer (mCRC): A pooled
analysis of 21 first-line trials in the ARCAD database. (Abstract 3537)
Lindsay A. Renfro
•
Translational Updates in BRAF-Mutated Colorectal Cancer
Gary William Middleton, MD
•
Mechanisms of Resistance to EGFR Inhibitors
Tony R. Reid, MD, PhD
•
Chance to Cut is a Chance to Cure
Nancy N. Baxter, MD, PhD, FRCS
•
Issues in Colorectal Cancer: From Epidemiology to Trials
Jeffrey A. Meyerhardt, MD, MPH
•
Panel Question and Answer
Session Title: Genitourinary (Prostate) Cancer
Session Type: Poster Highlights Session
Track: Genitourinary Cancer
Time: 1:15 PM - 6:00 PM
Display and Networking Time: 1:15 PM - 4:15 PM
Display and Networking Location: E354b
Discussion Time: 4:45 PM - 6:00 PM
Discussion Location: E Arie Crown Theater
•
Co-Chair
Rahul Raj Aggarwal, MD
•
Co-Chair
Himisha Beltran, MD
Board 27
•
Validation of a prognostic model for metastatic castrate-resistant prostate cancer (mCRPC)
patients receiving abiraterone acetate (AA). (Abstract 5013)
Praful Kumar Ravi
Board 28
•
Circulating tumor cells (CTCs) and LDH as prognostic factors in patients with metastatic
castration-resistant prostate cancer (mCRPC) progressing during or following docetaxel
treated in the orteronel phase 3 ELM-PC 5 trial. (Abstract 5014)
Howard I. Scher
Board 29
•
Association of serum (SR) and tissue (TX) abiraterone (ABI) levels with intraprostatic steroids
and pathologic outcomes in men with high-risk localized prostate cancer (PCa). (Abstract
5015^)
Elahe A. Mostaghel
Board 30
•
Pathologic correlation of 18F-16ß-fluoro-5a-dihydrotestosterone (FDHT) and FDG PET in
patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). (Abstract 5016)
Jarett L. Feldman
Board 31
•
Comparison of plasma microRNAs with CTCs and PSA in patients treated on SWOG S0925, a
randomized phase II study of androgen deprivation combined with cixutumumab versus
androgen deprivation alone for patients with new metastatic hormone-sensitive prostate
cancer. (Abstract 5017)
Heather H. Cheng
Board 32
•
Effect of HOXB13 and FOXA1 on the AR cistrome during prostate tumorigenesis in primary
human tissue. (Abstract 5018)
Mark M Pomerantz
Board 33
•
Concordance of ETS fusion status of matched metastatic castration-resistant prostate cancer
and primary prostate cancer: Data from NCI 9012, a randomized ETS fusion-stratified phase
II trial. (Abstract 5019)
Lakshmi Priya Kunju
Board 34
•
Androgen receptor (AR) amplification in patients with metastatic castration-resistant prostate
cancer (mCRPC) refractory to therapy with abiraterone acetate or enzalutamide: Preliminary
results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT).
(Abstract 5020)
Eric Jay Small
Board 35
•
Genomic analysis of circulating tumor DNA (ctDNA) in plasma of metastatic castrationresistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (abi) and
enzalutamide (enza). (Abstract 5021)
Arun Azad
Board 36
•
A randomized, open label, multicenter, phase 3, 2-arm study of androgen deprivation with
leuprolide (L), ± docetaxel (D) for clinically asymptomatic prostate cancer (PC) subjects with
a rising PSA following definitive local therapy: Safety results. (Abstract 5022)
Michael J. Morris
Board 37
•
A phase 2 trial of prostate-specific membrane antigen antibody drug conjugate (PSMA ADC)
in taxane-refractory metastatic castration-resistant prostate cancer (mCRPC). (Abstract
5023)
Daniel Peter Petrylak
Board 38
•
A phase I study of DSTP3086S, an antibody-drug conjugate (ADC) targeting STEAP-1, in
patients (pts) with metastatic castration-resistant prostate cancer (CRPC). (Abstract 5024)
Daniel Costin Danila
Board 40
•
Phase 1b study of abiraterone acetate (AA) and docetaxel (D) in patients (pts) with
metastatic castration-resistant prostate cancer (mCRPC). (Abstract 5025)
Scott T. Tagawa
Board 41
•
ARN-509 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with
and without prior abiraterone acetate (AA) treatment. (Abstract 5026)
Dana E. Rathkopf
Board 42
•
Phase 1 dose-finding study of cabozantinib (cabo) plus abiraterone (abi) combination
therapy in castration resistant prostate cancer (CRPC): An investigator-sponsored study.
(Abstract 5027^)
Christopher Sweeney
Board 43
•
Everolimus plus bicalutamide in men with castration-resistant prostate cancer (CRPC): Final
results of a phase II trial. (Abstract 5028)
Chong-xian Pan
Board 44
•
Galeterone in men with CRPC: Results in four distinct patient populations from the ARMOR2
study. (Abstract 5029)
Robert B. Montgomery
Board 45
•
Primary outcomes of the placebo-controlled phase 2 study PERSEUS (NCT01360840)
investigating two dose regimens of abituzumab (DI17E6, EMD 525797) in the treatment of
chemotherapy-naive patients (pts) with asymptomatic or mildly symptomatic metastatic
castration-resistant prostate cancer (mCRPC). (Abstract 5030)
Maha Hussain
Board 46
•
Adjuvant radiation, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: Results of RTOG 0621. (Abstract 5031)
Mark Hurwitz
Board 47
•
First double-blind placebo-controlled, multicenter, randomized trial of stabilized natural
sulforaphane in men with rising PSA following radical prostatectomy. (Abstract 5032)
Bernard G Cipolla
Board 48
•
15-year survival outcomes following primary androgen deprivation therapy for localized
prostate cancer. (Abstract 5033)
Grace L. Lu-Yao
Board 49
•
The risk of second malignancies after treatment for localized prostate cancer. (Abstract
5034)
Elizabeth J. Davis
Board 51
•
The natural history of progression to PSA recurrence and metastasis among at risk men
following radical prostatectomy. (Abstract 5036)
Ashley Ross
Board 52
•
A multicenter yearlong randomized controlled trial of different exercise modalities in prostate
cancer survivors on androgen deprivation therapy. (Abstract 5037)
Daniel Abido Galvao
•
Biomarkers, Diagnosis, Prediction and Prognosis in Prostate Cancer
Martin Edwin Gleave, MD, FRCSC, FACS
•
Improving Outcomes in Androgen-Sensitive and Castration-Resistant Prostate Cancer
Robert S. DiPaola, MD
•
Novel Therapeutics and Combinations in Castration Resistant Prostate Cancer
Tanya B. Dorff, MD
•
Natural History and Improving Outcomes with More than Diet and Exercise
Noel W. Clarke, MBBS, FRCS, ChM
•
Panel Question and Answer
Session Title: Leukemia, Myelodysplasia, and Transplantation
Session Type: Poster Highlights Session
Track: Leukemia, Myelodysplasia, and Transplantation
Time: 1:15 PM - 6:00 PM
Display and Networking Time: 1:15 PM - 4:15 PM
Display and Networking Location: S405
Discussion Time: 4:45 PM - 6:00 PM
Discussion Location: S406
•
Co-Chair
Ronan T. Swords, MD
•
Co-Chair
Hongtao Liu, MD, PhD
Board 1
•
A phase 1b/2 study evaluating activity and tolerability of the BTK inhibitor ibrutinib in
combination with ofatumumab in patients with chronic lymphocytic leukemia/small
lymphocytic lymphoma (CLL/SLL) and related diseases. (Abstract 7009)
Samantha Mary Jaglowski
Board 2
•
Association of disease progression on ibrutinib therapy with the acquisition of resistance
mutations: A single-center experience of 267 patients. (Abstract 7010)
Jennifer Ann Woyach
Board 3
•
Efficacy of idelalisib in CLL subpopulations harboring del(17p) and other adverse prognostic
factors: Results from a phase 3, randomized, double-blind, placebo-controlled trial. (Abstract
7011^)
Jeff Porter Sharman
Board 4
•
Second interim analysis of a phase 3 study evaluating idelalisib and rituximab for relapsed
CLL. (Abstract 7012)
Steven E. Coutre
Board 5
•
ABT-199 (GDC-0199) combined with rituximab (R) in patients (pts) with relapsed/refractory
(R/R) chronic lymphocytic leukemia (CLL): Interim results of a phase 1b study. (Abstract
7013)
Shuo Ma
Board 7
•
ABT-199 (GDC-0199) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and
small lymphocytic lymphoma (SLL): High complete-response rate and durable disease
control. (Abstract 7015)
John Francis Seymour
Board 8
•
BK virus as a predictor of chronic kidney disease in hematopoietic stem cell recipients.
(Abstract 7016)
Ala Abudayyeh
Board 9
•
Haploidentical transplantation (HaploSCT) with post-transplant cyclophosphamide (PTCy)
and melphalan-based conditioning: A retrospective analysis of the first 100 patients treated
at MD Anderson Cancer Center. (Abstract 7017)
Piyanuch Kongtim
Board 10
•
Outcomes after second allogeneic hematopoietic stem cell transplantation: A single-center
experience. (Abstract 7018)
Waseem Touma
Board 11
•
Inotuzumab ozogamicin (IO) in combination with low-intensity chemotherapy as front-line
therapy for older patients (pts) and as salvage therapy for adult with R/R acute
lymphoblastic leukemia (ALL). (Abstract 7019)
Elias Jabbour
Board 12
•
Phase I trial of autologous CD19-targeted CAR-modified t cells as consolidation after purine
analog-based first-line therapy in patients with previously untreated CLL. (Abstract 7020)
Jae Hong Park
Board 13
•
Efficacy and safety of imatinib in CML over 10 years. (Abstract 7021)
Rüdiger Hehlmann
Board 14
•
A phase 1b, dose-finding study of ruxolitinib plus panobinostat in patients with myelofibrosis.
(Abstract 7022^)
Florian Heidel
Board 15
•
EPIC: A phase III trial of ponatinib (PON) versus imatinib (IM) in patients (pts) with newly
diagnosed CP-CML. (Abstract 7023)
Jeffrey Howard Lipton
Board 16
•
Ten-year follow up of patients with newly diagnosed chronic myeloid leukemia in chronic
phase treated with 400 mg or 800 mg of imatinib daily. (Abstract 7024)
Koji Sasaki
Board 17
•
Effect of continued imatinib (IM) in pts with detectable BCR-ABL after = 2 years on study on
deep molecular responses (MR): 36-month update from ENESTcmr. (Abstract 7025)
Nelson Spector
Board 19
•
Clinical activity of Crenolanib in patients with D835 mutant FLT3-positive relapsed/refractory
acute myeloid leukemia (AML). (Abstract 7027)
Robert Collins
Board 20
•
A phase I study of the mitochondrial metabolism inhibitor CPI-613 in combination with highdose ara-C (HDAC) and mitoxantrone for relapsed or refractory acute myeloid leukemia
(AML). (Abstract 7028)
Timothy S. Pardee
Board 21
•
Phase I study of Debio1143 (AT406) in combination with daunorubicin (D) and cytarabine
(C) in patients with poor-risk acute myeloid leukemia (AML). (Abstract 7029)
John F. DiPersio
Board 22
•
First results of a phase 2 study using a 10-day subcutaneous (SC) regimen of the novel
hypomethylating agent (HMA) SGI-110 for the treatment of relapsed/refractory acute
myeloid leukemia (r/r AML). (Abstract 7030)
Elizabeth A. Griffiths
Board 23
•
Phase II trial of cladribine and low-dose AraC alternating with decitabine in older patients
with AML. (Abstract 7031)
Tapan M. Kadia
Board 24
•
A phase 1 dose-escalation study of the oral selective inhibitor of nuclear export (SINE) KPT330 (selinexor) in patients (pts) with relapsed/refractory acute myeloid leukemia (AML).
(Abstract 7032)
Karen W. L. Yee
Board 25
•
Mobilization and elimination of FLT3-ITD+ acute myelogenous leukemia (AML)
stem/progenitor cells by plerixafor, G-CSF, and sorafenib: Phase I trial results in
relapsed/refractory AML patients. (Abstract 7033)
Michael Andreeff
•
Small Molecular Inhibitors for Chronic Lymphocytic Leukemia
Javier Pinilla-Ibarz, MD, PhD
•
Harnessing the Immune System in Hematologic Malignancies
Veronika Bachanova, MD
•
Recent Developments in Tyrosine-Kinase Inhibitor Therapy for Myeloproliferative Neoplasms
Michael J. Mauro, MD
•
Novel Targets in Acute Myeloid Leukemia
Joseph G. Jurcic, MD
•
Panel Question and Answer
Session Title: Central Nervous System Tumors
Session Type: General Poster Session
Track: Central Nervous System Tumors
Time: 1:15 PM - 5:00 PM
Location: S Hall A2
Board 2
•
Diagnostic value of plasma and urinary 2-hydroxyglutarate to identify patients with IDHmutated glioma. (Abstract 2037)
Giuseppe Lombardi
Board 3
•
Features of adult clinical trial participants with glioblastoma (GB) at The University of Texas
MD Anderson Cancer Center (MDACC). (Abstract 2038)
Mark Daniel Anderson
Board 4
•
Recurrent glioblastoma: Does the timing of bevacizumab treatment impact survival?
(Abstract 2039)
Susmita Sakruti
Board 5
•
A model to predict the feasibility of concurrent chemoradiotherapy with temozolomide in
glioblastoma multiforme patients over age 65. (Abstract 2040)
Florian Putz
Board 6
•
Predicting GBM response to targeted therapeutics using simulation with ex vivo validations.
(Abstract 2041)
Sandeep C. Pingle
Board 7
•
Survival and quality of life in the randomized, multicenter GLARIUS trial investigating
bevacizumab/irinotecan versus standard temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma patients. (Abstract 2042^)
Ulrich Herrlinger
Board 8
•
An update on high-dose chemotherapy with autologous stem cell transplantation in adults
with recurrent embryonal tumors of the central nervous system. (Abstract 2043)
Ryan Eldredge Wilcox
Board 9
•
Primary central nervous system lymphoma: The influence of radiotherapy on patient
outcome in an unselected population. (Abstract 2044)
Scheryll Paula Alken
Board 10
•
Pilot study of pulse high-dose lapatinib in combination with temozolomide (TMZ) and
radiotherapy (RT) for upfront treatment of glioblastoma (GBM). (Abstract 2045)
Phioanh Leia Nghiemphu
Board 11
•
PC or PCV? That is the question: A retrospective review of primary anaplastic
oligodendroglial tumors treated with procarbazine and CCNU without or with vincristine.
(Abstract 2046)
Courtney C. Webre
Board 12
•
A meta-analysis of antiangiogenic therapy for glioblastoma (GBM). (Abstract 2047)
Mustafa Khasraw
Board 13
•
Association of high volume center with survival for glioblastoma patients: Results from a
prospective population-based registry (PERNO). (Abstract 2048)
Alba Ariela Brandes
Board 14
•
Changing trend of HIV-associated PCNSL over 15 years: A single-center experience.
(Abstract 2049)
Andrew Bayat
Board 15
•
Radiotherapy (RT), temozolomide (TMZ), procarbazine (PCB), and the integrin inhibitor
cilengitide in patients (pts) with glioblastoma (GBM) without methylation of the MGMT gene
promoter (ExCentric): Results of an Australian phase II clinical trial. (Abstract 2050^)
Mustafa Khasraw
Board 16
•
Patterns of tumor progression in a phase 3 study of bevacizumab (Bv) plus radiotherapy (RT)
plus temozolomide (T) for newly diagnosed glioblastoma (GB). (Abstract 2051^)
Wolfgang Wick
Board 17
•
A randomized clinical trial for the treatment of glioblastoma multiforme with the
individualized dendritic cell-based cancer immunotherapy AV0113. (Abstract 2052)
Thomas Felzmann
Board 18
•
Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade
gliomas: Final results. (Abstract 2053)
Andrew David Norden
Board 19
•
REBECA: A phase I study of bevacizumab (BEV) and whole-brain radiation therapy (WBRT)
for treatment of solid tumors brain metastases (BM), EudraCT: 2009-015977-11. (Abstract
2054)
Christelle Levy
Board 20
•
GEINOFOTE: Safety and activity analysis of the use of fotemustine (FT) in different
schedules in progressive high-grade glioma (HGG) in Spain. (Abstract 2055)
Pedro Pérez-Segura
Board 21
•
Management of primary intraocular lymphoma (PIOL): Results from the prospective German
PIOL registry (PIOL-R). (Abstract 2056)
Kristoph Jahnke
Board 22
•
Therapeutic implications of perivascular invasion in the context of high-density brain
microvascular networks: A study on recursive pattern formation in malignant glioma.
(Abstract 2057)
Gregory Joseph Baker
Board 23
•
Histogram analysis of apparent diffusion coefficient within enhancing and nonenhancing
tumor volumes in recurrent glioblastoma patients treated with bevacizumab. (Abstract 2058)
Rifaquat Rahman
Board 25
•
Expression profile of angiogenic factors in paired initial and recurrent glioblastoma. (Abstract
2060)
Emeline Tabouret
Board 26
•
Targetable signaling pathway mutations and progression of IDH-mutant glioma. (Abstract
2061)
Hiroaki Wakimoto
Board 27
•
QOL and neurocognitive functions in patients with GBM. (Abstract 2062)
Christine Marosi
Board 28
•
Delayed contrast MRI: A new paradigm in neuro-oncology. (Abstract 2063)
Yael Mardor
Board 29
•
Surgery for central nervous system tumors in the Brazilian National Health Care System: A
review of 57,361 cases in DATASUS. (Abstract 2064)
Julio Leonardo Barbosa Pereira
Board 30
•
Hypofractionated (HRT) versus standard (SRT) radiotherapy with or without temozolomide
(T) for elderly patients with glioblastoma (GBM). (Abstract 2065)
Shyam Kumar Tanguturi
Board 31
•
A phase 1 study of repeat radiation, minocycline, and bevacizumab in patients with recurrent
glioma (RAMBO). (Abstract 2066)
Adam Louis Cohen
Board 32
•
Prognostic value of pretreatment MRI in breast cancer related leptomeningeal metastases.
(Abstract 2067)
Emilie Le Rhun
Board 33
•
Venous thromboembolism in patients with glioblastoma multiforme. (Abstract 2068)
Natasha Edwin
Board 34
•
Outcomes in patients with unresected glioblastoma including assessment of treatment with
bevacizumab as a component of initial therapy. (Abstract 2069)
Stuart Burri
Board 35
•
Intratumoral heterogeneity of 1p/19q codeletion in brain tumors. (Abstract 2070)
Maria Martinez-Garcia
Board 36
•
Phase IB trial of carboxyamidotriazole orotate (CTO) and temozolomide for recurrent
malignant glioma (MG): A novel mechanism for modulation of multiple oncogenic pathways.
(Abstract 2071)
Antonio Marcilio Padula Omuro
Board 37
•
Phase II study of arsenic trioxide and temozolomide in combination with radiation therapy in
patients with malignant gliomas. (Abstract 2072)
Priya Kumthekar
Board 38
•
Application of a validated predictive model for venous thrombo-embolism in cancer to
patients with glioblastoma. (Abstract 2073)
Ajay Prakash Abad
Board 39
•
Plasma levels and tumor tissue RNA of MMP2 and MMP9 exhibit similar distribution in newly
diagnosed and recurrent glioblastoma (GB). (Abstract 2074)
Emeline Tabouret
Board 40
•
Impact of adverse effects of bevacizumab on survival outcomes of patients with recurrent
glioblastoma. (Abstract 2075)
Mohamed Ali Hamza
Board 41
•
Molecular profiling of low-grade gliomas (LGG) in Colombia (ONCOLGroup). (Abstract 2076)
Andres F. Cardona
Board 42
•
Cost utility analysis of a randomized radiation therapy trial among patients with one to three
brain metastases. (Abstract 2077)
Anna Likhacheva
Board 43
•
A phase II study of whole brain radiotherapy with simultaneous integrated boost using
volumetric modulated arc therapy for 1 to 10 brain metastases. (Abstract 2078)
Alan Nichol
Board 44
•
Lenalidomide in the treatment of relapsed primary central nervous system lymphoma
(PCNSL). (Abstract 2079)
Caroline Houillier
Board 45
•
Preoperative chemotherapy as a new strategy of treatment for low-grade gliomas in
eloquent areas: A phase II study. (Abstract 2080)
Roberta Ruda
Board 46
•
Preliminary evaluation of the tolerability and feasibility of combining 5-amino-levulinic acid (5
-ALA) with carmustine wafers (Gliadel) in the surgical management of primary glioblastoma.
(Abstract 2081)
Colin Watts
Board 47
•
Single-institution retrospective review of newly diagnosed glioblastoma (GBM) patients (pts)
treated on bevacizumab (BEV) in clinical practice. (Abstract 2082)
Henry S. Friedman
Board 48
•
“Salvage” neoadjuvant bevacizumab in newly diagnosed glioblastoma multiforme (GBM).
(Abstract 2083)
Ciprian Barlog
Board 49
•
Immune checkpoint blockade for glioblastoma: Preclinical activity of single agent and
combinatorial therapy. (Abstract 2084)
David A. Reardon
Board 50
•
Angiogenic and procoagulant factors in plasma of brain tumor patients treated with
bevacizumab. (Abstract 2085)
Andrea Pace
Board 51
•
Effect of inhibition of a-secretase activity on cleavage of p75 neurotrophin receptor (p75NTR)
and proliferation of brain tumor initiating cells (BTICs) and malignant gliomas (MGs).
(Abstract 2086)
Rajappa Kenchappa
Board 52
•
Association of increased progression-free survival in primary glioblastomas with lymphopenia
at baseline and activation of NK and NKT cells after dendritic cell immunotherapy. (Abstract
2087)
Marica Eoli
Board 53
•
Gene expression analysis of B-cell receptors (BCR) pathway for identification of PDE4B gene
as potential therapeutic target to overcome glucocorticoid resistance in primary CNS
lymphoma. (Abstract 2088)
Ariz Akhter
Board 54
•
Comparison of hypofractionated radiation with temozolomide to the current standard of care
in the treatment of glioblastoma: Results from a single institution. (Abstract 2089)
Melissa Azoulay
Board 55
•
Revised graded prognostic assessment (GPA) index for small cell lung cancer (SCLC) patients
(pts) with brain metastases (BM). (Abstract 2090)
Lingling Du
Board 56
•
The potential role of 18F-FDOPA PET imaging in low-grade gliomas. (Abstract 2091)
Carmine Maria Carapella
Board 57
•
A phase I study of niraparib in combination with temozolomide (TMZ) in patients with
advanced cancer. (Abstract 2092)
Razelle Kurzrock
Board 58
•
The frequency and impact of ROS1 rearrangement on clinical outcomes in GBM. (Abstract
2093)
Miriam Dorta
Board 59
•
Feasibility of lymphocyte harvesting and reinfusion in patients with newly diagnosed highgrade gliomas. (Abstract 2094)
Jian Li Campian
Board 60
•
Cognitive function and depressive symptoms in patients with newly diagnosed primary brain
tumors: A potential interactive relationship. (Abstract 2095)
John E. Schmidt
Board 61
•
Etirinotecan pegol (EP, NKTR-102) in the treatment of high-grade glioma (HGG): A phase 2
trial. (Abstract 2096)
Seema Nagpal
Board 62
•
Neurocognitive functions in adults treated with radiation for primary brain tumors: A
longitudinal study. (Abstract 2097)
Kim Edelstein
Board 63
•
The utility of MR enhancement as a noninvasive predictor for high-grade histology in patients
with progressive low-grade gliomas: Is histology needed to guide therapy? (Abstract 2098)
Amol Narang
Board 64
•
Primary and secondary malignant meningiomas: A clinical and histological comparison.
(Abstract 2099)
Tareq A. Juratli
Board 65
•
Comprehensive analysis of demographics and survival of pediatric medulloblastoma.
(Abstract 2100)
Therese A. Dolecek
Board 66A
•
Randomized phase IIb study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) alone or in
combination with ipilimumab versus bevacizumab in patients (pts) with recurrent
glioblastoma (GBM). (Abstract TPS2101)
John Howard Sampson
Board 66B
•
Phase II study of atorvastatin in combination with radiotherapy and temozolomide in patients
with glioblastoma. (Abstract TPS2102)
Abdullah Khalaf Altwairgi
Board 67A
•
A phase I trial of sorafenib with whole brain radiotherapy (WBRT) in breast cancer patients
with brain metastases and a correlative study of FLT-PET brain imaging to evaluate
treatment response after WBRT sorafenib. (Abstract TPS2103)
Aki Morikawa
Board 67B
•
Salvage therapy with bendamustine for temozolomide-refractory recurrent anaplastic
gliomas: A prospective phase II trial. (Abstract TPS2104)
Marc C. Chamberlain
Board 68A
•
An Internet-based registry for the documentation of neoplastic meningitis. (Abstract
TPS2105^)
Herwig Matthias Strik
Board 68B
•
Phase I study of the intratumoral administration of an oncolytic polio/rhinovirus recombinant
(PVSRIPO) in recurrent glioblastoma (GBM). (Abstract TPS2106)
Annick Desjardins
Board 69A
•
A phase I/II study of the combination of indoximod and temozolomide for adult patients with
temozolomide-refractory primary malignant brain tumors. (Abstract TPS2107)
Yousef Zakharia
Board 69B
•
Successful treatment of multiple intracranial meningiomas with mifepristone (RU486).
(Abstract TPS2108)
Patrizia Farina
Board 70A
•
Phase I/II study of dianhydrogalactitol in patients with recurrent malignant glioblastoma
multiforme (GBM). (Abstract TPS2109)
Kent C. Shih
Board 70B
•
GEINO-11: A prospective multicenter, open label, phase II pilot clinical trial to evaluate
safety and efficacy of PF-299804 (dacomitinib), a pan-HER irreversible inhibitor, in patients
with recurrent glioblastoma with EGFR amplification or presence of EGFRvIII mutation.
(Abstract TPS2110)
Juan Manuel Sepúlveda
Board 71A
•
First combined intravenous and intracerebral application of an oncolytic virus, parvovirus h-1,
in a phase I/IIa clinical trial in patients with recurrent glioblastoma multiforme (ParvOryx01).
(Abstract TPS2111)
Karsten Geletneky
Board 71B
•
Multidose oxygen therapeutic for radiation sensitization treatment of glioblastoma
multiforme. (Abstract TPS2112)
David Brown Wilson
Session Title: Head and Neck Cancer
Session Type: General Poster Session
Track: Head and Neck Cancer
Time: 1:15 PM - 5:00 PM
Location: S Hall A2
Board 72
•
GDF15 as a potential predictive biomarker for TPF induction chemotherapy in oral squamous
cell carcinoma. (Abstract 6037)
Lai-ping Zhong
Board 73
•
Prognostic significance of multifocalty in papillary thyroid carcinoma: A multivariate analysis
of prognostic factors. (Abstract 6038)
Ivan Markovic
Board 74
•
Risk factors predictive for poor outcomes in patients with human papillomavirus (HPV)initiated oropharyngeal cancer (OPC). (Abstract 6039)
Tobenna Igweonu Nwizu
Board 75
•
Minocycline for reduction of patient-reported symptoms during radiation therapy for head
and neck cancer: First results of a randomized trial. (Abstract 6040)
Gary Brandon Gunn
Board 76
•
Preoperative window-of-opportunity (WOO) study of dacomitinib (Dac) in patients (Pts) with
resectable oral cavity squamous cell carcinoma (OCC): Generation of a gene expression
signature (DGS) as a predictor of Dac activity. (Abstract 6041)
Irene Brana
Board 77
•
Adjuvant radiotherapy (RDT) plus cisplatinum (Cis) and cetuximab (Cet) in resected head
and neck squamous cell carcinoma. (Abstract 6042)
Frederic Peyrade
Board 78
•
Clinical dosimetry analysis of radiation-induced temporal lobe necrosis in nasopharyngeal
carcinoma patients treated with intensity-modulated radiotherapy. (Abstract 6043)
Jin Yi Lang
Board 79
•
Phase lb/ll study of the PI3Ka inhibitor BYL719 in combination with cetuximab in
recurrent/metastatic squamous cell cancer of the head and neck (SCCHN). (Abstract 6044)
Albiruni R. A. Razak
Board 80
•
Phase 2 study of dalantercept in recurrent or metastatic squamous cell carcinoma of the
head and neck. (Abstract 6045)
Antonio Jimeno
Board 81
•
Boron neutron capture therapy in patients with recurrent head and neck cancers who have
no other treatment options. (Abstract 6046)
Itsuro Kato
Board 82
•
Impact of tumor metabolic response by PET/CT on the survival after salvage re-irradiation of
head and neck cancers. (Abstract 6047)
Tawee Tanvetyanon
Board 83
•
Comparison of outcomes of locoregionally advanced oropharyngeal and non-oropharyngeal
SCC over two decades. (Abstract 6048)
Lauren C. Herman
Board 84
•
A dose-finding study of nanoparticle albumin-bound paclitaxel plus cisplatin in patients with
metastatic nasophyngeal carcinomas. (Abstract 6049)
Li Zhang
Board 85
•
Preliminary testing of a patient-reported outcome measure for recurrent or metastatic head
and neck cancer. (Abstract 6050)
Leanne Kolnick Jackson
Board 86
•
Internal lymphedema correlation with subjective and objective measures of dysphagia in
head and neck cancer. (Abstract 6051)
Leanne Kolnick Jackson
Board 87
•
Is there a survival benefit in patients with advanced squamous cell carcinoma of the head
and neck under chemoradiotherapy or radiotherapy alone after surgery administration: A
systematic review and meta-analysis. (Abstract 6052)
Jinbiao Shang
Board 88
•
Quality of life of patients with locally advanced head and neck cancer (LAHNC) treated with
docetaxel/cisplatin/5-fluorouracil (TPF) followed by cisplatin-containing chemoradiotherapy
(CRT). (Abstract 6053)
Chantal Driessen
Board 89
•
Gefitinib with concurrent chemoradiation in locally advanced head and neck cancers.
(Abstract 6054)
Charu Singh
Board 90
•
Surgery and definitive chemoradiation (CRT) for locally advanced oropharyngeal cancer and
impact of transoral robotic surgery (TORS). (Abstract 6055)
Charles Eric Wooten
Board 91
•
Degree of nephrotoxicity after intermediate or high-dose cisplatin-based chemoradiotherapy
(CRT) in patients with locally advanced head and neck cancer (LAHNC). (Abstract 6056)
Chantal Driessen
Board 92
•
Aggressive treatment and survival outcomes in NUT midline carcinoma (NMC) of the head
and neck (HN). (Abstract 6057)
Nicole Grace Chau
Board 93
•
Neck dissection for oral mucosal melanoma: Caution of nodular lesion. (Abstract 6058)
Wei Guo
Board 94
•
A double-blind, randomized, placebo-controlled trial of l-glutamine for the severe oral
mucositis induced by chemoradiotherapy in patients with locally advanced head and neck
cancer. (Abstract 6059)
Takae Tsujimoto
Board 95
•
Updated overall survival analysis of patients with locally advanced or metastatic radioactive
iodine-refractory differentiated thyroid cancer (RAI-rDTC) treated with sorafenib on the
phase 3 DECISION trial. (Abstract 6060^)
Marcia S. Brose
Board 96
•
Population PK modeling and exposure-response analyses of sorafenib in patients with
radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) in the phase III
DECISION trial. (Abstract 6061^)
Lars Bastholt
Board 97
•
Safety and tolerability of sorafenib for treatment of locally advanced or metastatic radioactive
iodine-refractory differentiated thyroid cancer (RAI-rDTC): Detailed analyses from the phase
III DECISION trial. (Abstract 6062^)
Francis P. Worden
Board 98
•
Pharmacokinetic and pharmacogenetic analysis in patients with advanced nasopharyngeal
carcinoma (NPC) treated with 5-flurouracil (5-FU) and cisplatin. (Abstract 6063)
Yuxiang Ma
Board 99
•
Association of young patient age with high-risk pathologic features and recurrence in
papillary thyroid cancer. (Abstract 6064)
Iris Wei
Board 100
•
Does age impact treatment of head and neck squamous cell carcinomas? A
retrospective monocentric study about 107 patients age 75 and over. (Abstract 6065)
Laurence Digue
Board 101
•
Survival disparities and trend of head and neck cancer in the United States: A Surveillance,
Epidemiology, and End Results (SEER) database study 1973-2010. (Abstract 6066)
Shahzad Raza
Board 102
•
Postsurgical erlotinib and cisplatin concurrent chemoradiotherapy (CRT) promotes favorable
outcomes in high-risk locally advanced head and neck squamous-cell cancer (LAHNSCC): A
GICOR Working Group trial. (Abstract 6067)
Fernando Arias
Board 103
•
Expressions of EGFR, HER2, and HER3 and their correlations with clinical characteristics in
oropharyngeal squamous cell carcinoma (OPSCC). (Abstract 6068)
Nabil F. Saba
Board 104
•
Head and neck cancer (HN) characteristics and outcomes in a human immunodeficiency virus
infected (HIV+) patient cohort: A 12-year experience of the Louisiana State University Health
Sciences Center (LSUHSC) and Charity Hospital in New Orleans. (Abstract 6069)
J. Nicholas Bodor
Board 105
•
Docetaxel (DOC) with concurrent radiation (CRT) and bevacizumab (BEV) or erlotinib (ERL)
for locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN). (Abstract
6070)
Panayiotis Savvides
Board 106
•
Patterns of distant metastases in HPV-positive head and neck squamous cell carcinoma.
(Abstract 6071)
Jennie York Law
Board 107
•
Detection of novel HPV mutations and chromosomal number imbalance (CNI) in laryngeal
cancer using next-generation sequencing (NGS). (Abstract 6072)
Howard B. Urnovitz
Board 110
•
Comparison of three different induction regimen in nasopharyngeal cancer: CF versus DC
versus DCF. (Abstract 6075)
Neyran Kertmen
Board 111
•
Dynamic changes in epithelial to mesenchymal composition and prognostic relevance of
circulating cancer cells (CTCs) in head and neck squamous cell carcinoma (HNSCC).
(Abstract 6076)
Elena Mihal Vagia
Board 112
•
Toxicities of tyrosine kinase inhibitors: Occurrence of hemoptysis and tracheo-oesophageal
fistula in 150 patients with advanced thyroid cancer. (Abstract 6077)
Livia Lamartina
Board 113
•
Expression of interleukin-1a (IL1-a) and risk of distant metastases (DM) in head and neck
squamous cell carcinoma (HNSCC). (Abstract 6078)
Antonio Lopez-Pousa
Board 114
•
The effect of proteolytic enzyme-containing gargling agents on severe stomatitis caused by
therapy for head and neck cancer. (Abstract 6079)
Masatoshi Ohmae
Board 115
•
Molecular profiling of HPV-positive and -negative HNSCC. (Abstract 6080)
Rebecca Feldman
Board 116
•
Prediction of HNSCC recurrence by using kinetic and volumetric FDG-PET parameters.
(Abstract 6081)
Ronan Abgral
Board 117
•
Phase I trial of intratumoral therapy using HF10, an oncolytic HSV-1, demonstrates safety in
HSV+/HSV- patients with refractory and superficial cancers. (Abstract 6082)
Robert L. Ferris
Board 118
•
Oropharyngeal cancer (OPC) and racial outcome disparities in squamous cell carcinoma of
the head and neck (HNSCC): Ten-year experience at the University of Maryland Greenebaum
Cancer Center (UMGCC). (Abstract 6083)
Dan Paul Zandberg
Board 119
•
Inferior local control for T2bN0 glottic carcinoma with impaired mobility treated with
radiation alone: A need for more chemotherapy? (Abstract 6084)
Priyanka Bhateja
Board 120
•
Racial disparities in the incidence and survival trends in women with squamous cell
carcinoma of the oral tongue based on the Surveillance, Epidemiology, and End Results
(SEER) analysis. (Abstract 6085)
Lindsay Joseph
Board 121
•
Expression of tumor biomarkers in HIV-infected patients with head and neck cancer.
(Abstract 6086)
Hongzheng Zhang
Board 122
•
Nasopharyngeal carcinoma patients with new primaries. (Abstract 6087)
Musa Altun
Board 123
•
Molecular predictors of response to sorafenib in patients with radioactive iodine-resistant
advanced thyroid cancer. (Abstract 6088)
Mark Yarchoan
Board 124
•
Effect of the addition of temsirolimus to cetuximab in cetuximab-resistant head and neck
cancers: Results of the randomized PII MAESTRO study. (Abstract 6089)
Apoorva Chawla
Board 125
•
Phase II trial of radiotherapy (RT) with concurrent cisplatin (C) plus panitumumab (pmAb)
for patients (pts) with high-risk, resected head and neck cancer (HNC). (Abstract 6090)
Robert L. Ferris
Board 126
•
Effect of FGFR1 on epithelial-mesenchymal transition and EGFR resistance in HNC: A systems
biology approach. (Abstract 6091)
Damian Rieke
Board 127
•
Impact of lymph node ratio on survival in advanced head and neck cancer: National Cancer
Data Base (NCDB). (Abstract 6092)
Sukamal Saha
Board 128
•
Phase II study of axitinib in patients with progressive, recurrent/metastatic adenoid cystic
carcinoma. (Abstract 6093)
Alan Loh Ho
Board 129
•
Correlation of homologous recombination deficiency in head and neck cancer with sensitivity
to PARP inhibition. (Abstract 6094)
Jana Heitmann
Board 130
•
Prognostic value of radiographic extracapsular extension in locally advanced head and neck
squamous cell cancers. (Abstract 6095)
Jerry T. Liu
Board 131
•
A retrospective study to determine the utility of measuring E6 and E7 antibody (Ab) levels in
sera as a biomarker of recurrence in patients (pts) with locally advanced (LA), human
papillomavirus-positive (HPV+) oropharyngeal squamous cell carcinoma (OPSCC). (Abstract
6096)
Assuntina Gesualda Sacco
Board 132A
•
A phase I/II randomized study of Debio1143 combined with concurrent chemoradiation
therapy (CCRT) in patients with locally advanced squamous cell carcinoma of the head and
neck (LA-SCCHN). (Abstract TPS6097^)
Christophe Le Tourneau
Board 132B
•
A randomized, multicenter phase III clinical trial comparing gemcitabine and cisplatin with 5fluorouracil and cisplatin in the treatment of recurrent or metastatic nasopharyngeal
carcinoma. (Abstract TPS6098)
Li Zhang
Board 133A
•
Elderly Head and Neck Cancer (ELAN) study: Personalized treatment according to geriatric
assessment in patients age 70 or older: First prospective trials in patients with squamous cell
cancer of the head and neck (SCCHN) unsuitable for surgery. (Abstract TPS6099)
Joel Guigay
Board 133B
•
Multicenter, randomized, controlled, open-label study of bevacizumab combined
with carboplatin and paclitaxel versus carboplatin and
paclitaxel in patients with metastatic nasopharyngeal carcinoma. (Abstract TPS6100)
Li Zhang
Board 134A
•
Personalized cancer therapy for patients with metastatic medullary thyroid cancer (MTC).
(Abstract TPS6101)
Krzysztof Misiukiewicz
Board 134B
•
Randomized phase II trial of weekly paclitaxel, carboplatin, cetuximab (PCC) versus
cetuximab, docetaxel, cisplatin, and fluorouracil (C-TPF) in previously untreated patients with
locally advanced head and neck squamous cell carcinoma. (Abstract TPS6102)
Erminia Massarelli
Board 135A
•
A phase I/II clinical trial of sorafenib in combination with cisplatin and docetaxel in patients
with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN). (Abstract
TPS6103)
Panayiotis Savvides
Board 135B
•
Phase I trial of cetuximab, intensity modulated radiotherapy (IMRT), and the anti-CTLA-4
monoclonal antibody (mAb) ipilimumab in previously untreated, locally advanced head and
neck squamous cell carcinoma (PULA HNSCC). (Abstract TPS6104)
Julie E. Bauman
Board 136A
•
Predictor: Randomized phase II study of preoperative afatinib in untreated nonmetastatic
head and neck squamous cell carcinoma patients (HNSCC) aiming at identifying predictive
and pharmacodynamic biomarkers of efficacy. (Abstract TPS6105)
Christophe Le Tourneau
Board 136B
•
PAZOTHYR: A randomized, multicenter, open-label, phase II study of the optimal scheme of
pazopanib in radioactive iodine-refractory differentiated thyroid carcinoma (RAIR-DTC).
(Abstract TPS6106)
Christelle De La Fouchardiere
Session Title: Lung Cancer - Non-small Cell Local-regional/Small Cell/Other Thoracic Cancers
Session Type: General Poster Session
Track: Lung Cancer
Time: 1:15 PM - 5:00 PM
Location: S Hall A2
Board 141
•
Postoperative chemotherapy as effective as preoperative for N2-positive stage III non-small
cell lung cancer. (Abstract 7533)
Daniel J Boffa
Board 142
•
When is a pathologic diagnosis preferred before stereotactic ablative radiotherapy for stage I
lung cancer? A decision analysis. (Abstract 7534)
Alexander V. Louie
Board 143
•
Analysis of treatment duration and safety of adjuvant erlotinib (E) versus placebo (P) after
surgery in patients (pts) with non-small cell lung cancer (NSCLC): RADIANT trial. (Abstract
7535)
Mary E.R. O'Brien
Board 144
•
Nonadherence of adjuvant radiation in NSCLC patients with N2 disease after lobectomy.
(Abstract 7536)
Yan Xing
Board 145
•
KIF5B-RET fusion gene and oncogenic mutations of EGFR or KRAS gene in lung
adenocarcinomas. (Abstract 7537)
Jin Hyoung Kang
Board 146
•
A novel gene signature to predict distant metastasis in stage I lung cancer patient following
local therapy with surgery or stereotactic body radiation therapy (SBRT). (Abstract 7538)
Sungjune Kim
Board 147
•
Final overall survival (OS) results from a phase II study of pemetrexed (Pem) and cisplatin
(Cis) with concurrent thoracic radiation (RT) after Pem-Cis induction in patients with
unresectable locally advanced (LA) nonsquamous non-small cell lung cancer (NS-NSCLC).
(Abstract 7539^)
Silvia Novello
Board 148
•
Impact of comorbidity and age on survival among older veterans with early stage non-small
cell lung cancer (NSCLC). (Abstract 7540)
Melisa L. Wong
Board 149
•
Patterns of surveillance after curative intent surgery in elderly stage I-IIIA non-small cell
lung cancer patients. (Abstract 7541)
Christine Agnes Ciunci
Board 150
•
Phase II study of induction chemotherapy with carboplatin, paclitaxel, and bevacizumab
followed by surgery in patients with stage III nonsquamous non-small cell lung cancer: The
Tokyo Cooperative Oncology Group trial (TCOG1002) (Abstract 7542)
Toshihiko Iizasa
Board 151
•
Stereotactic body radiotherapy versus lobectomy for operable clinical stage IA pulmonary
adenocarcinoma: Comparison of prospective clinical trials with propensity score analysis
(JCOG1313-A). (Abstract 7543)
Junko Eba
Board 152
•
Candidates for intensive local treatment in cIIIA-N2 NSCLC: Impact of mediastinal nodal
extent and appearance. (Abstract 7544)
Hidehito Horinouchi
Board 153
•
A randomized phase III trial comparing triple weekly usage with weekly usage of paclitaxel
in concurrent chemoradiotherapy for patients with locally advanced non-small cell lung
cancer. (Abstract 7545)
Guangying Zhu
Board 154
•
Genetic features of pulmonary adenocarcinoma presenting with ground-glass nodules (GGN):
Differences between those with growth potential and those without. (Abstract 7546)
Yoshihisa Kobayashi
Board 155
•
Early detection of lung cancer based on three-dimensional, morphometric analysis of cells
from sputum. (Abstract 7547)
Alan Nelson
Board 156
•
Computed tomography (CT) imaging features in early-stage lung adenocarcinoma
differentiating exon 19 and exon 21 epidermal growth factor receptor (EGFR) mutated
tumors. (Abstract 7548)
Benjamin F. Chu
Board 157
•
When should surgeons begin surveillance with CT scans after lobectomy for stage 1A nonsmall cell lung cancer? (Abstract 7549)
Mohan K. Mallipeddi
Board 158
•
Serum biomarker analysis of WJOG4107: A randomized phase II trial of adjuvant
chemotherapy with S-1 versus CDDP+S-1 for resected stage II-IIIA non-small cell lung
cancer (NSCLC). (Abstract 7550)
Tetsuya Mitsudomi
Board 159
•
The effect of institutional clinical trial enrollment volume on survival of patients with stage III
non-small cell lung cancer treated with chemoradiation: A report of the Radiation Therapy
Oncology Group (RTOG) 0617. (Abstract 7551)
Bree Ruppert Eaton
Board 160
•
Nodal stage of surgically resected non-small cell carcinoma of the lung and its effect on
recurrence pattern and survival. (Abstract 7552)
Satvik Ramakrishna
Board 161
•
Are the criteria indicating patients to be “medically inoperable” that are used in clinical trials
on stereotactic body radiotherapy appropriate for patients with early-stage non-small cell
lung cancer? (Abstract 7553)
Kazuya Takamochi
Board 162
•
Clinical characteristics and outcomes of atypical carcinoid (AC) tumor of the lung: A
Surveillance, Epidemiology, and End Results database analysis. (Abstract 7554)
Conor Ernst Steuer
Board 163
•
Lobectomy, sublobar resection, and stereotactic radiation for early-stage non-small cell lung
cancers in the elderly. (Abstract 7555)
Shervin Mohajer Shirvani
Board 164
•
Computed tomographic window setting for predicting invasive adenocarcinomas in
pulmonary nonsolid tumors. (Abstract 7556)
Takashi Eguchi
Board 165
•
A randomized phase II trial of concurrent chemoradiation of oral vinorelbine and two doses
of radiotherapy, 60 and 66 Gy, in local-regionally advanced non-small cell lung cancer (LANSCLC). (Abstract 7557)
Olfred Hansen
Board 166
•
The impact of EGFR mutation on definitive concurrent chemoradiation therapy for inoperable
stage III lung adenocarcinoma. (Abstract 7558)
Kosuke Tanaka
Board 167
•
MiRNA profiling by NGS in resectable non-small cell lung cancer: Prognostic implications.
(Abstract 7559)
Sandra Gallach
Board 168
•
Breath analysis as a noninvasive biomarker for early detection of lung cancer. (Abstract
7560)
Nir Peled
Board 169
•
Treatment-related deaths after concurrent chemoradiotherapy in locally advanced non-small
cell lung cancer: A meta-analysis of randomized studies. (Abstract 7561)
Jing Zhao
Board 170
•
Tumor expression levels of CSC markers in resectable non-small cell lung cancer. (Abstract
7562)
Silvia Calabuig
Board 171
•
A comparative study of blood-based KRAS mutation analysis in circulating tumor cells versus
circulating plasma DNA to predict primary tumor mutations in lung cancer. (Abstract 7563)
Eric Kian Saik Lim
Board 172
•
Cisplatin and etoposide versus carboplatin and paclitaxel with concurrent radiation for stage
III non-small cell lung cancer: An analysis of Veterans Health Administration data. (Abstract
7564)
Rafael Santana-Davila
Board 173
•
Significance of the estrogen signaling pathway in EGFR wild-type lung adenocarcinoma.
(Abstract 7565)
Kazumi Tanaka
Board 174
•
Evaluation of a lung cancer RNA expression subtyping panel and comparison with histologic
diagnosis in lung tumor samples from multiple data sets including The Cancer Genome Atlas
(TCGA). (Abstract 7566)
Mark Robert Miglarese
Board 175
•
Clinical characteristics and molecular profile in patients with non-small cell lung cancer
harboring CRKL amplification. (Abstract 7567)
Hirotsugu Kenmotsu
Board 176
•
Association between metformin (M) use and survival among non-small cell lung cancer
(NSCLC) patients (pts). (Abstract 7568)
Alice K Fortune-Greeley
Board 177
•
Concordance of PD-L1 expression by different immunohistochemistry (IHC) definitions and in
situ hybridization (ISH) in squamous cell carcinoma (SCC) of the lung. (Abstract 7569)
Alex Martinez Marti
Board 178
•
Clinicopathologic characteristics and prognostic impact of MET receptor overexpression in
patients with stage I-IIIA squamous cell lung carcinomas (SQCLCs). (Abstract 7570)
Matthew David Hellmann
Board 179
•
The impact of a novel lung gross dissection protocol on intrapulmonary lymph node (LN)
retrieval from lung cancer (LC) resection specimens. (Abstract 7571)
Raymond U. Osarogiagbon
Board 180
•
Phase II study of biomarker guided neoadjuvant treatment strategy for IIIA-N2 non-small
cell lung cancer based on EGFR-mutation status. (Abstract 7572)
Wenzhao Zhong
Board 181
•
Role for surgical resection in the multidisciplinary treatment of stage ???? non-small cell lung
cancer (NSCLC). (Abstract 7573)
Matthew Bott
Board 182
•
Role of PET scan in predicting response to neoadjuvant chemotherapy and long-term
outcomes for stage II lung cancer. (Abstract 7574)
Ankit Bharat
Board 183
•
Diffusion of stereotactic body radiotherapy (SBRT) for early-stage non-small cell lung cancer
(NSCLC) in the Medicare population, 2007-2009. (Abstract 7575)
James B. Yu
Board 184
•
A phase II study of S-1 and concurrent thoracic radiotherapy (TRT) for elderly pts with
locally advanced non-small cell lung cancer (LA-NSCLC): Okayama Lung Cancer Study Group
trial 0801. (Abstract 7576)
Yoshiro Fujiwara
Board 185
•
Increasing ER stress response in pemetrexed-resistant mesothelioma cells. (Abstract 7577)
Yuying Luo
Board 186
•
Malignant pleural mesothelioma: A 21-year single-center experience. (Abstract 7578)
Mathieu D. Saint-Pierre
Board 187
•
A phase II trial of prolonged, continuous infusion of low-dose gemcitabine plus cisplatin in
patients with advanced malignant pleural mesothelioma. (Abstract 7579)
Oscar Rodriguez
Board 188
•
Prognostic significance of circulating secreted protein acidic and rich in cysteine (SPARC) in
malignant pleural mesothelioma (MPM). (Abstract 7580)
Steven Chuan-Hao Kao
Board 189
•
A multicenter phase II toxicity study of lung-sparing intensity modulated radiation therapy
(IMRT) for malignant pleural mesothelioma (MPM). (Abstract 7581)
Marjorie Glass Zauderer
Board 190
•
Blood tests in malignant pleural mesothelioma (MPM). (Abstract 7582)
Kazue Yoneda
Board 191
•
Dendritic cell vaccination in malignant pleural mesothelioma: A phase I/II study. (Abstract
7583)
Zwi N. Berneman
Board 192
•
Impact of treatment-free interval (TFI) and disease control rate (DCR) on survival outcome
in relapsed malignant pleural mesothelioma (MPM). (Abstract 7584)
Vanesa Gregorc
Board 193
•
Association of activation of mTOR and MAPK signal pathway with prolonged survival in
patients with malignant pleural mesothelioma. (Abstract 7585)
Ayumi Kuroda
Board 194
•
Old and new prognostic factors in a series of 910 patients with malignant pleural
mesothelioma (MPM). (Abstract 7586)
Anthony Linton
Board 195
•
Metabolomic analysis of pegylated arginine deiminase treatment in patients with malignant
pleural mesothelioma. (Abstract 7587)
Essam Ahmed Ghazaly
Board 196
•
Enhancing accurate prediction of survival outcomes and aiding decision making in malignant
pleural mesothelioma (MPM) using a three-item index from the LCSS-meso PRO measure:
Results from a randomized 444 patient (pt) prospective trial. (Abstract 7588)
James Thomas Symanowski
Board 197
•
T-cell inflamed phenotype and PDL1 expression in malignant mesothelioma. (Abstract 7589)
Hedy Lee Kindler
Board 198
•
Clinical and molecular profiling of surgically resected small-cell lung cancer: Intergroup study
with FIGHT002 and HOT1301. (Abstract 7590)
Hiroshi Yokouchi
Board 199
•
Retrospective evaluation of prophylactic cranial irradiation in patients with limited-stage
small cell lung cancer with stereotactic radiotherapy: A multi-institutional study. (Abstract
7591)
Yuichi Ozawa
Board 200
•
Multiplex testing of potentially ‘actionable’ alterations in small cell lung cancer (SCLC).
(Abstract 7592)
Shirish M. Gadgeel
Board 201
•
Pharmacokinetics (PK) and exposure-response (ER) of rilotumumab (Rmab) in patients (pts)
with small-cell lung cancer (SCLC). (Abstract 7593)
Yilong Zhang
Board 202
•
Final results of a phase I study of amrubicin and cyclophosphamide in patients with
advanced solid organ malignancies: HOG LUN 07-130. (Abstract 7594)
Shadia Ibrahim Jalal
Board 203
•
A randomized, multicenter phase III study of lobaplatin/etoposide versus cisplatin/etoposide
as first-line therapy in patients with extensive-stage small-cell lung cancer and circulating
tumor cells (CTCs) as an exploratory biomarker. (Abstract 7595)
Ying Cheng
Board 204
•
Comparison of cisplatin- versus carboplatin-based concurrent chemoradiation for limitedstage small cell lung cancer using SEER-Medicare data. (Abstract 7596)
Ellen Kim
Board 205
•
Clinical outcomes of patients with recurrent small cell lung cancer receiving third-line
chemotherapy. (Abstract 7597)
Koichi Saruwatari
Board 206
•
Limited-stage small cell lung cancer treated with cisplatin/irinotecan and concurrent thoracic
radiation therapy. (Abstract 7598)
Salini Sathya Naidu
Board 207
•
Trends in small cell lung cancer (SCLC) survival: Predictors and impact of systemic therapy.
(Abstract 7599)
Madhusmita Behera
Board 208
•
Final outcome results of platinum-sensitive small cell lung cancer (SCLC) patients treated
with platinum-based chemotherapy rechallenge: A multi-institutional retrospective analysis.
(Abstract 7600)
Giovenzio Genestreti
Board 209
•
Phase 1b of anticancer stem cell antibody OMP-59R5 (anti-Notch2/3) in combination with
etoposide and cisplatin (EP) in patients (pts) with untreated extensive-stage small-cell lung
cancer (ED-SCLC). (Abstract 7601)
David R. Spigel
Board 210
•
Phase I trial of the hedgehog (Hh) inhibitor, LDE225, in combination with etoposide and
cisplatin (EP) for initial treatment of extensive stage small cell lung cancer (ES-SCLC).
(Abstract 7602)
Maria Catherine Pietanza
Board 211
•
Clinical characteristics and outcomes for patients with thymic carcinoma: Evaluation of
Masaoka staging. (Abstract 7603)
Anna Maria Litvak
Board 212
•
Outcomes of thymic neoplasms after the 1999 WHO classification. (Abstract 7604)
Yousif Yonan
Board 213
•
National multidisciplinary tumor board (MTB): Report of the first 526 questions raised within
RYTHMIC, the network for thymic malignancies in France. (Abstract 7605)
Benjamin Besse
Board 214
•
Programmed death receptor ligand-1 (PD-L1) expression in a thymoma (T) tissue microarray
(TMA). (Abstract 7606)
Sukhmani Kaur Padda
Board 215
•
Mesothelin expression in thymic epithelial tumors (TETs). (Abstract 7607)
Yuanbin Chen
Board 216A
•
START2: Tecemotide in unresectable stage III NSCLC after first-line concurrent
chemoradiotherapy. (Abstract TPS7608)
Suresh S. Ramalingam
Board 216B
•
Randomized, double-blind, placebo-controlled study of tremelimumab for second- and thirdline treatment of unresectable pleural or peritoneal mesothelioma. (Abstract TPS7609^)
Michele Maio
Board 217A
•
Phase I-Ib trial of tivantinib in combination with carboplatin and pemetrexed as first-line
treatment in patients (pts) with advanced nonsquamous NSCLC or malignant pleural
mesothelioma (MPM). (Abstract TPS7610)
Paolo A. Zucali
Board 217B
•
COMMAND: A phase II randomized, double-blind, placebo-controlled, multicenter study of
defactinib as maintenance therapy in subjects with malignant pleural mesothelioma that has
not progressed on at least four cycles of pemetrexed/platinum therapy. (Abstract TPS7611)
Dean Anthony Fennell
Board 218A
•
Nintedanib plus pemetrexed/cisplatin followed by maintenance nintedanib for unresectable
malignant pleural mesothelioma (MPM): An international, multicenter, randomized, doubleblind, placebo-controlled phase II study. (Abstract TPS7612)
Giorgio V. Scagliotti
Session Title: Lung Cancer - Non-small Cell Metastatic
Session Type: General Poster Session
Track: Lung Cancer
Time: 1:15 PM - 5:00 PM
Location: S Hall A2
Board 220
•
The KRAS-variant and treatment response in BATTLE-1. (Abstract 8135)
Joanne B. Weidhaas
Board 221
•
Sunitinib (S) switch maintenance in advanced non-small cell lung cancer (NSCLC): An
ALLIANCE (CALGB 30607), randomized, placebo-controlled phase III trial. (Abstract 8040)
Mark A. Socinski
Board 222
•
Randomized phase III study comparing gefitinib (G) with erlotinib (E) in patients (pts) with
previously treated advanced lung adenocarcinoma (LA): WJOG 5108L. (Abstract 8041)
Nobuyuki Katakami
Board 223
•
BATLLE-2: KRAS mutation and outcome in a biomarker-integrated study in previously
treated patients (pts) with advanced non-small cell lung cancer (NSCLC). (Abstract 8042)
Vassiliki Papadimitrakopoulou
Board 224
•
E7080 (lenvatinib) in addition to best supportive care (BSC) versus BSC alone in third-line or
greater nonsquamous, non-small cell lung cancer (NSCLC). (Abstract 8043)
Libor Havel
Board 225
•
Tivantinib plus erlotinib versus placebo plus erlotinib in Asian patients with previously treated
nonsquamous NSCLC with wild-type EGFR: First report of a phase III ATTENTION trial.
(Abstract 8044)
Koichi Azuma
Board 226
•
Phase 2 HERALD study of patritumab (P) with erlotinib (E) in advanced NSCLC subjects
(SBJs). (Abstract 8045)
Joachim Von Pawel
Board 227
•
Efficacy and safety results from CurrentS, a double-blind, randomized, phase III study of
second-line erlotinib (150 mg versus 300 mg) in current smokers with advanced non-small
cell lung cancer (NSCLC). (Abstract 8046)
Egbert F. Smit
Board 228
•
Updated efficacy and safety of the ALK inhibitor AP26113 in patients (pts) with advanced
malignancies, including ALK+ non-small cell lung cancer (NSCLC). (Abstract 8047)
Scott N. Gettinger
Board 229
•
Analysis of NTRK1 gene fusion incidence in an unselected cohort of non-small cell lung
cancer patients. (Abstract 8048)
Robert Charles Doebele
Board 230
•
Identifying ALK rearrangements that are not detected by FISH with targeted nextgeneration sequencing of lung carcinoma. (Abstract 8049)
Siraj M. Ali
Board 231
•
A randomized phase 2 study of a human antiplatelet-derived growth factor a (PDGFRa)
monoclonal antibody (olaratumab, IMC-3G3) with paclitaxel/carboplatin or
paclitaxel/carboplatin alone in previously untreated patients with advanced non-small cell
lung cancer (NSCLC). (Abstract 8050)
David E. Gerber
Board 232
•
A randomized phase 2 trial of MM-121, a fully human monoclonal antibody targeting ErbB3,
in combination with erlotinib in EGFR wild-type NSCLC patients. (Abstract 8051)
Lecia V. Sequist
Board 233
•
Phase II study of erlotinib plus tivantinib in patients with EGFR-mutation–positive NSCLC
who failed in immediately previous EGFR-TKI therapy. (Abstract 8052)
Tomonori Hirashima
Board 234
•
Variation in mechanisms of acquired resistance (AR) among EGFR-mutant NSCLC patients
with more than one post-resistant biopsy. (Abstract 8053)
Zofia Piotrowska
Board 235
•
Randomized phase 2 trial of plinabulin (NPI-2358) plus docetaxel in patients with advanced
non-small cell lung cancer (NSCLC). (Abstract 8054)
Rebecca Suk Heist
Board 236
•
The Lung Cancer Genomic Screening Project for Individualized Medicine in Japan (LCSCRUM-Japan): Screening for RET and ROS1 fusions in advanced EGFR mutation-negative
nonsquamous lung cancer and development of molecular targeted therapy. (Abstract 8055)
Kiyotaka Yoh
Board 237
•
An international, multicenter, randomized, double-blind phase III study of maintenance
belagenpumatucel-l in non-small cell lung cancer (NSCLC): Updated analysis of patients
enrolled within 12 weeks of completion of chemotherapy. (Abstract 8056)
Lyudmila Bazhenova
Board 238
•
Molecular profiling of non-small cell lung cancer by histologic subtype. (Abstract 8057)
Solange Peters
Board 239
•
The use of improved and complete enrichment co-amplification at lower denaturation
temperature (ICE COLD-PCR) method for the detection of EGFR and KRAS mutations from
cell-free plasma DNA of non-small cell lung cancer (NSCLC) patients. (Abstract 8058)
Hai T. Tran
Board 240
•
Prediction of lung cancer genotype noninvasively using droplet digital PCR (ddPCR) analysis
of cell-free plasma DNA (cfDNA). (Abstract 8059)
Adrian G. Sacher
Board 241
•
HER2 mutations in lung adenocarcinoma: A report from the Lung Cancer Mutation
Consortium (LCMC). (Abstract 8060)
Rathi Narayana Pillai
Board 242
•
Retrospective analysis of type of KRAS mutation (mut) and response to first-line platinumbased chemotherapy (PC) in non-small cell lung cancer (NSCLC) patients (pts). (Abstract
8061)
Wouter Willem Mellema
Board 243
•
Description of ALK+ NSCLC patient characteristics and ALK testing patterns. (Abstract 8062)
Heather A. Wakelee
Board 244
•
Regulation of tumor cell PD-L1 expression by microRNA-200 and control of lung cancer
metastasis. (Abstract 8063)
Don Lynn Gibbons
Board 245
•
Domain-specific PD-L1 protein measurement in non-small cell lung cancer (NSCLC). (Abstract
8064)
Joseph Francis McLaughlin
Board 246
•
Improving clinical prognostic categories beyond performance status: Enhancing accuracy in
survival prediction with a three-item patient-reported outcome (PRO) index from the LCSS in
lung cancer and mesothelioma. (Abstract 8065)
Richard J. Gralla
Board 247
•
PD-L1 expression and survival in patients with non-small cell lung cancer (NSCLC) in Korea.
(Abstract 8066)
Jong-Mu Sun
Board 248
•
Spatiotemporal T790M heterogeneity in individual patients with non-small cell lung cancer
(NSCLC) after acquired resistance to EGFR-tyrosine kinase inhibitor (TKI). (Abstract 8067)
Akito Hata
Board 249
•
A phase 1 study evaluating the safety and efficacy of DKN-01, an investigational monoclonal
antibody (Mab) in patients (pts) with advanced non-small cell lung cancer. (Abstract 8068)
William Jeffery Edenfield
Board 250
•
Effect of angiotensin system inhibitors on survival in patients receiving chemotherapy for
advanced non-small cell lung cancer. (Abstract 8069)
Alex R. Menter
Board 251
•
Canadian ALK (CALK): A multicenter, prospective study of concurrent ALK
immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) in NSCLC.
(Abstract 8070)
Jean Deschenes
Board 252
•
Observational study of treatment with epidermal growth factor receptor tyrosine kinase
inhibitors (EGFR-TKI) in activating EGFR-mutation–positive (EGFRm+) advanced or recurrent
non-small cell lung cancer (NSCLC) after radiologic progression to first-line therapy with
EGFR-TKI. (Abstract 8071)
Yukio Hosomi
Board 253
•
Effect of BIM and mTOR expression on clinical outcome to erlotinib in EGFR-mutant nonsmall cell lung cancer (NSCLC) patients (p). (Abstract 8072)
Niki Karachaliou
Board 254
•
Exploring therapeutic targets in pulmonary sarcomatoid carcinoma by comprehensive
genomic profiling. (Abstract 8073)
Xuewen Liu
Board 255
•
Alterations in two oncogenic drivers: Impact of concurrent PIK3CA or AKT1 mutations in
patients with oncogene-driven lung adenocarcinomas. (Abstract 8074)
Juliana Eng
Board 256
•
Clinicopathologic features of lung cancer patients harboring de novo EGFR T790M mutation.
(Abstract 8075)
Young Joo Lee
Board 257
•
Clinicopathologic features of advanced RET fusion-positive lung cancers and outcomes in
comparison to other fusion-positive lung cancers. (Abstract 8076)
Alexander E. Drilon
Board 258
•
A phase II clinical trial of the CDK 4/6 inhibitor palbociclib (PD 0332991) in previously
treated, advanced non-small cell lung cancer (NSCLC) patients with inactivated CDKN2A.
(Abstract 8077)
Priya Kadambi Gopalan
Board 259
•
Ceritinib in Asian versus Caucasian patients (Pts) with advanced anaplastic lymphoma kinase
(ALK)-rearranged (ALK+) NSCLC: Subgroup analysis of the ASCEND-1 trial. (Abstract 8078^)
Daniel Shao-Weng Tan
Board 260
•
Phase IB study to evaluate efficacy and tolerability of olaparib (AZD2281) plus gefitinib in
patients (P) with epidermal growth factor receptor (EGFR) mutation positive advanced nonsmall cell lung cancer (NSCLC) (NCT=1513174/GECP-GOAL). (Abstract 8079)
Rosario Garcia Campelo
Board 261
•
A prospective, multicenter phase II trial of low-dose erlotinib monotherapy for patients with
previously treated non-small cell lung cancer (NSCLC) with activating mutation of epidermal
growth factor receptor (EGFR): Thoracic Oncology Research Group (TORG) 0911. (Abstract
8080)
Yoshiro Nakahara
Board 262
•
EGFR mutation status in cerebrospinal fluid of NSCLC patients who developed
leptomeningeal metastasis after EGFR-TKI treatment. (Abstract 8081)
Jing Zhao
Board 263
•
Clinical significance of TILs subtypes in non-small cell lung cancer. (Abstract 8082)
Kurt A. Schalper
Board 264
•
Integrated genomic analysis for revealing broad remodeling of EGFR-targeted therapyresistant lung cancers. (Abstract 8083)
Petros Giannikopoulos
Board 266
•
A phase II trial of first-line nab-paclitaxel/carboplatin versus gemcitabine/carboplatin in
advanced squamous cell carcinoma of the lung (CTONG1002). (Abstract 8085)
Jinji Yang
Board 267
•
Genomic characterization of non-small cell lung cancer by targeted massively parallel
sequencing in African Americans. (Abstract 8086)
Luiz H. Araujo
Board 268
•
Further molecular profiling of tumors harboring therapeutic targets within non-small cell lung
cancer. (Abstract 8087)
Solange Peters
Board 269
•
A multicenter randomized phase II trial of erlotinib with and without hydroxychloroquine
(HCQ) in TKI-naive patients (pts) with epidermal growth factor receptor (EGFR) mutant
advanced non-small cell lung cancer (NSCLC). (Abstract 8088)
Joel W. Neal
Board 270
•
A randomized phase II study of paclitaxel-carboplatin-bevacizumab (PCB) with or without
nitroglycerin patches (NTG) in patients (pts) with stage IV nonsquamous non-small cell lung
cancer (NSCLC): Nvalt 12 (NCT01171170). (Abstract 8089)
Anne-Marie C. Dingemans
Board 271
•
Implementation of clinical next-generation sequencing (NGS) of non-small cell lung cancer
(NSCLC) to identify EGFR amplification as a potentially targetable oncogenic alteration.
(Abstract 8090)
Geoffrey R. Oxnard
Board 272
•
Randomized, controlled, multicenter, multinational phase 2 study of docetaxel (DCT) or
AXL1717 treatment in patients with squamous cell carcinoma (SCC) or adenocarcinoma (AC)
of non-small cell lung cancer (NSCLC). (Abstract 8091)
Michael Bergqvist
Board 273
•
EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison
of technologies to support the clinical development of AZD9291. (Abstract 8092)
Kenneth Thress
Board 274
•
Detection of sensitizing and resistance EGFR mutations from circulating tumor DNA (ctDNA)
in blood using multiplexed next-generation sequencing in patients with advanced EGFRmutant lung adenocarcinoma. (Abstract 8093)
Sarah B. Goldberg
Board 275
•
Randomized, open-label trial evaluating the preventive effect of tetracycline on afatinib
induced-skin toxicity in non-small cell lung cancer patients. (Abstract 8094)
Oscar Arrieta
Board 276
•
Multiplex genomic profiling of non-small cell lung cancer patients enrolled in the LETS phase
III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin (WJOG6611LTR). (Abstract
8095)
Hiroshige Yoshioka
Board 277
•
Immunohistochemically determined EGFR mutations in NSCLC. (Abstract 8096)
Nina Turnsek
Board 278
•
Molecular testing prior to first-line therapy in patients with stage IV nonsquamous non-small
cell lung cancer (NSCLC): A survey of U.S. medical oncologists. (Abstract 8097)
Mark R. Green
Board 279
•
Effect of reflex testing by pathologists on molecular testing rates in lung cancer patients:
Experience from a community-based academic center. (Abstract 8098)
Cengiz Inal
Board 280
•
Lung cancer in never-smokers from the Princess Margaret Cancer Centre. (Abstract 8099)
Grzegorz Korpanty
Board 281
•
Antiangiogenic-specific adverse events (AEs) in patients with non-small cell lung cancer
(NSCLC) treated with nintedanib (N) and docetaxel (D). (Abstract 8100)
Martin Reck
Board 282
•
A meta-analysis of smoking status on clinical outcomes of non-small cell lung cancer patients
harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line
EGFR tyrosine kinase inhibitor. (Abstract 8101)
Yoshikazu Hasegawa
Board 283
•
A phase II trial of cabazitaxel in patients with metastatic NSCLC progressing after docetaxelbased treatment. (Abstract 8102)
Athanasios Kotsakis
Board 284
•
Antitumor activity of alectinib (CH5424802/RO5424802) for ALK-rearranged NSCLC with or
without prior crizotinib treatment in bioequivalence study. (Abstract 8103)
Kazuhiko Nakagawa
Board 285
•
An updated systematic review and meta-analysis of randomized controlled trials on duration
of chemotherapy for advanced non-small cell lung cancer. (Abstract 8104)
Yu Yang Soon
Board 286
•
PIK3CA as a prognostic marker in non-small cell lung cancer of squamous cell carcinoma
type. (Abstract 8105)
Odd Terje Brustugun
Board 287
•
Characterization of heart rate (HR) changes during crizotinib treatment: A retrospective
analysis of 1,053 ALK+ NSCLC patients. (Abstract 8106)
Sai-Hong Ignatius Ou
Board 288
•
Exon 19 deletion association with progression-free survival compared to L858R mutation at
exon 21 in treatment with first-line EGFR-TKIs: A meta-analysis of subgroup data from eight
phase III randomized controlled trials. (Abstract 8107)
Wenhua Liang
Board 289
•
Clinical impact of gastric acid suppressing medication use on the efficacy of elrotinib and
gefitinib in patients with advanced non-small cell lung cancer harboring EGFR mutations.
(Abstract 8108)
Yoshitaka Zenke
Board 290
•
TRY: A phase II study to evaluate safety and efficacy of combined trastuzumab and AUY922
in advanced non-small cell lung cancer (NSCLC) with HER2 overexpression or amplification or
mutation. (Abstract 8109)
Lucia Nogova
Board 291
•
Phase I trial of icotinib combined with whole brain radiotherapy for EGFR-mutated non-small
cell lung cancer patients with brain metastases. (Abstract 8110)
Lin Zhou
Board 292
•
Stage at diagnosis as a prognostic marker for patients with KRAS-mutant metastatic lung
adenocarcinomas. (Abstract 8111)
Helena Alexandra Yu
Board 293
•
Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients (pts) with advanced non-smallcell lung cancer (NSCLC): Survival and clinical activity by subgroup analysis. (Abstract
8112^)
Julie R. Brahmer
Board 294
•
Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet
chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC). (Abstract 8113)
Scott Joseph Antonia
Board 295
•
Tumor regression as a continuous variable and survival in advanced non-small cell lung
cancer (NSCLC). (Abstract 8114)
David J. Stewart
Board 296
•
Advanced NSCLC: Finding the right prescription for oncologist education. (Abstract 8115)
Tara Herrmann
Board 297
•
Validation study of graded prognostic assessment (GPA) of non-small cell lung cancer
(NSCLC) patients with brain metastasis (BM). (Abstract 8116)
Eberechi Sandra Agwa
Board 298
•
Final overall survival results of WJTOG 3405, a randomized phase 3 trial comparing gefitinib
(G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small
cell lung cancer (NSCLC) harboring mutations of the epidermal growth factor receptor
(EGFR). (Abstract 8117)
Hiroshige Yoshioka
Board 299A
•
Galaxy-2 trial (NCT01798485): A randomized phase 3 study of ganetespib in combination
with docetaxel versus docetaxel alone in patients with advanced lung adenocarcinoma.
(Abstract TPS8118^)
Suresh S. Ramalingam
Board 299B
•
A single arm, open-label, phase II study to assess the efficacy of lucitanib in patients with
FGFR1-amplified squamous NSCLC (sqNSCLC). (Abstract TPS8119^)
David R. Spigel
Board 300A
•
Multiarm, nonrandomized, open-label phase IB study to evaluate FP1039/GSK3052230 with
chemotherapy in NSCLC and MPM with deregulated FGF pathway signaling. (Abstract
TPS8120)
Pilar Garrido Lopez
Board 300B
•
Phase I/II multicenter, randomized, open-label trial of the c-Met inhibitor MSC2156119J and
gefitinib versus chemotherapy as second-line treatment in patients with MET-positive (MET
+), locally advanced, or metastatic non-small cell lung cancer (NSCLC) with epidermal
growth factor mutation (EGFRm+) and progression on gefitinib. (Abstract TPS8121)
Yi-Long Wu
Board 301A
•
A phase II cluster study of single agent AUY922, BYL719, INC280, LDK378, and MEK162 in
Chinese patients with advanced non-small cell lung cancer (NSCLC). (Abstract TPS8122)
Qing Zhou
Board 301B
•
Clinical trials of MPDL3280A (anti-PDL1) in patients (pts) with non-small cell lung cancer
(NSCLC). (Abstract TPS8123)
Naiyer A. Rizvi
Board 302A
•
A phase II/III randomized trial of two doses of MK-3475 versus docetaxel in previously
treated subjects with non-small cell lung cancer. (Abstract TPS8124)
Roy S. Herbst
Board 303A
•
A phase 2 study of defactinib (VS-6063), a cancer stem cell inhibitor that acts through
inhibition of focal adhesion kinase (FAK), in patients with KRAS-mutant non-small cell lung
cancer. (Abstract TPS8126)
David E. Gerber
Board 303B
•
Open, phase II randomized trial of gefitinib alone versus olaparib (AZD2281) plus gefitinib in
advanced non-small cell lung cancer (NSCLC) patients (P) with epidermal growth factor
receptor (EGFR) mutations: Spanish Lung Cancer Group trial (NCT=1513174/GECP-GOAL).
(Abstract TPS8127)
Bartomeu Massuti
Board 304A
•
A phase III, randomized, open-label trial of nivolumab (anti-PD-1; BMS-936558, ONO-4538)
versus investigator's choice chemotherapy (ICC) as first-line therapy for stage IV or recurrent
PD-L1+ non-small cell lung cancer (NSCLC). (Abstract TPS8128)
David Paul Carbone
Board 304B
•
Stimulating an immune response through bavituximab in a phase III lung cancer study.
(Abstract TPS8129)
David E. Gerber
Board 305A
•
A randomized, double-blind, multicenter phase 2 trial of denosumab in combination with
chemotherapy as first-line treatment of metastatic non-small cell lung cancer. (Abstract
TPS8130)
David R. Spigel
Board 305B
•
NEJ009 trial: A randomized phase III study of gefitinib (G) in combination with carboplatin
(C) plus pemetrexed (P) versus G alone in patients with advanced nonsquamous non-small
cell lung cancer (NSCLC) with EGFR mutation. (Abstract TPS8131)
Akira Inoue
Board 306A
•
Metformin with a carbohydrate-restricted diet in combination with platinum-based
chemotherapy in advanced-stage lung adenocarcinoma. (Abstract TPS8132)
Benjamin Philip Levy
Board 306B
•
NLG-0301: An open-label, randomized phase 2B active control study of second-line
tergenpumatucel-L immunotherapy versus docetaxel in patients with progressive or relapsed
non-small cell lung cancer (NSCLC). (Abstract TPS8133)
Ramaswamy Govindan
Session Title: Tumor Biology
Session Type: General Poster Session
Track: Tumor Biology
Time: 1:15 PM - 5:00 PM
Location: S Hall A2
Board 319
•
Differences in circulating angiogenic biomarkers as prognosticator for outcome in
bevacizumab-treated nonsquamous non-small cell lung cancer (NSCLC) patients. (Abstract
11037)
Marta Batus
Board 320
•
Biologic pathways associated with breast cancer metastases to the brain. (Abstract 11038)
Vinay Varadan
Board 321
•
Antitumor activity of MP0250, a bispecific VEGF- and HGF-targeting darpin, in patient-derived
xenograft models. (Abstract 11039)
Ulrike Fiedler
Board 322
•
A Markov chain model of a longitudinal breast cancer data set. (Abstract 11040)
Paul K. Newton
Board 323
•
A pilot study for cellular detection of circulating tumor cells and disseminated tumor cells of
patients with hepatocellular carcinoma. (Abstract 11041)
Nozomi Minagawa
Board 324
•
Effect of exemestane plus everolimus on CTC counts and Ki-67 expression on CTCs in
patients with advanced hormone receptor-positive, HER2-negative breast cancer. (Abstract
11042)
Sofia Agelaki
Board 325
•
Tumorspheres cultured from circulating epithelial tumor cells (CETCs) as diagnostic marker in
patients with solid cancers. (Abstract 11043)
Katharina Pachmann
Board 326
•
Bisphosphonate treatment of primary breast cancer patients with disseminated tumor cells in
the bone marrow. (Abstract 11044)
Andreas D. Hartkopf
Board 327
•
Epithelial-to-mesenchymal (EMT) markers and nanomechanical signatures of circulating
tumor cells (CTC) for prediction of men with castrate-sensitive versus castration-resistant
prostate cancer (PCa). (Abstract 11045)
Devalingam Mahalingam
Board 328
•
Identification through genome-wide association study (GWAS) of single nucleotide
polymorphisms (SNPs) associated with extreme phenotypes of tobacco-induced non-small
cell lung cancer (NSCLC) risk. (Abstract 11046)
Jose Luis Perez-Gracia
Board 329
•
Systematic review of a personalized strategy in cancer clinical trials leading to FDA approval.
(Abstract 11047)
Denis Leonardo Fontes Jardim
Board 330
•
Targeted next-generation sequencing (NGS) of carcinoma of unknown primary site (CUP):
Actionable genomic alterations (GA) and new routes to targeted therapies. (Abstract 11048)
Jeffrey S. Ross
Board 331
•
Noninvasive monitoring of dynamics of acquired EGFR-T790M mutation and discovery of its
heterogeneity in patients with advanced NSCLC treated with EGFR-TKI. (Abstract 11049)
Di Zheng
Board 332
•
Clinical utility of the 12-gene DCIS score assay: Impact on treatment (Tx) recommendations.
(Abstract 11050)
Michael Alvarado
Board 333
•
Targeted deep sequencing from circulating plasma DNA as a multipurpose biomarker in pts
(pts) referred for phase I trials. (Abstract 11051)
Jean-Sebastien Frenel
Board 334
•
Prediction of recurrence with the Oncotype DX recurrence score in node-positive, HRpositive, breast cancer patients treated with adjuvant chemotherapy: Results from PACS01
trial. (Abstract 11052)
Frederique Madeleine Penault-Llorca
Board 335
•
Molecular abnormalities of 17 types of gastrointestinal cancer in an international cohort of
11,324 patients. (Abstract 11053)
Gargi Dan Basu
Board 336
•
Quantification of T790M mutation in EGFR-mutant lung adenocarcinoma with nanofluidic
digital PCR arrays. (Abstract 11054)
Kazutoshi Isobe
Board 337
•
Prognostic potential of MDM2 309T>G polymorphism in stage I lung adenocarcinoma.
(Abstract 11055)
Kimihiro Shimizu
Board 338
•
Association of KRAS mutations in cell-free circulating tumor DNA with occurrence of
resistance to TKIs in NSCLC. (Abstract 11056)
Marzia Del Re
Board 339
•
Genomic characterization of metastatic cisplatin-resistant samples from urothelial cancer
patients. (Abstract 11057)
Yohann Loriot
Board 340
•
Aromatase inhibitors in elderly patients with advanced breast cancer: An exploratory
pharmacogenetic study. (Abstract 11058)
Enrica Rumiato
Board 341
•
The FGFR landscape in cancer: An analysis of 4,869 cases. (Abstract 11059)
Teresa L Helsten
Board 342
•
Evaluation of PI3K-pathway–activation status in matched primary (P) and metastatic (M) ER
+/HER2- breast cancer (BC) lesions according to PIK3CA-mutation status. (Abstract 11060)
Debora Fumagalli
Board 343
•
Prognostic and predictive role of circulating angiopoietin-2 in multiple solid tumors: An
analysis of approximately 500 patients treated with lenvatinib across tumor types. (Abstract
11061)
Ignace Vergote
Board 344
•
Prognostic ability of CD44 expression in ER-positive breast cancer. (Abstract 11062)
Yesim Gokmen-Polar
Board 345
•
INDUCT: A risk score to predict relapse in estrogen-receptor–positive breast cancer.
(Abstract 11063)
Steven Buechler
Board 346
•
Classifying endometrioid endometrial cancer by long noncoding RNA profiling: Indication of
prognosis and therapy selection. (Abstract 11064)
Yunyun Jiang
Board 347
•
Prediction of late relapse in patients with estrogen receptor-positive breast cancer. (Abstract
11065)
Steven Buechler
Board 348
•
A 5-gene signature based on TLR4 signaling as predictive of risk of distant relapse in breast
cancer treated with taxane-anthracycline neoadjuvant chemotherapy. (Abstract 11066)
Joseph A. Pinto
Board 349
•
Genomic profiling of breast cancer in African American women. (Abstract 11067)
Raquel Nunes
Board 350
•
Incidence of inconsistent driver mutations between multiple lung ground-glass nodules in
patients with non-small cell lung cancer. (Abstract 11068)
Shengxiang Ren
Board 351
•
TP53-mutation status by gene-expression signature (TP53 signature) and prediction of
efficacy of neoadjuvant chemotherapy (NAC) and recurrence after surgery in breast cancer.
(Abstract 11069)
Shin Takahashi
Board 352
•
Whole genome sequencing (WGS) to identify H. pylori and its impact on the gastric
microbiome. (Abstract 11070)
Manish A. Shah
Board 354
•
A tool to predict post-transcriptional instability related to the dysregulation of the SETD2
histone methyltransferase in renal cell carcinoma (RCC). (Abstract 11072)
Mia D. Champion
Board 355
•
GBM cell microvesicles carrying gDNA oncogenic sequences cross the BBB and reach the
peripheral blood. (Abstract 11073)
Esther Holgado
Board 356
•
Variation in the ESR-1 gene as a prognostic marker in early breast cancer survival. (Abstract
11074)
Danny Houtsma
Board 357
•
Whole-genome bisulfite sequencing of a complex karyotype AML and identification of
regulatory aberrations distinct from normal karyotype AML. (Abstract 11075)
Stephen Capone
Board 358
•
Next-generation sequencing (NGS) as part of pathologic diagnostic armamentarium.
(Abstract 11076)
Lorna Rodriguez-Rodriguez
Board 359
•
Inferring clonal composition from multiple sections of a breast cancer. (Abstract 11077)
C. Anthony Blau
Board 360
•
Pathway-based signature analysis of RNA-seq data to reveal new targetable avenues for
metastatic castration-resistant prostate cancer (mCRPC) patients (pts): Preliminary results
from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT). (Abstract
11078)
Adrian Bivol
Board 361
•
A national platform for molecular diagnostics: Results of the Cancer Research U.K. Stratified
Medicine Programme. (Abstract 11079)
Emily Shaw
Board 362
•
FGFR and FGF ligand overexpression in lung cancer: Implications for targeted therapy.
(Abstract 11080)
Krishna Maddula
Board 363
•
Effects of concomitant therapies on ?d T-cell responses to zoledronate in patients with
advanced prostate cancer. (Abstract 11081)
Deborah Enting
Board 364
•
Effect of lymphoid tissue inducer cells on lymphatic tumor cell invasion via activation of the
RANKL/RANK axis within triple-negative breast cancers. (Abstract 11082)
Sheeba Irshad
Board 365
•
PD-L1 specific tumor infiltrating lymphocytes occur frequently in melanoma and HNSCC
patients. (Abstract 11083)
Niels Junker
Board 366
•
Incidence and localization of tumor-infiltrating CD163+ macrophages and T-cells in early
breast cancer patients. (Abstract 11084)
Anna Koumarianou
Board 367
•
Prognostic role of immune checkpoint-related genes in resectable lung adenocarcinomas.
(Abstract 11085)
Marta Usó
Board 368
•
Gene-expression profiling to demonstrate select neutrophils from breast cancer patients
versus healthy women as cytotoxic against breast cancer cells via novel chemokine-mediated
mechanisms. (Abstract 11086)
Elizabeth Anne Comen
Board 369
•
Prognostic and predictive value of tumor infiltrating lymphocytes (TIL) in two phase III
randomized adjuvant breast cancer (BC) trials. (Abstract 11087)
Maria Vittoria Dieci
Board 370
•
Preclinical profile of ASPH_0047, a potent and selective antisense oligonucleotide targeting
transforming growth factor beta 2 (TGF-ß2). (Abstract 11088)
Michel Janicot
Board 371
•
Enabling a genetically informed approach to cancer medicine: A retrospective evaluation of
the impact of comprehensive tumor profiling using a targeted next-generation sequencing
panel. (Abstract 11089)
Douglas Buckner Johnson
Board 372
•
89Zr-bevacizumab PET imaging of disease manifestations in patients with Von Hippel-Lindau
disease. (Abstract 11090)
Sjoukje Oosting
Board 373
•
Highly sensitive and quantitative detection of EGFR T790M mutationin tumor samples by
nanofluidic digital PCR. (Abstract 11091)
Eiji Iwama
Board 374
•
Quality assurance study of real-time targeted massive parallel sequencing (MPS)
comprehensive cancer panel (CCP) and network pathway analysis in early breast cancer
(EBC). (Abstract 11092)
Paul N. Mainwaring
Board 375
•
Circulating tumor DNA (ctDNA) as a molecular monitoring tool in metastatic breast cancer
(MBC). (Abstract 11093)
Laura Katherine Austin
Board 376
•
Detection of EGFR mutations of serum circulating DNA. (Abstract 11094)
Zongfei Li
Board 377
•
Phase I imaging study of the HER3 antibody RG7116 using 89Zr-RG7116-PET in patients
with metastatic or locally advanced HER3-positive solid tumors. (Abstract 11095)
Frederike Bensch
Board 378
•
Usefulness of l-[3-18f]-a-methyl tyrosine (18F-FAMT) PET as therapeutic monitoring for
patients with advanced lung cancer. (Abstract 11096)
Kyoichi Kaira
Board 379
•
Copenhagen prospective personalized oncology (CoPPO): Sequencing and array-based
pipeline for selection of patients to phase 1 studies. (Abstract 11097)
Ida Elisabeth Viller Tuxen
Board 380
•
Integrative whole-genome copy number analysis and mutation profiling of FFPE brain tumor
specimens and potential in designing multi-arm clinical trials. (Abstract 11098)
Shakti Ramkissoon
Board 381
•
Correlation of circulating miRNA levels with progression-free survival (PFS) and overall
survival (OS) in early-stage lung adenocarcinoma. (Abstract 11099)
Francesco Grignani
Board 382
•
Correlation of hypoxia measured by fluorine-18 fluoroerythronitroimidazole (18F-FETNIM)
PET/CT and the malignant progression of gliomas. (Abstract 11100)
Man Hu
Board 383
•
Sensitivity and specificity of an oral uracil-loading test dose for screening for DPD deficiency.
(Abstract 11101)
M C van Staveren
Board 384
•
ImmunoPET imaging with 89Zr-cetuximab in patients with advanced colorectal cancer.
(Abstract 11102)
Catharina Wilhelmina Menke
Board 385
•
Preclinical evaluation of anti-MET antibodies for immunohistochemical staining. (Abstract
11103)
Hartmut Koeppen
Board 386
•
The NIH genetic testing registry: Hereditary, pharmacogenetic, and somatic tests for
oncology practice. (Abstract 11104)
Wendy S. Rubinstein
Board 387
•
Incorporation of FGFR1 and FGFR2 amplification status determination in routine molecular
prescreening for targeted therapies. (Abstract 11105)
Ludmila Prudkin
Board 388
•
Identification of a rare germ-line variant in the TP53 3’UTR in individuals with the LiFraumeni-like phenotype: A new mechanism of cancer predisposition? (Abstract 11106)
Gabriel de Souza Macedo
Board 389
•
Subtype analysis from the GEICAM/2003-02 study: High-risk, node-negative breast cancer
patients treated with adjuvant fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus
FAC followed by weekly paclitaxel. (Abstract 11107)
Federico Rojo
Board 390
•
Development of a histology-guided gene expression tumor classifier for cancer of unknown
primary (CUP). (Abstract 11108)
Linda R. Mileshkin
Board 391
•
Effect of clinical NGS-based cancer genomic profiling on physician treatment decisions in
advanced solid tumors. (Abstract 11109)
Fadi S. Braiteh
Board 392
•
PET/CT assessment of tumor perfusion in metastatic renal cell carcinoma (RCC) before and
during sunitinib: A comparison of 15O-water with 62Cu-ETS. (Abstract 11110)
Theodore F. Logan
Board 393
•
First-in-human phase I study of a selective c-Met inhibitor volitinib (HMP504/AZD6094) in
patients with advanced solid tumors. (Abstract 11111)
Hui Kong Gan
Board 394
•
Effect of adoptive T-cell therapy and intratumoral heat-killed bacteria on large tumors.
(Abstract 11112)
David C. Binder
Board 395
•
First-in-human phase 1 dose-escalation study of AV-203, a monoclonal antibody against
ERBB3, in patients with metastatic or advanced solid tumors. (Abstract 11113)
John Sarantopoulos
Board 397
•
Clinical next-generation sequencing to identify actionable alterations in a phase I program.
(Abstract 11115)
Genevieve Marie Boland
Board 398
•
A chemogenomic screening platform for identification of protein kinase CK2 as a novel target
for prosenescence therapy in PTEN-null tumors. (Abstract 11116)
Madhuri Kalathur
Board 399
•
Frequency of concurrent gene mutations and copy number alterations in circulating cell-free
DNA (cfDNA) from refractory metastatic CRC patients. (Abstract 11117)
M. Pia Morelli
Board 400
•
Clinical significance of CD169-positive lymph node macrophages in human malignant tumors.
(Abstract 11118)
Koji Ohnishi
Board 401
•
Mesothelin expression as a predictive biomarker of breast cancer outcomes. (Abstract 11119)
Yun Rose Li
Board 402
•
Hedgehog signalling in primary cervix xenograft (OCICx) models: A potential new
therapeutic target in combination with chemoradiotherapy. (Abstract 11120)
Naz Chaudary
Board 403
•
Reduction rate of the maximal value of the baseline standardized uptake value on fluorine-18
fluorodeoxyglucose positron emission tomography/computed tomography to predict
response of breast cancer to neoadjuvant chemotherapy. (Abstract 11121)
Takayuki Kadoya
Board 404
•
The CXCL12/CXCR4 pathway, bone marrow-derived myeloid cells, and survival in locally
advanced cervical cancer. (Abstract 11122)
Naz Chaudary
Board 405
•
Investigations into the antiradition effects of BP-C2, a benzene-poly-carboxylic acid complex
with molybdenum. (Abstract 11123)
Stig Larsen
Board 406
•
WNT inhibitory factor-1 (WIF-1): A new role in carcinogenesis? (Abstract 11124)
Tan Wei Chow
Board 407
•
Combined immunophenotyping of tumor-infiltrating lymphocytes as a prognostic factor in
resected patients with non-small cell lung cancer. (Abstract 11125)
Ross A. Soo
Board 408
•
The association of treatment-emergent proteinuria (TEP) with baseline/treatment variables in
patients (pts) treated with antiangiogenic tyrosine kinase inhibitors (AA-TKIs): A pooled
analysis of NCIC Clinical Trial Group (NCIC CTG) trials. (Abstract 11126)
Maria Bonomi
Board 409
•
Essential experimental steps and estimates of renal carcinoma initiating cells. (Abstract
11127)
Craig Gedye
Board 410
•
RANKL circulating levels in the evaluation of bone response in breast cancer (BC) patients.
(Abstract 11128)
Toni Ibrahim
Board 411
•
Association of stromal cell gene expression with response to neoadjuvant chemotherapy in
locally advanced breast cancer. (Abstract 11129)
Rene Aloisio da Costa Vieira
Board 412
•
Patient-derived xenografts from breast cancer patients before and after neoadjuvant
chemotherapy: A prospective study. (Abstract 11130)
Judy Caroline Boughey
Board 413
•
Immune responses induced by the TLR-4 agonist-based adjuvant prothymosin alpha.
(Abstract 11131)
Pinelopi Samara
Board 414A
•
DETECT III/IV: Two combined clinical trials based on the phenotype of circulating tumor
cells (CTCs). (Abstract TPS11132)
Susanne Albrecht
Board 414B
•
Pharmacist-led lung cancer biomarker detection. (Abstract TPS11133)
Emer Ann Sheridan
Board 415A
•
GEFCAPI 04: A phase III trial comparing a treatment oriented by a molecular analysis with
CancerTYPE ID test to cisplatin-gemcitabine in patients with carcinoma of an unknown
primary (CUP). (Abstract TPS11134)
Geraldine Martineau
Board 415B
•
A phase I study of the safety and activation of a cathepsin-activatable fluorescent cancerspecific probe LUM015. (Abstract TPS11135)
Melodi Javid Whitley
Board 416A
•
A prospective study to compare qPCR to IHC and FISH for the detection of anaplastic
lymphoma kinase (ALK) fusions in FFPE specimens from NSCLC patients ( PCRTALK).
(Abstract TPS11136)
David Richard Hout
Session Title: ASCO/American Association for Cancer Research (AACR) Joint
Session: Inflammatory Cells and Cancer
Session Type: Special Session
Track: Special Session
Time: 3:00 PM - 4:15 PM
Location: S100a
•
Welcome and Introductions
Charles L. Sawyers, MD - Co-Chair
•
Stromal Inflammation and Solid Tumors
Andrew Dannenberg, MD
•
Immunoscore and Cancer
Jerome Galon, PhD
•
Microbiome: Role in Tumor Promotion
Michael Karin, PhD
•
Closing Comments
Clifford A. Hudis, MD, FACP - Co-Chair
Session Title: Clinical Utility of Genetic Profiling in Myeloid Malignancies
Session Type: Education Session
Track: Leukemia, Myelodysplasia, and Transplantation
Time: 3:00 PM - 4:15 PM
Location: E450
•
Mutational Profiling in the Management and Prognosis of Acute Myeloid Leukemia
Ross L. Levine, MD - Chair
•
Making Sense of the Mutations in Myelodysplastic Syndrome: Can We Improve Outcomes?
Benjamin Levine Ebert, MD, PhD
•
Molecular Monitoring and Mutations in Chronic Myelogenous Leukemia: How to Get the Most
Out of Your Tyrosine-Kinase Inhibitors
Michele Baccarani, MD
•
Panel Question and Answer
Session Title: Community Oncology Town Hall: Ongoing and Future Issues for Practice
Session Type: Education Session
Track: Practice Management and Information Technology
Time: 3:00 PM - 4:15 PM
Location: S404
•
Challenges and Strategies to Improve Community Practice
John Vernon Cox, DO - Chair
•
Meaningful Physician Payment Reform in Oncology
Mark B. McClellan, MD, PhD
•
Fee-for-Service and Reimbursement Issues
Jeffery C. Ward, MD
•
Issues Related to the Cost and the Value of New Drugs
John C. Hornberger, MD, MS, FACP
•
Issues Related to Palliative Care Clinics
Jennifer S. Temel, MD
•
Patient-Centered Oncology Homes
Barbara L. McAneny, MD
•
Panel Question and Answer
Session Title: From Coley to Cure? Past, Present, and Future of Immunotherapy for Melanoma
Session Type: Education Session
Track: Melanoma/Skin Cancers
Time: 3:00 PM - 4:15 PM
Location: S406
•
History and Future of Cytokines and Vaccine Therapy for Melanoma
Walter John Urba, MD, PhD - Chair
•
Update on Immune Checkpoint Blockade
F. Stephen Hodi, MD
•
The Future of Adoptive Cell Transfer as a Treatment Modality for Melanoma
Patrick Hwu, MD
•
Panel Question and Answer
Session Title: Management of Oligometastatic Disease and Oligoprogression of Non-Small Cell
Lung Cancer - Ticketed Session
Session Type: Meet the Professor Session
Track: Lung Cancer
Time: 3:00 PM - 4:15 PM
Location: E451a
•
Management of Oligometastatic Disease and Oligoprogression of Non-Small Cell Lung Cancer
Corey J. Langer, MD
Session Title: Treatment of Elderly Patients with Complications Related to Colorectal Cancer Ticketed Session
Session Type: Clinical Problems in Oncology Session
Track: Gastrointestinal (Colorectal) Cancer
Time: 3:00 PM - 4:15 PM
Location: E451b
•
Approaches to the Geriatric Patient
Gregory A. Masters, MD
•
Dermatologic Issues with the New Targeted Agents
Mario E. Lacouture, MD
•
Management of Cancer and Cancer Treatment–Related Fatigue
Eduardo Bruera, MD - Chair
Session Title: Outcomes and Interventions in Older Cancer Patients and Survivors
Session Type: Clinical Science Symposium
Track: Patient and Survivor Care
Time: 3:00 PM - 4:30 PM
Location: E253
•
Chair
William W. Tse, MD
•
Chair
Stuart M. Lichtman, MD
•
Decline of cognitive functions among elderly localized breast cancer patients after adjuvant
treatment: COG-AGE study. (Abstract 9509)
Florence Joly
•
Is Chemo Brain Worse in the Elderly?
Arti Hurria, MD
•
Standardized, progressive exercise program (EXCAP) to reduce psychological distress and
improve inflammatory cytokines of distress among prostate cancer survivors. (Abstract 9510)
Charles Stewart Kamen
•
The Benefits of Exercise in the Elderly
Nathan A. Berger, MD
•
Predictive factors of early death during 100 days after a comprehensive geriatric assessment
in older patients with cancer: A prospective cohort study of 576 patients. (Abstract 9511)
Rabia Boulahssass
•
Using Geriatric Assessment to Predict Early Mortality
Martine Extermann, MD, PhD
•
Panel Question and Answer
Session Title: Unleashing the Immune System in Genitourinary Cancers
Session Type: Clinical Science Symposium
Track: Genitourinary Cancer
Time: 3:00 PM - 4:30 PM
Location: E Arie Crown Theater
•
Chair
Sumanta Kumar Pal, MD
•
Nivolumab for metastatic renal cell carcinoma (mRCC): Results of a randomized, doseranging phase II trial. (Abstract 5009)
Robert J. Motzer
•
Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib
in patients (pts) with metastatic renal cell carcinoma (mRCC). (Abstract 5010)
Asim Amin
•
Tipping the Balance Towards Immunosurveillance with PD-1 Blockade
Lauren Christine Harshman, MD
•
Inhibition of PD-L1 by MPDL3280A and clinical activity in pts with metastatic urothelial
bladder cancer (UBC). (Abstract 5011)
Thomas Powles
•
Immunomodulatory activity of nivolumab in previously treated and untreated metastatic
renal cell carcinoma (mRCC): Biomarker-based results from a randomized clinical trial.
(Abstract 5012)
Toni K. Choueiri
•
PD-1/PD-L1 Inhibition: Identifying Relevant Biomarkers
Padmanee Sharma, MD, PhD
•
Panel Question and Answer
Session Title: Breast Cancer - HER2/ER
Session Type: Oral Abstract Session
Track: Breast Cancer
Time: 3:00 PM - 6:00 PM
Location: N Hall B1
•
Chair
Charles E. Geyer, MD, FACP
•
Chair
Cornelia Liedtke, MD
•
Bevacizumab (Bv) in the adjuvant treatment of HER2-negative breast cancer: Final results
from Eastern Cooperative Oncology Group E5103. (Abstract 500)
Kathy Miller
•
Arobase: A phase III trial of exemestane (Exe) and bevacizumab (BEV) as maintenance
therapy in patients (pts) with metastatic breast cancer (MBC) treated in first line with
paclitaxel (P) and BEV—A Gineco study. (Abstract 501)
Olivier Tredan
•
A phase 1b study of trebananib plus paclitaxel (P) and trastuzumab (T) in patients (pts) with
HER2+ locally recurrent or metastatic breast cancer (MBC). (Abstract 502)
Peter Andrew Kaufman
•
Antiangiogenic Therapy in Breast Cancer: The Next Chapter
Erica L. Mayer, MD, MPH
•
Panel Question and Answer
•
Effect of obesity in premenopausal ER+ early breast cancer: E?C?CG data on 80,000 patients
in 70 trials. (Abstract 503)
•
Effect of obesity in premenopausal ER+ early breast cancer: E?C?CG data on 80,000 patients
in 70 trials. (Abstract 503)
Hongchao Pan
•
Prognostic associations of 25OH vitamin D in NCIC CTG MA.21, a phase III adjuvant RCT of
three chemotherapy regimens (EC/T, CEF, AC/T) in high-risk breast cancer (BC). (Abstract
504)
Ana Elisa Lohmann
•
Phase III trial (Prevention of Early Menopause Study [POEMS]-SWOG S0230) of LHRH
analog during chemotherapy (CT) to reduce ovarian failure in early-stage, hormone receptornegative breast cancer: An international Intergroup trial of SWOG, IBCSG, ECOG, and CALGB
(Alliance). (Abstract LBA505)
Halle C. F. Moore
•
Lifestyle and Survivorship in Early Breast Cancer
Sharon Hermes Giordano, MD, MPH
•
Panel Question and Answer
Panel Discussion
•
Gene expression signatures in pre- and post-therapy (Rx) specimens from CALGB 40601
(Alliance), a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without
lapatinib for HER2-positive breast cancer (BrCa). (Abstract 506)
Lisa A. Carey
•
AVATAXHER: An open-label, randomized, multicenter study investigating the addition of
bevacizumab (B) to neoadjuvant trastuzumab (T) plus docetaxel (D) in patients with early
stage HER2-positive breast cancer (HER2+ BC) stratified according to PET change after one
therapy cycle. (Abstract 507)
Bruno P. Coudert
•
Efficacy of adjuvant trastuzumab (T) compared with no T for patients (pts) with HER2positive breast cancer and tumors = 2cm: A meta-analysis of the randomized trastuzumab
trials. (Abstract 508)
Ciara Catherine Maria O'Sullivan
•
Biomarkers for Treatment Stratification in HER2+ Breast Cancer
John Robert Mackey, MD, FRCPC
•
Panel Question and Answer
Panel Discussion
Session Title: Pediatric Oncology I
Session Type: Oral Abstract Session
Track: Pediatric Oncology
Time: 3:00 PM - 6:00 PM
Location: S504
•
Co-Chair
Steven G. DuBois, MD
•
Chair
Najat C. Daw, MD
•
Real-time central review: A report of the first 3,000 patients enrolled on the Children’s
Oncology Group Renal Tumor Biology and Risk Stratification protocol AREN03B2. (Abstract
10000)
Elizabeth Anne Mullen
•
Treatment of stage IV favorable histology Wilms tumor with incomplete lung metastasis
response after chemotherapy: A report from Children’s Oncology Group study AREN0533.
(Abstract 10001)
David B. Dix
•
Outcome of localized blastemal-type nephroblastoma patients treated according to
intensified treatment in the SIOP 2001 protocol: A report of the SIOP-RTSG. (Abstract
10002)
Marry M van den Heuvel-Eibrink
•
Renal Tumors: Refining Diagnosis and Therapy
Daniel M. Green, MD
•
Panel Question and Answer
•
Randomized phase II trial of bevacizumab and temsirolimus in combination with vinorelbine
(V) and cyclophosphamide (C) for first relapse/disease progression of rhabdomyosarcoma
(RMS): A report from the Children’s Oncology Group (COG). (Abstract 10003)
Leo Mascarenhas
•
Vincristine, dactinomycin, cyclophosphamide (VAC) versus VAC/V plus irinotecan (VI) for
intermediate-risk rhabdomyosarcoma (IRRMS): A report from the Children’s Oncology Group
Soft Tissue Sarcoma Committee. (Abstract 10004)
Douglas S. Hawkins
•
Which patients with rhabdomyosarcoma (RMS) do need radiotherapy (RTX)? The long-term
results of the CWS studies -81, -86, -91, and -96. (Abstract 10005)
Ewa Koscielniak
•
Rhabdomyosarcoma: Optimizing Approaches to Better Outcome
Leonard H. Wexler, MD
•
Panel Question and Answer
Panel Discussion
•
Maintaining outstanding outcomes using response- and biology-based therapy for
intermediate-risk neuroblastoma: A report from the Children’s Oncology Group study
ANBL0531. (Abstract 10006)
Clare Twist
•
Tandem high-dose chemotherapy with stem cell rescue followed by risk-adapted radiation in
children with high-risk cerebral primitive neuroectodermal tumor: Results of the prospective
SFCE-trial PNET HR+5. (Abstract 10007)
Christelle Dufour
•
Risk-based treatment for nonrhabdomyosarcoma soft tissue sarcomas (NRSTS) in patients
under 30 years of age: Children’s Oncology Group study ARST0332. (Abstract 10008)
Sheri L. Spunt
•
Risk-Based Therapy in Nonrhabdomyosarcoma Soft Tissue Sarcoma: Setting a New
Standard?
Robert G. Maki, MD, PhD
•
Panel Question and Answer
Panel Discussion
Session Title: B. J. Kennedy Award and Lecture for Scientific Excellence in Geriatric Oncology
Session Type: Special Session
Track: Special Session
Time: 4:45 PM - 6:00 PM
Location: S100a
•
Adventures in Geriatric Oncology: Inspirations, Lessons Learned and Hopes for the Future
Stuart M. Lichtman, MD
Session Title: Companion Diagnostics and Biomarker Development in Oncology Drug Development
Session Type: Education Session
Track: Developmental Therapeutics
Time: 4:45 PM - 6:00 PM
Location: S100bc
•
Biomarker Development and Accelerated Drug Approval: Neoadjuvant Treatment of Breast
Cancer as the Poster Child
William Fraser Symmans, MD
•
Guidelines for Biomarker Assays Used in Cancer Therapy Evaluation Program–Sponsored,
Early-Phase Clinical Trials
Donald A. Berry, PhD - Chair
•
Rational Integration of Biomarkers in Clinical Trials: The National Cancer Institute
Perspective
Tracy G. Lively, PhD
•
Panel Question and Answer
Session Title: Health Care in America in 2014: Current and Future Implications of the Patient
Protection and Affordable Care Act
Session Type: Education Session
Track: Professional Development
Time: 4:45 PM - 6:00 PM
Location: S404
•
The Impact of Accountable Care Organizations on Oncology Practice
Lawrence N. Shulman, MD
•
Health Care Reform 101: Summary of the Recent and Planned Changes Related to the
Patient Protection and Affordable Care Act
Blase N. Polite, MD, MPP - Chair
•
Bracing for the Future: Impact of Changes in Health Care Policy on Drug Development
Rena M. Conti, PhD
•
Panel Question and Answer
Session Title: Management and Future Directions in Non-Small Cell Lung Cancer with Known
Activating Mutations
Session Type: Education Session
Track: Lung Cancer
Time: 4:45 PM - 6:00 PM
Location: E Hall D1
•
Epidermal Growth Factor Receptor–Mutated Disease
Daniel Botelho Costa, MD, PhD
•
Current and Future Management of Anaplastic Lymphoma Kinase-Translocated Disease
Leena Gandhi, MD, PhD
•
Other Mutations and Translocations: ROS, RET, etc.
David E. Gerber, MD - Chair
•
Panel Question and Answer
Session Title: Radiotherapy for Central Nervous System Tumors: Harnessing Radioactivity from
Curie to Cure
Session Type: Education Session
Track: Central Nervous System Tumors
Time: 4:45 PM - 6:00 PM
Location: E450
•
Moderator
Jay Steven Loeffler, MD - Chair
•
Is Current Technology Improving Outcomes with Radiation Therapy for Gliomas?
Michael Brada, DSc, FRCP, FRCR
•
On the Growth Curve: Continuing to Optimize Radiation Therapy for Pediatric Brain Tumors
Thomas E. Merchant, DO, PhD
•
For the Next Trick: New Discoveries in Radiobiology Applied to Glioblastoma
Juergen Debus, MD, PhD
•
Panel Question and Answer
Session Title: Selecting the Best Therapy for Recurrent Ovarian Cancer: Progress in Response
Prediction over the Last 50 Years
Session Type: Education Session
Track: Gynecologic Cancer
Time: 4:45 PM - 6:00 PM
Location: E354a
•
Lesson Learned from the Past That Help Predict the Future: Moving beyond Resistance
Assays for Patients with Gynecologic Malignancies
Thomas C. Krivak, MD
•
Assay-Driven Therapy: Fact or Fiction?
Robert L. Coleman, MD - Chair
•
Molecular Profiling and Commercial Prediction Assays in Ovarian Cancer: Still Not Ready for
Prime Time
Elise C. Kohn, MD
•
Panel Question and Answer
Session Title: Tumor Genomic Profiling in Cancer Care: Field of Dreams or Ethical Minefield?
Session Type: Education Session
Track: Ethics
Time: 4:45 PM - 6:00 PM
Location: E253
•
Case Studies: Ethical Questions That Arise from Tumor Genotyping
Jennifer B. McCormick, PhD, MPP
•
The Sleeping Giant of Liability: Managing Incidental Germ-Line Findings from Tumor
Genotyping
Mark E. Robson, MD
•
Clinical Promise and Ethical Pitfalls of Tumor Genomic Profiling
Angela R. Bradbury, MD - Chair
•
Panel Question and Answer
Session Title: Challenging Cases in T-Cell Lymphoma - Ticketed Session
Session Type: Meet the Professor Session
Track: Lymphoma and Plasma Cell Disorders
Time: 4:45 PM - 6:00 PM
Location: E451a
•
Challenging Cases in T-Cell Lymphoma
Steven M. Horwitz, MD
Session Title: Optimizing the Use of New Targeted Therapies in the Face of Toxicity - Ticketed
Session
Session Type: Clinical Problems in Oncology Session
Track: Developmental Therapeutics
Time: 4:45 PM - 6:00 PM
Location: E451b
•
PI3K Inhibitors and Glucose Homeostasis
Dejan Juric, MD - Chair
•
BRAF, MEK, and BRAF/MEK: Rash, Cutaneous Malignancy, and Fever
Georgina V. Long, MD, PhD
•
PD-1/PD-L1- and CTLA-4-Associated Autoimmune Toxicity
Evan J. Lipson, MD